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Frontotemporal dementia (FTD) is a heterogeneous form of dementia that characteristi-
cally presents at a presenile age with progressive behavioural disturbances (behavioural 
variant FTD) and/or language problems (semantic or nonfluent variant primary progres-
sive aphasia).1,2 Concomitant motor symptoms frequently occur, represented by FTD with 
motor neuron disease, corticobasal syndrome, and progressive supranuclear palsy as 
part of the same clinicopathological spectrum. An autosomal dominant genetic form of 
FTD is present in 10-20% of patients, most commonly caused by mutations in either MAPT 
(microtubule-associated protein tau), GRN (progranulin), or a repeat expansion in C9orf72 
(chromosome 9 open reading frame 72).3 Postmortem brain examination shows fronto-
temporal lobar degeneration (FTLD) with inclusions of either tau protein (FTLD-tau), TAR 
DNA-binding protein 43 (TDP-43; FTLD-TDP), or FET (fused in sarcoma, Ewing’s sarcoma 
and TAT-binding protein-associated factor 15).4,5
During the past decades, major advances have been made in understanding the 
pathology and genetics of FTD, which are now actively being translated into trials with 
therapeutic interventions. To appropriately select and monitor patients in these trials, 
robust biomarkers are urgently needed. For sporadic FTD patients, diagnostic markers 
that identify clinical and pathological subgroups are essential for the selection of patients, 
and monitoring markers to measure therapeutic effects. For genetic FTD, biomarkers are 
required to determine disease onset, disease progression and target engagement. For 
example neurofilament light chain (NfL) is a promising biomarker for neurodegenerative 
diseases,6 but was at the start of this PhD project limitedly studied in FTD.
This thesis investigated the utility of biomarkers for FTD in cerebrospinal fluid (CSF) and 
blood, the so-called fluid biomarkers. The aims of the current thesis were twofold:
1. To investigate the application of NfL across the sporadic FTD spectrum (Chapter 2); and
2. To identify and study the value of blood and CSF biomarkers in genetic forms of FTD 
(Chapter 3).
Chapter 1.2 provides a general introduction into FTD and its imaging and fluid biomark-
ers. The utility of NfL and the phospho- to total tau ratio across the entire clinical and 
pathological FTD spectrum is described in Chapter 2.1. Next, the thesis outlines the value 
of NfL in two specific sporadic subtypes: semantic variant primary progressive aphasia 
(Chapter 2.2) and progressive supranuclear palsy (Chapter 2.3). In Chapter 3, the focus 
shifts towards fluid biomarkers in hereditary forms, starting with serum and CSF NfL and 
their clinical and imaging correlations in genetic FTD (Chapter 3.1). Subsequently poly(GP) 
and NfL levels were studied in relation to grey matter deficits in C9orf72 repeat expansion 
carriers (Chapter 3.2), and progranulin protein levels were measured over time in GRN mu-
tations carriers (Chapter 3.3). Chapter 3.4 describes the identification of novel candidate 
biomarkers in GRN mutations carriers by proteomics on CSF. The results of this thesis are 
discussed in light of the current literature along with methodological considerations and 
future directives in Chapter 4. Lastly, Chapter 5 summarizes the main results of this thesis.
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Abstract
Frontotemporal dementia (FTD), the second most common type of presenile dementia, 
is a heterogeneous neurodegenerative disease characterized by progressive behavioural 
and/or language problems, and includes a range of clinical, genetic and pathological sub-
types. The diagnostic process is hampered by this heterogeneity, and correct diagnosis is 
becoming increasingly important to enable future clinical trials of disease-modifying treat-
ments. Reliable biomarkers will enable us to better discriminate between FTD and other 
forms of dementia and to predict disease progression in the clinical setting. Given that 
different underlying pathologies probably require specific pharmacological interventions, 
robust biomarkers are essential for the selection of patients with specific FTD subtypes. 
This Review emphasizes the increasing availability and potential applications of structural 
and functional imaging biomarkers, and cerebrospinal fluid and blood fluid biomarkers 
in sporadic and genetic FTD. The relevance of new MRI modalities — such as voxel-based 
morphometry, diffusion tensor imaging and arterial spin labelling — in the early stages of 
FTD is discussed, together with the ability of these modalities to classify FTD subtypes. We 
highlight promising new fluid biomarkers for staging and monitoring of FTD, and underline 
the importance of large, multicentre studies of individuals with presymptomatic FTD. Har-
monization in the collection and analysis of data across different centres is crucial for the 
implementation of new biomarkers in clinical practice, and will become a great challenge 
in the next few years. 
15
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Box 1. Main clinical characteristics of FTD
Behavioural variant frontotemporal dementia (bvFtD) 
bvFtD is characterized by personality and behavioural changes (including disinhibition, apathy, loss of 
sympathy, perseverative behaviour, and abnormal appetite), and executive dysfunction 
primary progressive aphasia (ppa) 
ppa features progressive prominent language difficulties that impair daily living. Subtypes include: 
•	 	Semantic variant PPA (svPPA). Fluent speech characterized by anomia and impaired single word 
comprehension 
•	 Nonfluent variant PPA (nfvPPA). Nonfluent speech with agrammatism and/or apraxia of speech 
•	 	Logopenic variant (lvPPA). Nonfluent speech with word-finding difficulties in spontaneous speech and 
in repetition 
Introduction 
Frontotemporal dementia (FTD) is the second most common form of dementia in people 
aged under 65 years, and encompasses two main clinical manifes tations: behavioural 
changes with executive dysfunc tion, so-called behavioural-variant FTD (bvFTD), or pre-
dominant language impairment, so-called primary progressive aphasia (PPA) (Box 1).1,2 PPA 
can be further divided into semantic variant PPA (svPPA), nonflu ent variant PPA (nfvPPA) 
and logopenic variant PPA (lvPPA).2 Patients can develop concomitant parkin sonism or 
motor neuron disease (MND) at an early or late stage in the disease course, which results 
in a broad clinical phenotype that ranges from amyotrophic lateral sclerosis (ALS) to 
progressive supranuclear palsy (PSP) and corticobasal syndrome (Figure 1).3 Patients who 
present with nfvPPA can develop characteristic features of PSP or corticobasal syndrome 
over time, whereas lvPPA is frequently associated with underlying Alzheimer disease (AD). 
Postmortem examination of the brains of people who present clinically with FTD 
reveals frontotemporal lobar degeneration (FTLD) associated with inclusions of either 
microtubule-associated protein tau (referred to as FTLD-tau), TAR DNA-binding protein 43 
(TDP-43; referred to as FTLD-TDP), or RNA-binding protein fused in sarcoma (referred to as 
FTLD-FUS).3 Rare cases of FTLD are characterized by ubiquitin-positive inclusions without 
immunoreactivity for TDP-43 or FUS (referred to as FTLD-UPS). Correlation between the 
clinical presentation and specific underlying pathol ogy is poor in bvFTD compared with 
svPPA and FTD associated with MND, both of which are associated with TDP-43 pathology.4 
Postmortem examination of patients who developed symptoms consistent with PSP or 
corticobasal syndrome often reveals FTLD-tau. In contrast to sporadic FTD, the underlying 
pathology in genetic FTD can be accurately predicted (Figure 1). 
FTD is highly heritable, and 10–20% of all cases are caused by mutations in three genes: 
MAPT (encoding microtubule-associated protein tau), GRN (encod ing progranulin, also 
known as acrogranin), and C9orf72 (encoding protein C9orf72).3 Other rare FTLD-associated 
genes include CHMP2B (encoding charged multivesicular body protein 2B), VCP (encod-
ing valosin containing protein), SQSTM1 (encoding sequestosome-1), TARDP (encoding 
TDP-43), and TBK1 (encoding the serine–threonine-protein kinase TBK1) — the latter being 
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the most recently discovered FTLD-associated gene, identified in 2015.5 Although some 
phenotypes are associated with specific mutations — for example the co-occurrence of 
MND with C9orf72 mutations — genotype–phenotype correlations are generally poor, even 
within families.3 
Figure 1. Clinical, pathological and genetic spectrum of FTD. 
Genetic forms of frontotemporal dementia (FtD) have predictable pathology: GRN mutations and C9orf72 
repeat expansions result in tDp-43 pathology, whereas MAPT mutations result in tau pathology. By contrast, 
variable underlying pathologies and genetic forms are found across the clinical spectrum of FtD. amyotrophic 
lateral sclerosis (aLS) and FtD with concurrent motor neuron disease (FtD–MND) phenotypes are infrequently 
caused by FtLD-FUS pathology or FUS mutations, but for simplicity this detail is not included in the figure. 
bvFtD: behavioural variant FtD; CBD corticobasal degeneration; FUS: rNa-binding protein FUS; nfvppa: 
nonfluent variant primary progressive aphasia; pSp: progressive supranuclear palsy; svppa: semantic variant 
primary progressive aphasia; tDp-43: transactive response DNa-binding protein 43. Modified with permission 
from BMJ publishing Group © Seelaar, h. et al. J. Neurol. Neurosurg. Psychiatry 82, 476–86 (2011). 
Sensitive biomarkers for FTD are crucial owing to the heterogeneity of the disorder. 
Great efforts to iden tify these biomarkers have been made over the past two decades, 
with a predominant focus on fluid biomaterial and neuroimaging features. According to 
previous con sensus, the ideal biomarker should detect a fundamental pathological fea-
ture of the disease, should be validated in pathological proven cohorts, and should be 
precise, reliable, inexpensive and detectable through a proce dure that is noninvasive and 
simple to perform (Box 2).6 Different biomarkers can be used for specific purposes, so the 
value of a biomarker depends on its application. In FTD, diagnostic biomarkers should 
discriminate between individuals with FTD, control individuals and individuals with other 
neurodegenerative diseases, or should differentiate between clinical, genetic or patho-
logical subtypes. Staging biomarkers should enable us to assess disease severity and to 
discriminate between presymptomatic, prodromal, and early or late sympto matic stages 
17
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of the disease. Pharmacodynamic biomark ers are important for the evaluation of the bio-
logical and clinical effect of future therapeutic interventions. Prediction of the underlying 
pathology in FTD (tau versus TDP-43) is one of the greatest challenges, as this distinction 
will be essential when specific disease-mod ifying interventions become available. Ideally, 
these interventions should be applied at an early stage in the disease when only minimal 
neuronal damage is present, which highlights the need for early biomarkers; at-risk indi-
viduals from families with genetic forms of FTD are the ideal study population for detecting 
these earliest changes. 
Box 2. Biomarkers: requirements and applications
requirements: (adapted from 6)
•	 Able	to	detect	fundamental	feature	of	FTD	pathology
•	 Validated	in	neuropathologically	confirmed	FTD
•	 Precise
•	 Reliable
•	 Noninvasive
•	 Simple	to	perform
•	 Inexpensive
applications:
•	 Prediction
•	 Diagnostic
•	 Staging
•	 Monitoring	of	disease	progression
•	 Monitoring	of	treatment	response	(surrogate	endpoint,	target	engagement)
•	 Prognostic
In this Review, we focus on fluid and neuroimaging biomarkers in FTD. We discuss 
previous studies on biomarkers with their current application in clinical prac tice and we 
highlight the development of new, promising biomarkers. 
Neuroimaging biomarkers 
Most FTD imaging studies have focused on structural changes by assessing grey matter 
atrophy, but studies within the past 5–10 years have examined white matter integrity using 
diffusion tensor imaging (DTI); these white matter changes are probably more sensitive for 
the ear liest changes in FTD than are grey matter changes. In neurodegenerative diseases, 
structural abnormalities are often preceded by functional changes; in the following sections 
we describe both the structural and functional changes identified with different imaging 
modalities. Most imaging studies have focused on group analyses, but these group-based 
results cannot always be trans lated to the individual patient, as a strong discriminative 
power between patient groups or outcomes is needed to apply these biomarkers in clinical 
practice. 
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Structural changes 
Grey matter. The majority of imaging studies in FTD have used volumetric T1-weighted MRI 
to investigate changes in grey matter structure.7–10 This technique is used to measure brain 
volume, the rate of brain atrophy, and the volumes of specific brain regions of interest — for 
example, the frontal lobe or hippocampus. Several post processing analytical techniques 
have also been applied to T1-weighted imaging; for example, investigation of changes at 
the voxel level (such as voxel-based mor phometry) or measurement of cortical thickness 
(using software such as FreeSurfer), each of which provide an alternative way to investigate 
grey matter loss in the brain. 
On an individual patient level, semiquantitative assessment of atrophy using visual rating 
scales, performed by experienced dementia experts, has provided good diagnostic perfor-
mance in the discrimination of FTD from AD (with more posterior cortical involvement seen 
in the latter than the former), with a specificity of 81%.11 Clinical, genetic and pathological 
syndromes of FTD can also be distinguished to some degree by distinct and dissociable pat-
terns of grey matter atrophy at a group level (Figure 2). Clinically, bvFTD is associated with 
atro phy in the frontal and temporal lobes, the insula and the anterior cingulate cortex, with 
the earliest involvement of frontal paralimbic cortices and insula.12–14 Cluster analyses suggest 
that four anatomical forms of bvFTD exist: frontal-dominant, temporal-dominant, frontotem-
poral and distributed frontotemporoparietal.15,16 However, these analyses have underplayed 
the involvement of sub cortical structures in bvFTD: atrophy of the hippocam pus, amygdala, 
basal ganglia and thalamus clearly occur as the disease progresses.14,17 In the PPA syndromes, 
svPPA is associated with asymmetrical (commonly left-sided) anteroinferiortemporal lobe 
atrophy, nfvPPA with predominantly left-sided inferior frontal and insula involvement, and 
lvPPA with left temporoparietal junc tion loss.18,19 In each of the PPA syndromes, the extent of 
atrophy progresses over time, not only within the same hemisphere but also — later in the 
disease course — in the opposite hemisphere.20–22 In the genetic forms of FTD, GRN muta-
tions are associated with asymmetrical frontotemporoparietal atrophy, MAPT mutations are 
associated with relatively symmetrical involvement of the anteromedial-temporal and orbi-
tofrontal lobes, and C9orf72 expansions are associated with a symmetrical and widespread 
pattern of atrophy with involvement of the thalamus and superior cerebellum.16,23–26 Despite 
the presence of group-level patterns, identification of individuals with specific pathological 
forms of FTD has proved difficult when structural T1-weighted imaging is used alone, and 
the distinction between patients with FTLD-TDP or FTLD-tau has not been possible.9 Patients 
with FTLD-FUS pathology generally present with prom inent caudate atrophy, accompanied 
by orbitofrontal, anteromedial temporal, anterior cingulate, and insula atrophy.27,28 
Across clinical, genetic and pathological forms of FTD, less research has been conducted 
to assess lon gitudinal changes in grey matter loss than loss at sin gle time points. However, 
rates of atrophy clearly vary between different groups, with some being relatively fast (for 
example, in patients with GRN mutations), and some very slow (for example, a subgroup 
of patients with C9orf72 repeat expansions).29 If longitudinal structural imaging could be 
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used for monitoring in clinical trials, sample size estimations show that focal atrophy rates, 
such as in the temporal lobe in svPPA, would enable use of a smaller sample than do whole 
brain atrophy rates.7 
Findings from several small studies of individuals who are at risk of genetic FTD have 
been inconsistent, with some showing grey matter atrophy before onset of symp toms and 
others not. However, in 2015, a large multicen tre analysis from the Genetic Frontotemporal 
Dementia Initiative (GENFI) study identified the presence of atro phy in individuals with 
FTD-associated mutations at least 10 years before expected symptom onset (Figure 3A), 
with diff erent genetic groups showing diff erent patterns.30 In individuals with MAPT muta-
tions, atrophy was first noted in the hippocampus and amygdala, followed by the tem-
poral lobe and later the insula; in GRN mutation carriers, diff erences started in the insula, 
followed by the temporal and parietal lobes and thereaft er the striatum; in the C9orf72 
group, changes were found very early (25 years before expected onset) in subcortical areas 
(including the thalamus), the insula and the occipital cor tex, then the frontal and temporal 
lobes and subsequently the cerebellum.30 In individuals with GRN mutations, but not in the 
other genetic subgroups, prominent asymme try was found in the atrophy at 5 years before 
expected symptom onset. Examination of changes in this cohort over time is important, 
as small-scale longitudinal studies have proven more sensitive than cross-sectional stud-
ies, as illustrated by the identification of a significant reduc tion in left  temporal cortical 
thickness over time in pre symptomatic GRN carriers, with no diff erences found between 
presymptomatic individuals and noncarriers at baseline.31 
Figure 2. Grey matter atrophy in FTD. 
Characteristic patterns of grey matter atrophy (highlighted in red) in diff erent clinical and genetic subtypes 
of frontotemporal dementia (FtD). patients with behavioural variant FtD (bvFtD) exhibit prominent frontal, 
insular and anterior cingulate atrophy. typical temporal atrophy in semantic variant primary progressive 
aphasia (svppa) is asymmetrical (most oft en left -sided). patients with nonfluent variant primary progressive 
aphasia	(nfvPPA)	exhibit	left	 	frontal	and	insular	atrophy.	In	patients	with	underlying	RNA-binding	protein	
FUS (FUS) pathology, nucleus caudatus atrophy is pronounced. patients with GRN mutations oft en exhibit 
asymmetrical frontotemporoparietal atrophy. patients with a C9orf72 repeat expansion present mostly with 
a generalized symmetrical atrophy. patients with MAPT mutations exhibit marked symmetrical temporal 
atrophy.
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White matter. DTI is a valuable noninvasive imaging technique for the assessment 
of the white matter struc ture of the brain. This technique measures the micro structural 
integrity of white matter by determining the rate of diffusion (that is, the motion of water 
molecules) in different directions. Changes in different DTI metrics are thought to reflect 
different pathological changes in microstructure: a decrease in axial diffusivity correlates 
with axonal degeneration; an increase in radial diffu sivity indicates myelin breakdown; 
and a decrease in fractional anisotropy — a composite measure of both axial diffusivity 
and radial diffusivity — represents a general, nonspecific loss of white matter integrity.32 
Abnormalities in white matter diffusivity have been found to precede grey matter atrophy 
in FTD and to have a more widespread distribution in the brain, supporting the importance 
of white matter involvement in FTD.33–38 DTI findings could become valuable biomarkers, as 
the approach has at least four potential applications: differ entiation between individuals 
with FTD, individuals with other types of dementia, and individuals without dementia; dif-
ferentiation between subtypes of FTD; dis ease monitoring; and detection of early changes 
before disease onset. However, white matter integrity has only been investigated with DTI 
at a group level and not at a single-patient level. 
DTI enables highly sensitive differentiation between individuals with FTD, individuals 
with other types of dementia (such as AD) and controls without demen tia.32–36,38–45 Evidence 
has shown that changes in white matter microstructure are more widespread in people 
with FTD than in those with AD,32,34,39,40 and whole-brain mean fractional anisotropy en-
ables discrimina tion between these conditions with a high sensitivity (78%) and moderate 
specificity (68%).34 White matter degradation co-occurs with frontal, temporal and insu lar 
atrophy in FTD, and probably results from axonal degeneration associated with grey mat-
ter neuronal loss. This degeneration encompasses the anterior corpus callosum, bilateral 
anterior and descending cingulum, and uncinate fasciculus tracts,42 which are part of mo-
tor, executive and language neural networks. 
Although patterns of white matter damage on DTI largely overlap between subtypes of 
FTD, some distinc tive DTI changes have been found in clinical, pathological and genetic 
subtypes.33,35,36,38,40,42–44,46 The uncinate fascic ulus, cingulum bundle and genu of the corpus 
callosum seem to be key tracts involved in the bvFTD disease process.34,41,44 Different spatial 
patterns of white matter damage have been found in PPA subtypes: patients with nfvPPA 
show damage to the left orbitofrontal and anterior temporal white matter (superior longi-
tudinal fasciculus); patients with svPPA show asymmetric (mostly left-sided) changes in the 
anterior and inferior temporal white mat ter (including the inferior longitudinal fasciculus), 
and bilateral uncinate fasciculi; and patients with lvPPA show posterior abnormalities, 
such as in the posterior region of the left inferior longitudinal fasciculus.33,35,36,38,42–44 DTI 
might be able to differentiate FTLD-tau from FTLD-TDP in vivo: two studies have found 
more severe loss of white matter integrity in FTLD-tau than in FTLD-TDP.33,46 This obser-
vation parallels post-mortem findings in which tau pathology is associated with marked 
axonal loss and glial tau inclusions, and TDP-43 pathology is associated with greater grey 
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matter neuronal loss than white matter pathology.46 Larger studies are needed to enable 
conclu sive observations to be made before this technique can be used to differentiate 
pathological subtypes in individual patients. DTI studies have revealed different patterns 
of white matter loss across patients with different genetic subtypes of FTD: patients with 
MAPT mutations have consistent alterations in the uncinate fasciculus and right parahip-
pocampal cingulum,34,41 whereas patients with C9orf72-FTD tend to have a greater amount 
of dorsal white matter tract pathology located in the cingulum, corpus callosum and the 
superior cerebellar peduncles.34,41 
Figure 3. Imaging abnormalities in the presymptomatic stage of genetic FTD. 
(A)	Grey	matter	changes	from	the	Genetic	Frontotemporal	Dementia	Initiative	(GENFI)	study:	standardized	
difference between all (presymptomatic and symptomatic) mutation carriers and noncarriers in cortical 
grey matter volumetric imaging measures, versus estimated number of years from expected symptom onset 
for a given difference in volume between carriers and noncarriers. Dotted lines on the x-axis show the time 
at which the upper 95% confidence intervals for each curve crosses zero on the y-axis (that is, the point at 
which a statistically significant difference exists between mutation carriers and noncarriers). (B) Changes in 
fractional anisotropy (red) as measured by diffusion tensor imaging. presymptomatic carriers of GRN and 
MAPT mutations have decreased fractional anisotropy in the uncinate fasciculus versus control individuals. (C) 
Changes in brain perfusion (red) as measured by arterial spin labelling. presymptomatic GRN mutation carriers 
have a lower cross-sectional cerebral blood flow at follow-up than in control individuals. part a modified with 
permission from elsevier © rohrer, J. D. et al. Lancet. Neurol.14, 253–262 (2015) under a Creative Commons 
CC BY 4.0 license. part B reproduced with permission from Lippincott Williams & Wilkins © Dopper, e. G. et al. 
NeuroIogy 80, 814–823 (2013) http://bit.ly/2rasnKd. part C reproduced with permission from elsevier © Dopper, 
e. G. et al. NeuroImage. Clin. 12, 460–465 (2016). 
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Longitudinal assessment of white matter changes with DTI could also be used to 
monitor the disease process and evaluate therapeutic effects in future clinical trials in FTD, 
although studies so far are limited.41 Over time, white matter changes have been found to 
be more widespread than the changes in grey matter atrophy, and have shown distinct 
patterns between clinical and genetic FTD sub types, which reflect different propagation 
of the neuro degenerative process within large-scale brain networks.35 In bvFTD, the larg-
est reduction in fractional anisotropy has been seen in the bilateral uncinate fasciculus 
and para callosal cingulum,35,41 whereas left-to-right sided progres sion is detected in both 
svPPA and nfvPPA.35,43 In svPPA, longitudinal white matter changes extend to bilateral 
frontotemporal tracts, whereas changes in nfvPPA seem to remain comparatively focal.35,43 
Finally, the use of white matter pathology detected by DTI as a biomarker might even 
enable the detection of pathological changes before the onset of clinical symp toms and 
before grey matter atrophy in FTD. Decreased fractional anisotropy and increased radial 
diffusivity have been found in the bilateral uncinate fasciculi in a group of presymptomatic 
carriers of MAPT or GRN mutations who did not have grey matter atrophy (Figure 3B).37,47 
In conclusion, white matter changes detected with DTI are a promising biomarker for 
early diagnosis of FTD and for monitoring the effect of pharmacologi cal interventions in 
the future. For DTI to be used in individual patients, reference data are essential to ena ble 
identification of abnormal changes in white matter integrity, as in automated quantitative 
MRI.48 However, the assembly of such normative data is challenging, owing to variability 
across scanners and field strengths, and choices of DTI metric, tract to assess, and method 
of analysis (for example, tracking or skeletonized analysis). Region of interest analyses of 
specific tracts, such as the uncinate fasciculus, inferior longitudinal fasciculus and superior 
longitudinal fasciculus, will probably provide the best opportunity to move forward from 
the current group-level studies to single-patient analyses. 
Functional changes 
FDG-PET. The use of PET with 18F-fluorodeoxyglucose as the tracer (FDG-PET) enables 
visualization of alter ations in brain metabolism that precede grey matter atrophy in FTD 
and different forms of dementia.49–52 Distinct patterns of regional hypometabolism de-
tected with FDG-PET enables an accurate clinical diagnosis to be made at an individual 
patient level, both by visual inspection and especially by quantitative assessment.53 Low 
glucose metabolism (often asymmetrical) in the orbitofrontal cortex, dorsolateral cortex, 
medial prefron tal cortex, anterior temporal poles, and basal ganglia, is highly specific for 
bvFTD, and differentiates patients with bvFTD from those with other dementia types and 
healthy controls with a sensitivity and specificity of 80–95%.50,51,53–56 These patterns of hy-
pometabolism are early features of symptomatic bvFTD, but also occur a few years before 
patients fulfil the criteria for probable bvFTD.50 However, FDG-PET has produced false posi-
tive findings in some primary psychiatric disorders that mimic FTD, so future quantitative 
23
Chapter 1.2  |  ImagIng and fluId bIomarkers In frontotemporal dementIa
Ch
ap
te
r 1
assessment of metabolism patterns with PET are needed to increase the diagnostic value 
of the technique.54 
The patterns of focal hypometabolism vary between subtypes of PPA and between 
different genetic forms of FTD, and mirror those of the structural changes described in 
the previous section. svPPA is characteris tically associated with asymmetrical bilateral 
temporal hypometabolism, whereas nfvPPA is associated with a higher variability in hy-
pometabolic patterns of the left inferior frontal gyrus, dorsolateral frontal cortex, anterior 
cingulate cortex, insula, and — occasionally — the parietal cortex.57 Distinct patterns of 
metabolic abnormalities in PPAs might predict progression to spe cific dementia subtypes: 
evidence suggests that bilateral temporoparietal hypometabolism predicts conversion to 
AD, parietal hypometabolism predicts conversion to corticobasal syndrome, and involve-
ment of the basal ganglia, midbrain and cerebellum predicts conversion to PSP.57 Longitu-
dinal changes of metabolism detected by FDG-PET could provide additional information 
about the patterns and speed of pathological spread.31,56 For example, patients with svPPA 
exhibit a bilateral reduction of glucose metabolism in the temporal lobes over time, which 
extends to the anterior cingulate cortex and the posterior temporal lobes.58 Regarding 
genetic subtypes, GRN mutations are associated with asymmetrical hypo metabolism in 
frontal and temporal brain regions,31,59 ALS and/or FTD resulting from C9orf72 expansions is 
associated with hypometabolism in the limbic system, basal ganglia and thalamus,60 and 
MAPT mutations are associated with hypometabolism in the medial temporal lobe and the 
frontal and parietal cortices.24 
Interestingly, FDG-PET can reveal abnormalities in the presymptomatic stage of FTD, and 
could serve as a surrogate endpoint in future therapeutic trials; asymmetrical hypome-
tabolism was found in the fron tal and temporal lobes of asymptomatic GRN carriers before 
the onset of clinical symptoms and of grey matter atrophy.31,59 
Arterial spin labelling. The MRI technique arterial spin labelling (ASL) measures brain 
perfusion noninvasively by magnetically labelling water protons in arterial blood, which 
creates an endogenous tracer of cerebral blood flow.61 Brain perfusion measured by ASL 
correlates very well with metabolism measured by FDG-PET,51,53 but ASL has several advan-
tages over FDG-PET: ASL can be combined with other MRI techniques in a single session, is 
noninvasive, involves no radiation exposure, is widely available and is less costly.62
In patients with FTD, ASL has detected hypoperfusion in the insula, the amygdala and 
several parts of the medial frontal lobes, including the anterior cingulate.51,53,63–65 ASL has 
also been used to differentiate bvFTD from AD at an early phase, with a diagnostic accuracy 
(area under the receiver operating characteristic curve) of up to 0.87 for cerebral blood flow 
in specific frontal or parietal regions.51,53,63 In two comparative studies, the regions of hypo-
perfusion identified on ASL MRI scans largely over lapped with those identified on FDG-PET 
scans,51,53 and diagnostic performance for distinguishing bvFTD from AD and controls was 
similar for both modalities.53 
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Brain perfusion measured by ASL could also be an early biomarker in the preclinical 
stage of genetic FTD. Decreases in cerebral blood flow over time are signifi cantly larger 
in presymptomatic individuals who carry GRN or MAPT mutations than in control indi-
viduals (Figure 3C), independent of grey matter atrophy, in wide spread frontal, temporal, 
parietal, and subcortical regions; the largest decline in perfusion was observed in those 
who converted to the disease stage.62 Some regional changes in brain perfusion might be 
specific for particular gene defects, as hypoperfusion can extend into posterior temporal 
and parietal regions in those with a GRN mutation.62
Resting-state functional MRI. Another potential bio marker for early diagnosis and dis-
ease staging in FTD is functional connectivity measured with resting-state functional MRI 
(RS-fMRI). RS-fMRI measures intrinsic functional connectivity between brain regions, which 
can be detected as synchronous patterns of spontane ous, low-frequency fluctuations in 
blood oxygen level-dependent signals. RS-fMRI is a safe, noninvasive and repeatable tool 
that is sensitive to changes in brain func tional connectivity before the onset of clinical 
symp toms or atrophy at the group level, as opposed to the individual level.37,66,67 Decreased 
connectivity between the frontoinsula and anterior cingulate cortex, part of the salience 
network, is the most consistent RS-fMRI finding in patients with FTD,67–71 but some studies 
have found normal or increased connectivity.72–74 Inconsistent differences (increased and 
decreased connectivity) have been found in the default mode network in FTD.67–69 These 
discrepancies in functional connectivity might partly be explained by differences between 
cohorts and scanners, and by the wide variation in analytical meth ods used, such as in-
dependent component analyses, seed-based or region-of-interest-based approaches, or 
regional homogeneity analyses.66,68,72,74,75 
Specific network alterations are also found in differ ent clinical and genetic subtypes of 
FTD. Reduced left temporal lobe connectivity is found in svPPA,76,77 atten uated connectiv-
ity in salience and sensorimotor net works is found in patients with C9orf72 bvFTD,26 and 
reduced left frontal connectivity is found in patients with GRN mutations.78 In the pre-
symptomatic phase of FTD, RS-fMRI might be sensitive to connectivity diff erences: altered 
(reduced and increased) frontoinsula and/or anterior cingulate cortex connectivity have 
been reported in presymptomatic mutation carriers.37,66,78,79 
Amyloid and tau PET tracers. Several tracers other than 18F-fluorodeoxyglucose could be 
used to iden tify diagnostic biomarkers in the differential diagnosis between FTD and AD, 
and between different patholog ical subtypes of FTD. PET with an amyloid tracer, such as 
Pittsburgh compound B (PiB), robustly and sensi tively detects amyloid-β deposits, which 
indicate AD pathology in vivo,80 whereas bvFTD, svPPA and nfvPPA are mostly PiB-negative. 
Most lvPPA cases are atypical AD cases and are associated with a PiB binding pattern simi-
lar to that seen in AD,81–83 but lvPPA with negative PiB-PET is accompanied by structural 
and FDG-PET abnormalities, which support an underlying FTLD pathology.83,84 Unexpected 
positive PiB-PET findings in patients with FTD can result from mild coincidental AD pathol-
ogy, unrelated to the clinical FTD presentation.85 
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Several tracers have been developed that visual ize tau pathology in vivo; however, an 
ideal ligand that captures the wide range of tau pathology in existence has not yet been 
developed. Selectivity to different tau isoforms and their intracellular aggregation probably 
requires the application of different tau ligands.86 In tau PET with the 18F-AV-1451 ligand 
(also known as flortaucipir), increased uptake in the temporal cortex, frontal cortex, and 
basal ganglia is seen in patients with FTD who have an Arg406Trp MAPT mutation, which 
is associated with both 3-repeat and 4-repeat tau pathol ogy. In these patients, increased 
regional 18F-AV-1451 uptake correlated with decreased glucose metabo lism and with the 
post-mortem burden of tau pathol ogy.87 However, conditions in which only 4-repeat tau 
pathology is present are associated with poor binding of 18F-AV-1451, as illustrated by the 
lack of correlation between 18F-AV-1451 binding and post-mortem tau pathology in PSP.88,89 
A 2017 study of post-mortem brains reported that the ligand 11C-PBB3 could more robustly 
capture a wide range of tau pathologies than 18F-AV-1451, including 3-repeat and 4-repeat 
tau conditions.90 Furthermore, the 18F-THK-5351 ligand produced prom ising results in the 
4-repeat tau diseases PSP and corticoba sal syndrome, in post-mortem tissue and in vivo.91,92 
Once validated, tau PET could become effective for the diagno sis of underlying tau pathol-
ogy in FTD and could provide a surrogate marker for trials with anti-tau therapeutics.86 
Summary of imaging biomarkers 
Grey matter atrophy and hypometabolism are validated diagnostic biomarkers that show 
fairly consistent changes between studies at a group level, and are clinically applied at 
an individual level for the differentiation between FTD, AD and control individuals (Table 
1). More work is required on the use of imaging modalities to distinguish FTD subtypes 
at an individual level, with a need for larger studies of longitudinally acquired imaging 
data, before these techniques can be used as an outcome measure to monitor disease 
progression in clinical trials.
We expect that new modalities, such as DTI, ASL and RS-fMRI, will become valuable tools 
for detecting bio markers in clinical practice, especially owing to their sen sitivity, and have 
the potential to enable early diagnosis and longitudinal monitoring of disease (Table 1). 
Crucial to the implementation of these techniques is the harmo nization of methodology 
across different centers, as scan ners and protocols can vary considerably. For example, 
the diversity of ASL scanning protocols influences perfusion quantification, which could 
be overcome by a proposed international standardization of protocols.61 Additionally, the 
integration of different types of information through the combination of imaging modali-
ties holds great prom ise for the future, as demonstrated by multimodal analyses that have 
improved the discrimination between FTD and AD,40,45,52,65,93,94 and between clinical FTD 
subtypes.94 
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Table 1. Potential biomarkers in FTD and their application in clinical practice
Biomarker
 
application
ability to differentiate 
between diagnoses
Staging and monitoring of 
disease progression
prognosis Monitoring 
treatment 
responseFtD 
versus 
aD
Clinical, 
genetic and/
or pathologic 
subtypes of FtD 
Symptomatic presymptomatic
Imaging biomarkers
Grey matter atrophy 
(detected by volumetric 
T1-weighted	MRI)
++ ++ + + NS +
White matter integrity 
loss	(detected	by	DTI)
++ + + + NS +
Brain metabolism 
(detected by FDG-pet)
++ ++ + + NS +
tau pathology (detected 
by tau-pet)
+ + NS NS NS NS
Brain perfusion 
(detected by aSL)
++ + + + NS NS
Functional connectivity 
(detected	by	RS-fMRI)
+ + + + NS NS
Fluid biomarkers
p-tau, t-tau and aβ1-42 ++ + NS NS +* NS
NfL + + ++ + ++ +
progranulin NS ++ NS NS NS +
poly(Gp) NS + NS NS NS +
Summary of current or potential biomarkers and their applications reported thus far. *p-tau:t-tau ratio. ++: ro-
bust biomarker, replicated in independent cohorts; +: potential biomarker; Aβ1–42: amyloid beta1–42; aD: alzheim-
er	disease;	ASL:	arterial	spin	labelling;	DTI:	diffusion	tensor	imaging;	FDG-PET:	18F-fluorodeoxyglucose pet; FtD: 
frontotemporal dementia; NfL: neurofilament light chain; NS: not studied; poly(Gp): glycine–proline repeating 
protein; p-tau: phospho-tau181;	RS-fMRI:	resting-state	functional	MRI;	tau-PET:	tau	PET;	t-tau:	total-tau.	
Fluid biomarkers 
Alterations in the concentrations of specific proteins in different human fluid compartments 
could reflect pathophysiological changes in disease processes. The proximity of cerebro-
spinal fluid (CSF) to the brain means that it is likely to contain disease-specific biomarkers 
in patients with neurological disease. Subsequent valida tion of such biomarkers in blood 
would be of great value, as the acquisition of blood samples is minimally invasive and 
would enable repeated measurements to be taken over time. Some brain-specific proteins 
in neurodegen erative disorders can be detected reliably in blood by novel ultrasensitive 
assays — such as single molecule array technology. In the next few years, the progress 
resulting from these developments will offer new opportunities for the diagnosis, staging 
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and monitoring of patients with FTD. In this section, we will first review the current CSF 
markers used to differentiate FTD from AD, then highlight promising CSF and blood-derived 
biomarkers in sporadic and genetic FTD. 
CSF amyloid‑β and tau 
The core CSF biomarkers for AD are phospho-tau181 (p-tau), total-tau (t-tau), and 
amyloid-β1–42 (Aβ1-42); these species correspond to the pathological changes that occur in 
AD — that is, accumulation of hyperphosphorylated tau in neurofibrillary tangles, neuronal 
loss (associated with increased CSF levels of t-tau), and Aβ deposition in senile plaques, re-
spectively.95 These biomarkers have been comprehensively validated to exclude AD in the 
diagnostic work-up of FTD, both in clinical cohorts and in small, pathologically confirmed 
case series: higher levels of p-tau and t-tau, and lower levels of Aβ1–42 are found in patients 
with AD than in those with FTD.96 A high ratio of p-tau:Aβ1–42 or t-tau:Aβ1–42 enables an espe-
cially accurate diagnostic performance for the differen tiation of FTD from AD (p-tau:Aβ1–42 
— specificity 80% and sensitivity 87%; t-tau:Aβ1–42 — specificity 79% and sensitivity 89%). 
The use of ratios of other Aβ isoforms could improve diagnostic accuracy, especially when 
differentiating between AD and vascular dementia or dementia with Lewy bodies, but also 
for distinguishing AD from FTD.97,98 
The core AD biomarkers are also valuable for differ entiating between underlying AD 
or FTLD pathology in the differential diagnosis of PPA, in which an AD-like CSF profile is 
often found in patients with clinically diagnosed lvPPA, but not in patients with svPPA 
or nfvPPA.99–102 An AD-like CSF profile occasionally occurs in patients with FTD, even in 
pathologically proven cases, which could partly be explained by the co-occur rence of AD 
pathology with FTLD in these patients.103 Moreover, decreased Aβ1–42 levels (compared with 
refer ence ranges) were found in up to 25% of patients with the C9orf72 repeat expansion in 
a Finnish cohort, but not in patients with a GRN mutation; additional clinicopatho logical 
and genetic studies are required to elucidate the pathophysiological relevance of Aβ1–42 in 
these cases.104–106 
CSF levels of tau are not increased in patients with FTD with underlying tau pathology 
or in patients with MAPT mutations, compared with patients with tau-negative or sporadic 
FTD.107,108 The ratio of p-tau:t-tau is lower in FTLD-TDP than in FTLD-tau, and enables a spe-
cific differentiation between these subtypes; how ever, this relationship seems to be driven 
by the presence of concomitant MND in some individuals with FTLD-TDP.109–112 Whether 
the lower ratio of p-tau to t-tau is the result of an increase in t-tau owing to neuronal loss 
or a reduction of p-tau is not completely clear. Interestingly, in line with the hypothesis of 
neuronal damage, one study found an association between reduced p-tau:t-tau ratio and 
survival in patients with FTD.111 
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Neurofilament proteins 
Neurofilament light chain (NfL) probably has the most promising short-term prospects 
of all fluid bio markers for FTD disease monitoring and prognosis. Neurofilaments are the 
major constituent of the neuroaxonal cytoskeleton and play an important part in axonal 
transport and in the synapse.113 NfL is the most abundant and soluble neurofilament sub-
unit, and increased levels are thought to reflect axonal damage. 
Blood and CSF levels of NfL are 2.5–11-fold higher in patients with FTD than in control 
individuals, and the clinical value of this protein lies in its correla tion with disease severity 
and progression, survival, and cerebral atrophy (Figure 4).111,114–119 CSF NfL is also increased, 
although to a lesser extent, in several other neurodegenerative diseases (such as ALS, AD, 
PSP and vascular dementia), and should, therefore, be com bined with disease-specific 
biomarkers.114,117,120–122 Levels of NfL are equally elevated among the FTD subtypes bvFTD, 
nfvPPA and svPPA, and are strongly increased in FTD with MND.111,114–116,118 High CSF levels 
of NfL were found in patients with TDP-43 pathology compared with tau pathology, a dif-
ference that was largely driven by ALS co-occurrence.111,118 Among the genetic subgroups, 
particularly high NfL levels were found in FTD patients with GRN mutations, levels varied 
greatly in patients with C9orf72 expansions (ranging from high levels in concomitant MND 
to low levels in patients who progress slowly), and patients with MAPT mutations had 
comparatively low levels (Figure 4C).115 Interestingly, presymptomatic individuals with FTD-
associated muta tions have normal levels of NfL in CSF and blood, with a sharp increase 
reported after conversion to the dis ease stage in two individuals (Figure 4C).115 Whether 
and in what manner NfL levels fluctuate over time in FTD is unknown, but longitudinal data 
in ALS have shown stable NfL levels or a minor increase over time.120,123 A strong correlation 
has been shown between NfL levels in CSF and serum, which makes this biomarker meas-
urable in blood and, therefore, especially suitable for repeated measurements.115,119 
In mouse models of neurodegenerative diseases that exhibited tau, Aβ or α-synuclein 
pathology, an increase in blood and CSF levels of NfL coincided with the onset and 
progression of brain pathology; inhibition of Aβ production — thus, reducing Aβ lesions 
— attenuated the NfL increase.124 This observation suggests that we can use NfL to moni-
tor treatment response in neurodegenerative diseases. In conclusion, NfL is a promising, 
noninvasive biomarker for disease staging, monitoring and prognosis in FTD. Longitudinal 
studies in FTD need to be conducted to better understand the role of NfL as a marker of 
disease progression. 
Gene‑specific biomarkers 
Progranulin. The multifunctional protein progranu lin plays an important part in neurite 
outgrowth and inflammation.125 Pathogenic loss-of-function mutations in GRN reduce 
the blood and CSF levels of progranu lin to 25–40% of normal levels, owing to haploinsuf-
ficiency.125–129 Blood or CSF levels of progranulin are diagnostic biomarkers of pathogenic 
GRN mutations, as they enable the discrimination of presymptomatic and symptomatic 
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GRN mutation carriers from non carriers with high sensitivity (96–100%) and specificity 
(93–100%)(Figure 5A).128,129 Consequently, blood levels of progranulin can help to assess 
the pathogenicity of unclassified variants in GRN. Currently, therapeutic trials are focusing 
on interventions that increase pro granulin expression, such as histone deacetylase inhibi-
tors.130 In these trials, target engagement is assessed using blood progranulin levels, as 
they seem to be constant over time.129,131 However, blood and CSF levels of pro granulin are 
differentially regulated, as demonstrated by the moderate correlation between these com-
partments in GRN mutation carriers; therefore, CSF should also be sampled.129 Progranulin 
levels thus provide a good phar macodynamic biomarker, but do not reflect the extent of 
neurodegeneration in the brain, for which additional biomarkers are needed as surrogate 
endpoints. 
Dipeptide-repeat proteins translated from the C9orf72 repeat expansion. C9orf72 repeat 
expansions are tran scribed to G4C2 repeat RNA, which forms RNA foci. In parallel, this RNA 
is translated into proteins of repeat ing dipeptides (dipeptide-repeat (DPR) proteins) by 
repeat-associated nonATG-initiated translation.132 RNA foci and DPRs are both thought to 
have a key role in the pathophysiology resulting from the G4C2 expansion.132–134 Elevated 
levels of glycine–proline-repeating protein (poly(GP)), one of the DPR proteins, have been 
found in the CSF of patients with C9orf72 repeat expansions, and also in presymptomatic 
carriers of the expansion (Figure 5B+C).134,135 Moreover, poly(GP) levels remained fairly con-
stant over time, which supports the use of poly(GP) as a potential pharmacodynamic bio-
marker in future thera peutic trials.135 In human cell models of C9orf72 FTD– ALS, antisense 
oligonucleotides that bind to G4C2 RNA reduce the levels of extracellular poly(GP), and in 
mice harbouring a G4C2 expansion, they reduce the number of RNA foci and total levels of 
DPR proteins, as well as CSF levels of poly(GP).133–135 These findings indicate that poly(GP) is 
a potential biomarker for therapeutic target engagement and enables the measurement of 
biochemical responses to treatment with agents such as anti sense oligonucleotides.134,135 
As CSF levels of poly(GP) did not correlate with age at onset, disease duration, symptom 
severity or survival in patients with C9orf72 repeat expansions, future clinical trials in these 
patients could benefit from the combination of poly(GP) lev els as a pharmacodynamic 
marker and NfL levels as a prognostic marker. 
Potential fluid biomarkers 
As FTLD with phosphorylated TDP-43 (pTDP-43) aggregates constitutes one of the major 
pathological subgroups of FTLD, levels of pTDP-43 protein in CSF or blood would be an in-
teresting biomarker. However, to date, results have been contradictory. Strongly elevated 
CSF levels of pTDP-43 have been found in a small series of patients with C9orf72 or GRN 
mutations, but did not differ between FTD with TDP-43 or tau pathology in a pathology-
proven cohort.112,136 Quantification of levels of pTDP-43 in CSF is challenging owing to low 
concen trations, the presence of different isoforms, and various antibodies that recognize 
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different regions of pTDP-43 and vary in specificity;112,137 the development of better TDP-43 
assays is warranted. 
Neuroinflammation plays an important part in FTD and other neurodegenerative dis-
eases, as it is a conse quence and a trigger of pathology.138 Microglia are the major immune 
component of the CNS, and are activated by damaged neurons and misfolded proteins, 
resulting in the initiation of a chronic inflammatory response.138 A study of patients with 
Figure 4. Cerebrospinal fluid levels of neuro‑
filament light chain. 
(a) Cerebrospinal fluid (CSF) levels of neurofilament 
light chain (NfL) in clinical frontotemporal dementia 
(FtD) subtypes and other neurodegenerative diseas-
es; horizontal lines represent medians. (B) Kaplan–
Meier survival curves in genetic FtD stratified for CSF 
NfL levels in tertiles; vertical ticks represent censored 
data (patients known to be alive at that time from 
CSF collection). (C) CSF levels of NfL in presymptom-
atic and symptomatic genetic FtD of the three major 
genes (GRN, C9orf72 and MAPT), including two indi-
viduals who converted from the presymptomatic to 
symptomatic stage (connecting line). aD: alzheimer 
disease; bvFtD: behavioural variant frontotemporal 
dementia; CBS: corticobasal syndrome; MND: motor 
neuron disease; nfvppa: nonfluent variant primary 
progressive aphasia; pD: parkinson disease; pSp: pro-
gressive supranuclear palsy; svppa: semantic variant 
primary progressive aphasia. part a modified with 
permission from Wiley & Sons © Scherling, C. S. et al. 
Ann. Neurol. 75, 116–126 (2014). parts B+C modified 
with permission from Wiley & Sons © Meeter, L. h. et 
al. Ann. Clin. Transl. Neurol. 3, 623–636 (2016) under a 
Creative Commons license. 
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sporadic FTD or AD found reduced levels of soluble triggering receptor expressed on my-
eloid cells 2 (TREM2), a protein involved in inflammation and phagocytosis and mainly 
expressed by microglia.139 CSF levels of chitinase-3-like protein 1 (also known as YKL-40 or 
cartilage glycoprotein-39), an inflammatory protein produced by astrocytes, were found to 
be elevated in pathologically proven FTD, but also in AD, vascular dementia, normal ageing 
and other neurological disorders, such as multiple sclerosis.140–142 Similarly, glial fibrillary 
acidic protein, an astrocytic cytoskeletal protein, was found to be increased in FTD and 
other dementia types.143 In the past few years, a strong link between GRN mutations and 
microglial activation has been established, with excessive complement production lead-
ing to synaptic pruning.144 Promisingly, data suggest that proteins involved in complement 
acti vation are potential biomarkers of disease progression in GRN mutation carriers.144 
Various changes in CSF and/or blood levels of cytokines (primarily pro-inflammatory 
cytokines, such as MCP-1, IL-6 and TNF) have been found in FTD, but these changes seem 
to reflect nonspecific mech anisms, as they are also present in AD.145–150 The role of several 
neuropeptides in FTD has been extensively reviewed elsewhere;151 for example, levels of 
neurogra nin, a postsynaptic protein involved in synaptic plas ticity, were lower in patients 
with FTD than in control individuals and patients with AD.141 Larger cohorts with patho-
logically proven and genetically determined disease are needed for validation of these 
cytokines and neuropeptides. 
Figure 5. Gene‑specific fluid biomarkers.
horizontal red lines represent the sample medians in a given group. (a) plasma levels of progranulin (pGrN) are 
significantly lower (***: p<0.001), without overlap, in individuals with GRN mutations (including both presymp-
tomatic (aSX) and symptomatic (SX) carriers) than in control individuals. (B) Cerebrospinal fluid (CSF) levels of 
glycine–proline repeating protein (poly(Gp)) are significantly higher in carriers of a C9orf72 repeat expansion 
than in noncarriers. (C) CSF levels of poly(Gp) are already raised in the presymptomatic stage when compared 
to the symptomatic stage. part a modified with permission from Karger © Meeter, L. h. h. et al. Dement. Geriatr. 
Cogn. Dis. Extra 6, 330–340 (2016) under a Creative Commons license. part B modified with permission from the 
american association for the advancement of Science © Gendron, t. F. et al. Sci. Transl. Med. 9, eaai7866 (2017). 
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Novel approaches are focusing on enriched protein fractions and microRNAs in exo-
somes as potential bio markers. Exosomes are vesicles secreted from cells; they facilitate 
intercellular communication and are enriched sources of biomolecules. The value of the 
examination of exosomes is supported by a small study that reported reduced levels of 
synaptic proteins in blood-derived exosomes in FTD.152 microRNAs regulate gene expres-
sion, and seem to have a role in TDP-43 and FUS pathology, but have not yet been reported 
as biomarkers in FTD.153 
Summary of fluid biomarkers 
Several fluid biomarkers for FTD are currently usable (for example, core AD biomarkers 
such as tau and Aβ levels) or show promise (for example, levels of NfL) (Table 1). Combina-
tions of metabolites in the CSF are likely to yield more information than single markers; for 
example, one biomarker panel enabled highly sen sitive differentiation between TDP-43 
pathology and tau pathology.145 Generally, more validation and longi tudinal data are 
needed to determine the full potential of fluid biomarker candidates. Lastly, harmoniza-
tion of fluid biomarker collection and analysis is important, as levels of the markers can 
be influenced by multiple pre-analytical and analytical factors, including sam pling and 
storage methods, and choice and implemen tation of assays.154 Multicentre standardization 
of these procedures and the establishment of quality control programmes will facilitate 
collaborative research and the implementation of new fluid biomarkers in clinical practice. 
Conclusions 
Neuroimaging and fluid biomarkers are becoming increasingly important in the context of 
future thera peutic interventions in sporadic and genetic forms of FTD. Several imaging and 
CSF biomarkers (such as grey matter atrophy, FDG-PET findings and CSF bio markers of AD) 
are already established and being used in clinical practice, often in the differential diagno-
sis of FTD versus AD. Progress is being made in the identifi cation of gene-specific markers 
and the discovery of new biomarkers for disease staging, the prediction of under lying 
pathology and monitoring of treatment responses. For example, DTI has performed well 
in discriminat ing between FTD and AD, and in demonstrating early pathological changes; 
NfL can be used to differentiate patients with FTD from control individuals and is a promis-
ing staging and prognostic biomarker for FTD; and genetic-specific biomarkers (such as 
progranulin and DPR proteins) could be valuable for the assessment of target engagement 
in therapeutic trials. Importantly, combinations of biomarkers will be valuable in enabling 
the accurate definition of FTD subtype and disease onset, and for the monitoring of disease 
progression and, eventually, treatment response. For example, in a trial in which the aim is 
to increase progranulin production, tar get engagement could be assessed by progranulin 
levels, but additional surrogate endpoints would be needed to assess the physiological 
effect (that is, the reduction of neurodegeneration). 
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Most alterations of these novel biomarkers have been demonstrated at a group level 
and need to be validated for individual patients, which is challenging because FTD is fairly 
rare. Multicentre research can help to increase statistical power and prove clinical utility; 
prime examples of longitudinal observational cohorts include GENFI, ARTFL (Advancing 
Research and Treatment for Frontotemporal Lobar Degeneration Consortium), LEFFTDS 
(Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects), and a collabora-
tion including these consortia in the FPI (FTD Prevention Initiative). Research in genetic FTD 
pro vides a unique opportunity to study the earliest disease effects and consequently offers 
good prospects for the identification of valuable biomarkers. Despite similar ities between 
genetic and sporadic FTD, biomarkers identified in genetic cases require validation for use 
in sporadic cohorts, as biomarker profiles and trajectories can differ, as they do in AD.155 
Interestingly, researchers are now emphasizing that FTD, which has typically been con-
sidered an early-onset dementia, frequently manifests after the age of 65 years and can 
include clinical features sug gestive of AD.156,157 This finding stresses the need for diagnostic 
biomarkers that are specific for FTD, as the co-occurrence of AD pathology with FTD in-
creases with age. The value of FTD biomarkers in different age groups with comorbidities 
remains to be elucidated. Additionally, future research should focus on the com bination of 
different biomarkers (both fluid and imag ing) to make optimal use of these modalities, as 
well as on harmonization of collection and analysis proto cols to facilitate dissemination in 
research and clinical practices. 
Key points
•	 Most	 of	 the	 validated	biomarkers	 in	 frontotemporal	 dementia	 (FTD)	 are	 used	 to	 dif-
ferentiate patients with FTD from patients with Alzheimer disease or from control 
individuals 
•	 Currently	validated	biomarkers	in	FTD	include	grey	matter	atrophy,	alterations	in	brain	
metabolism as detected by 18F-fluorodeoxyglucose-PET and cerebrospinal fluid levels 
of amyloid-β1–42, phospho-tau181 and total-tau. 
•	 New	imaging	biomarkers,	detected	via	techniques	such	as	arterial	spin	 labelling	and	
diffusion tensor imaging, are sensitive to the subtle changes that precede grey matter 
atrophy in FTD, potentially enabling use in diagnosis and disease monitoring 
•	 Promising	fluid	biomarkers	include	neurofilament	light	chain	(for	staging,	monitoring	
and prognosis in all FTD subtypes) and dipeptide-repeat proteins and progranulin (for 
target engagement in gene-specific forms of FTD) 
•	 Reliable	biomarkers	 that	differentiate	between	 tau	pathology	and	TDP‑43	pathology	
are still needed, to facilitate trials of disease-modifying treatments 
•	 Future	research	should	focus	on	the	multimodal	combination	of	fluid	and	imaging	bio-
markers, as well as the harmonization of biomarker collection and analysis protocols 
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Abstract
Objective: To examine the clinical value of neurofilament light chain (NfL) and the phospho-
tau/total tau ratio (p/t-tau) across the entire frontotemporal dementia (FTD) spectrum in a 
large, well-defined cohort. 
Methods: CSF NfL and p/t-tau levels were studied in 361 patients with FTD: 179 behavioural 
variant FTD (bvFTD), 17 FTD with motor neuron disease (FTD-MND), 36 semantic variant 
primary progressive aphasia (PPA), 19 non-fluent variant PPA, 4 logopenic variant PPA 
(lvPPA), 42 corticobasal syndrome, and 64 progressive supranuclear palsy. Forty-five cogni-
tively healthy controls were also included. Definite pathology was known in 68 patients (49 
frontotemporal lobar degeneration [FTLD]-TDP, 18 FTLD-tau, 1 FTLD-FUS). 
Results: NfL was higher in all diagnoses, except lvPPA (n=4), than in controls, equally 
elevated in behavioural variant FTD, semantic variant PPA, nonfluent variant PPA, and cor-
ticobasal syndrome, and highest in FTD-MND. The p/t-tau was lower in all clinical groups, 
except lvPPA, than in controls and lowest in FTD-MND. NfL did not discriminate between 
TDP and tau pathology, while the p/t-tau ratio had a good specificity (76%) and moderate 
sensitivity (67%). Both high NfL and low p/t-tau were associated with poor survival (hazard 
ratio on tertiles 1.7 for NfL, 0.7 for p/t-tau).
Conclusion: NfL and p/t-tau similarly discriminated FTD from controls, but not between 
clinical subtypes, apart from FTD-MND. Both markers predicted survival and are promising 
monitoring biomarkers for clinical trials. Importantly, p/t-tau, but not NfL, was specific to 
discriminate TDP from tau pathology in vivo. 
Classification of Evidence: This study provides Class III evidence that for patients with cog-
nitive issues, CSF NfL and p/t-tau levels discriminate between those with and without FTD 
spectrum disorders.
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Introduction
Frontotemporal dementia (FTD) is a heterogeneous disease encompassing behavioural 
FTD (bvFTD) and the primary progressive aphasias (PPAs): the semantic variant (svPPA), 
the nonfluent variant (nfvPPA) and the logopenic variant (lvPPA).1,2 Motor neuron disease 
(MND), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS) are con-
sidered as part of the FTD spectrum.3 The underlying pathology, frontotemporal lobar 
degeneration (FTLD), is heterogeneous with tau (FTLD-tau), TAR DNA-binding protein 43 
(FTLD-TDP), or fused in sarcoma inclusions (FTLD-FUS).4 Underlying pathology can only 
be predicted in genetic FTD: microtubule-associated protein tau (MAPT) mutations cause 
FTLD-tau, and progranulin (GRN) and chromosome 9 open reading frame 72 (C9orf72) 
mutations cause FTLD-TDP.5 The svPPA and FTD-MND are often associated with FTLD-TDP, 
and PSP with FTLD-tau, whereas underlying pathology can poorly be predicted in bvFTD.6
Disease-modifying therapies against FTD are currently under development, thus robust 
markers to track disease progression are essential. Neurofilament light chain (NfL), reflect-
ing neuroaxonal damage, is a promising monitoring biomarker for FTD and other neurode-
generative diseases.7–12 For pathology-specific therapies, biomarkers predicting pathology 
are paramount, and lower phospho-tau181 to total tau (p/t-tau) ratios were found in small 
series of patients with FTLD-TDP compared to FTLD-tau.10,13,14 However, both biomarkers 
have scarcely been validated and directly compared in large series across the entire FTD 
spectrum, which is needed before implementation in practice. In the current study, we 
compared the clinical value of NfL versus the p/t-tau ratio across all clinical and pathologi-
cal subtypes of the FTD spectrum. 
Methods
Subjects
From our previously described cohorts from the Erasmus Medical Center and the VU 
University Medical Center,15,16 we selected 361 patients based on the following criteria: (1) 
clinical diagnosis of bvFTD, nfvPPA, svPPA, FTD-MND, PSP, CBS, or lvPPA with a probable 
underlying FTLD1,2,17,18; (2) CSF available for research. Patients with CSF results suggesting 
Alzheimer disease (AD) (low CSF amyloid-β1-42 [Aβ42] and high p- or t-tau level, applying 
local laboratory standards) were not included, unless a definite FTD diagnosis was estab-
lished (n=3).1,19 As control group (n=45), we used controls and participants with subjective 
memory complaints with normal CSF Aβ42 levels (>550 pg/ml) from previous studies.9,10 A 
definite diagnosis was ascertained in 68 patients based on known FTD-causing mutations 
(genotyping was performed when family history was positive) or autopsy-confirmation: 
underlying FTLD-TDP pathology in 49 patients (12 GRN, 26 C9orf72 [of whom 7 underwent 
autopsy], 1 optineurin, 10 FTLD-TDP), FTLD-tau pathology in 18 patients (11 MAPT [of whom 
1 underwent autopsy], 5 FTLD-tau, 1 CBD and 1 PSP) and 1 patient with autopsy-confirmed 
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FTLD-FUS. For subanalyses on suspected pathology, patients with svPPA and FTD-MND 
were added to the FTLD-TDP group and patients with PSP to the FTLD-tau group. Concomi-
tant AD pathology in autopsied patients was scored by an experienced neuropathologist 
(A.J.R.) as low (n=21, ABC score “not” or “low”) or high (n=4, ABC score “intermediate” or 
“high”).20 For 1 of 26 autopsied patients, insufficient information was available for this scor-
ing.
Disease onset was defined as the time of first symptoms (e.g. first personality change or 
language difficulties) noted by a caregiver. Age at death was acquired by web-based con-
sultation of the Dutch municipal personal records database (not available for one patient). 
The Mini-Mental State Examination (MMSE) was used to examine global cognition; the 
Frontal Assessment Battery (FAB) for executive function; and the Clinical Dementia Rating 
scale (CDR), including Sum of Boxes (CDR-SB) if available, for disease severity. 
Standard Protocol Approvals, Registrations, and Patient Consents
All patients (or legal representatives) provided written informed consent, and this study 
was approved by the local ethics committees. 
CSF analyses
CSF was collected and stored at -80 °C until analyses according to international consensus 
protocols.21 All measurements were performed blinded to clinical information and in one 
single center. CSF NfL was determined with the enzyme-linked immunosorbent assay 
(ELISA) of UmanDiagnostics (Umeå, Sweden) in duplicate, according to the manufacturer’s 
instructions over 5 different batches. Mean intra-assay coefficient of variation (CV) was 
1.2% (±1.2% standard deviation), interassay CV ranged from 6.1% to 16.7%. Samples with 
too low volume for a duplicate (n=9), were included in the analysis as overall intra-subject 
CV was low. CSF phospho-tau181 (p-tau) and total tau (t-tau) were measured by commercial 
ELISAs (Innotest, Fujirebio, Ghent, Belgium) and remeasured when CV was >15%. 
For controls, all 3 biomarkers were measured, but for some patients insufficient CSF 
volume was available; NfL levels were available in 335 patients, the p/t-tau ratio in 352 
patients, and both in 324 patients. 
Statistical analyses
Statistical analyses were performed in SPSS 21.0 for Windows (IBM Corp., Armonk, NY) 
applying a significance level of p<0.05, and graphs were drafted with GraphPad Prism 7 
(GraphPad Software, La Jolla, CA). Demographic data were compared by Kruskal-Wallis 
tests with post-hoc Dunn tests (Bonferroni corrected), or chi-square tests. Both CSF NfL 
and p/t-tau ratio were nonnormally distributed (Shapiro-Wilk test) and normalized after 
log transformation. Biomarker levels across (clinical or pathological) groups were com-
pared on log-transformed data with correction for age by analyses of covariance with 
post-hoc Šidák tests. In case of missing data, patients were removed from respective 
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subanalyses. Diagnostic performance was assessed by areas under the curve (AUCs) with 
95% confidence intervals (CIs) obtained by receiver operating characteristic analyses, with 
optimal cutoff levels at the highest Youden index.22 Diagnostic performance combining 
the 2 markers was analyzed by receiver operating characteristic analyses on probabilities 
obtained by binary logistic regression when comparing 2 groups (patients vs controls, 
TDP vs tau pathology) or multinominal logistic regression for different clinical diagnoses. 
Diagnostic performance was compared between the markers by the Hanley&McNeil 
method in MedCalc (Ostend, Belgium).23 Biomarkers were correlated to clinical variables 
using Spearman correlation coefficient (rs). Survival was examined by Kaplan-Meier curves 
on NfL tertiles with living patients as censored data, and Cox regressions on tertiles or 
continuous biomarker levels, adjusted for age, sex, disease duration (time between onset 
and CSF collection), and presence of MND. Five-year survival rates were extracted from the 
Kaplan-Meier curves. Multivariate regression examined the following influencing factors in 
the association between logNfL levels (dependent variable) and log-transformed p/t-tau 
ratio: age, disease duration, CSF Aβ42 as proxy for AD co-pathology, and MND (covariates 
entered in second block). 
Classification of Evidence
This case-control study provides Class III evidence that patients across the entire FTD spec-
trum can be discriminated from healthy controls by high CSF NfL levels (sensitivity 79%, 
specificity 89%, p<0.001) or by low p/t-tau levels (sensitivity 73%, specificity 93%, p<0.001). 
Results
Subject characteristics
Demographic characteristics of the 361 patients and 45 controls are displayed in Table 
1. Patients with CBS or PSP were older than controls, and patients with PSP were older 
than patients with bvFTD. Sex did not differ among the diagnostic groups. Age at onset, 
disease duration at CSF collection, and survival per clinical diagnosis is displayed in Table 
1. In total, 195 patients had deceased and their mean survival after CSF collection was 3.7 
(±2.6) years. Survival did not differ between patients with definite TDP versus tau pathology 
(p=0.44, log-rank test). 
Discrimination of clinical diagnosis
All clinical diagnoses, except for lvPPA (n=4), had higher CSF NfL levels than controls (Figure 
1A, p-values and median differences are displayed in Supplementary Table 1), with the 
strongest elevation in patients with FTD-MND. CSF NfL was lower in patients with PSP than 
in those with bvFTD. No differences were found among the other clinical subgroups. 
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Figure 1. NfL and p/t‑tau ratio levels by clinical diagnosis and by underlying pathology. 
(a) NfL levels and (C) the p/t-tau ratio in clinical FtD subgroups; patients with confirmed underlying pathology 
are depicted in black. (B) NfL levels and (D) the p/t-tau ratio in patients with known underlying pathology 
based on autopsy-confirmed pathology (FtLD-tau: blue circles; pSp: red squares; CBD: grey filled upward 
triangles; FtLD-tDp: acqua upward triangles) or a known pathogenic mutation (MAPT: filled light-purple 
squares, GRN: filled blue downward triangles, C9orf72 repeat expansion: purple filled diamonds; OPTN: green 
diamonds); a low p/t-tau ratio (cut-off ≤0.121, dashed line) discriminated FtLD-tDp from FtLD-tau with a 
specificity of 76% and a sensitivity of 67%. horizontal lines represent means. 
***: p<0.001; **: p<0.01; *:(a) higher NfL or (C) lower p/t-tau ratio compared with controls; †: (a) lower NfL or (C) 
higher p/t-tau ratio compared with FtD-MND, ‡: (a) higher NfL or (C) lower p/t-tau ratio compared with pSp.
bvFtD: behavioural variant frontotemporal dementia; CBD: corticobasal degeneration; CBS: corticobasal 
syndrome; CSF: cerebrospinal fluid; FtD-MND: frontotemporal dementia with concomitant motor neuron 
disease; FtLD-tau: frontotemporal lobar degeneration with tau inclusions; FtLD-tDp: frontotemporal lobar 
degeneration with tar DNa-binding protein 43 inclusions; lvppa: logopenic variant primary progressive 
aphasia; NfL: neurofilament light chain; nfvppa: non-fluent variant primary progressive aphasia; n.s.: not 
significant; pSp: progressive supranuclear palsy; p/t-tau: phospho/total-tau; svppa: semantic variant primary 
progressive aphasia.
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The p/t-tau ratio mirrored the results of NfL, as it was lower in all clinical diagnoses 
compared to controls, except for lvPPA (n=4), and FTD-MND patients had the lowest values 
(Figure 1C, Supplementary Table 2). In addition, patients with bvFTD had lower levels than 
patients with PSP. The decreased p/t-tau ratio in clinical patients compared to controls 
was driven by elevated t-tau levels in patients (p<0.001, for p-tau: p=0.52).
Diagnostic performance: clinical diagnosis
To discriminate patients from controls, CSF NfL achieved an AUC of 0.87 (95% CI 0.81-0.92, 
p<0.001), with a sensitivity of 79% and specificity of 89% (cut-off ≥1,613 pg/ml, Supple-
mentary Table 3, including negative and positive predictive values). A low p/t-tau ratio 
showed a similar performance (AUC 0.86 [0.83-0.90], p<0.001, sensitivity 73%, specificity 
93% at ratio≤0.153; compared to AUC NfL: p=0.74). Combining these 2 markers by logistic 
regression yielded a higher AUC of 0.91 (0.88-0.95, p<0.001, Nagelkerke R2=0.45, sensitivity 
80%, specificity 93%; compared to AUC NfL: p=0.03, compared to AUC ratio: p<0.01).
Discrimination of pathologic diagnosis
When NfL levels were analyzed based on definite pathology, no difference between FTLD-
tau and FTLD-TDP was found (p=0.96, Figure 1B). However, when suspected pathologies 
were added in the analysis (i.e. PSP in tau group; svPPA and FTD-MND in TDP group), higher 
levels were observed in patients with suspected TDP than in patients with suspected tau 
(p<0.001, Supplementary Figure 1A). NfL levels were similar in autopsied patients with low 
versus high concomitant AD pathology (p=0.83, Mann Whitney test).
The p/t-tau ratio was lower in definite or suspected TDP pathology than in those with 
definite or suspected tau pathology (p=0.005 and p<0.001 respectively, Figure 1D and 
Supplementary Figure 1B). The decreased ratio in FTLD-TDP was driven by lower p-tau 
levels (median 38 pg/ml [interquartile range 29-44]) than in FTLD-tau (54 [42-67] pg/ml), 
while t-tau levels were similar (335 [252-448] pg/ml and (408 [310-522] pg/ml, respectively). 
The ratio did not differ between low and high concomitant AD-pathology (p=0.78, Mann-
Whitney test).
Diagnostic performance: pathologic diagnosis
NfL did not differentiate between underlying TDP and tau pathology (p=0.26), while the p/t-
tau ratio did (AUC 0.73 [0.60-0.87], p=0.005, sensitivity 67%, specificity 76% at ratio≤0.121, 
Figure 1D and Supplementary Table 3). Combining NfL and p/t-tau ratio did not improve 
the differentiation on underlying pathology (AUC 0.75 [0.62-0.88], p=0.004; p=0.94 versus 
AUC of ratio alone).
Associations between biomarkers and clinical parameters
NfL correlated moderately with t-tau (rs=0.51, p<0.001), weakly with p-tau (rs=0.13, p=0.02) 
and moderately with the p/t-tau ratio (rs=-0.62, p<0.001, Figure 2). This association between 
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the p/t-tau ratio and NfL was influenced by MND and disease duration (ΔR2=0.11; MND: 
β=0.29, p<0.001; disease duration: β=-0.09, p=0.04), but not by age or CSF Aβ42. In definite 
patients, this association was not influenced by type of pathology (TDP versus tau, p=0.25).
NfL associated weakly with disease duration, MMSE, and FAB, moderately with CDR-SB, 
but not with age, sex, or global CDR; the p/t-tau ratio associated weakly with age and 
disease duration, moderately with CDR-SB, but not with sex, MMSE, FAB or global CDR 
(Supplementary Table 4). Patients with GRN mutation had higher NfL levels and lower p/t-
tau ratios than those with C9orf72, MAPT, or no known mutations (Supplementary Table 4). 
Prediction of survival 
Five-year survival was 73% in patients with low CSF NfL levels, 55% in moderate levels, 
and 36% in high levels (Figure 3A; estimated hazard ratio 1.7 [95% CI 1.3-2.1], p<0.001). After 
stratification on diagnosis, this association between high NfL levels and poor survival was 
confirmed in bvFTD (p<0.001), CBS (p=0.001), and PSP (p<0.001; Cox regression on continu-
ous NfL levels). 
For the p/t-tau ratio, 5-year survival was 37% in patients with a low ratio, 56% in moder-
ate ratios, and 63% in high ratios (Figure 3B, estimated hazard ratio 0.70 [95% CI 0.56-0.86], 
p=0.001). Subanalyses by clinical diagnosis showed associations of lower p/t-tau ratios 
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Figure 2. Association between NfL and the p/t‑tau ratio. 
In	(A)	the	clinical	diagnoses	are	marked:	controls	(blue	filled	circles),	bvFTD	(purple	filled	squares),	FTD-MND	
(grey filled upward triangles), svppa (acqua filled downward triangles), nfvppa (blue filled diamonds), lvppa 
(black	circles),	CBS	(green	squares)	and	PSP	(orange	triangles).	 In	(B)	the	association	in	definite	diagnoses	is	
shown: FtLD-tDp pathology (blue upward triangles), FtLD-tau pathology (purple downward triangles), controls 
(grey circles), and patients without a definite diagnosis (grey squares).
bvFtD: behavioural variant frontotemporal; CBS: corticobasal syndrome; CSF: cerebrospinal fluid; FtD: fronto-
temporal dementia; FtD-MND: frontotemporal dementia with motor neuron disease; FtLD-tau: frontotemporal 
lobar degeneration with tau inclusions; FtLD-tDp: frontotemporal lobar degeneration with tar DNa-binding 
protein 43 inclusions; lvppa: logopenic variant primary progressive aphasia; NfL: neurofilament light chain; 
nfvppa: non-fluent variant primary progressive aphasia; pSp: progressive supranuclear palsy; p/t-tau: phospho-
tau/total tau; svppa: semantic variant primary progressive aphasia.
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with a poorer survival in bvFTD and PSP (p<0.001 and p=0.04 respectively, Cox regression 
on continuous p/t-tau ratios). 
0 5 10 15
0
50
100
Time from CSF collection (years)
Pe
rc
en
ts
ur
vi
va
l
Low
Moderate
High
Hazard ratio 1.7 (95%CI 1.3-2.1), p<0.001*
NfL
0 5 10 15
0
50
100
Time from CSF collection (years)
Pe
rc
en
ts
ur
vi
va
l
Low p/t-tau ratio
Moderate p/t-tau ratio
High p/t-tau ratio
Hazard ratio 0.70 (95%CI 0.56-0.86), p<0.001*
A B
Figure 3. Association of NfL and the p/t‑tau ratio with survival. 
Kaplan-Meier curves of (a) NfL levels stratified to tertiles: lowest (green line; NfL < 1989 pg/ml), middle (blue line; 
NfL 1989-3675 pg/ml) or highest (red line, NfL > 3675 pg/ml), and (B) the p/t-tau ratio stratified into lowest (green 
line, ratio < 0.115), middle (blue line, ratio 0.115-0.146) or highest (red line, ratio > 0.146) tertiles; vertical ticks 
represent living patients. *Corrected for age, sex, disease duration, and motor neuron disease. 
CI:	confidence	 interval;	CSF:	cerebrospinal	 fluid;	MND:	motor	neuron	disease;	NfL:	neurofilament	 light	chain;	
p/t-tau: phospho-tau/total tau.
Discussion
This study compared the clinical value of CSF biomarkers NfL and p/t-tau ratio in a large 
cohort of FTD patients. We showed that both biomarkers (1) discriminate patients with FTD 
from controls, (2) are altered in FTD-MND versus other clinical FTD subtypes, and in PSP 
versus bvFTD, but not between the other clinical FTD subtypes, and (3) predict survival, 
and that (4) p/t-tau ratio differentiates underlying TDP from tau pathology. 
In clinical practice, there is a need for diagnostic markers in FTD. Prior research on 
NfL in CSF9,24–26 and in blood9,24,27 demonstrated a good discrimination between FTD and 
controls or non-neurodegenerative diseases including primary psychiatric disorders, while 
diagnostic performance analyses on p/t-tau ratio to discriminate patients with FTD from 
controls are rare. Our results show that both biomarkers, and their combination, have a 
good specificity to discriminate patients with clinical FTD from controls, at the drawback 
of a poorer sensitivity. Few false-positive results were found, but a considerable number 
of false negatives, and thus these markers support – but cannot exclude – underlying 
neuronal damage. Both markers are indeed involved in neuronal loss: NfL is increased and 
overlaps in various neurodegenerative syndromes (e.g. AD, PSP, and vascular dementia), 
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but increases are most pronounced in FTD and amyotrophic lateral sclerosis;7,8,28–30 p/t-
tau is decreased in various diseases characterized by marked neuronal loss, including 
Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis, AD, and FTLD-TDP.10,13,14,31–33 
Overlap in underlying pathophysiology is supported by our results showing correlation 
between the 2 markers. 
Since both NfL and the p/t-tau ratio are aspecific neurodegeneration markers, we 
anticipated a limited role in subtyping different phenotypes. Indeed, NfL levels were com-
parable across bvFTD, nfvPPA, svPPA and CBS, in concordance with prior results in other 
series.7,27,30,34 This study demonstrates a similar pattern for the p/t-tau ratio for the first time. 
Meanwhile, both CSF markers discriminated FTD-MND from other subtypes as supported 
by previous research;10,24 in the clinical practice, the added value of these markers may 
seem limited because MND is ascertained by clinical and electromyographic examination, 
but they could warn for subclinical MND. NfL and the p/t-tau ratio also differed between 
patients with PSP and bvFTD; nevertheless, levels considerably overlapped, yielding a 
diagnostic performance that is insufficient to implement in clinical practice. The lack of 
higher NfL and lower p/t-tau ratio in lvPPA compared with controls is likely explained by 
the small subgroup (n=4) and not by underlying AD pathology because they had a definite 
FTD diagnosis (one C9orf72 repeat expansion, one optineurin mutation) and/or normal AD 
CSF biomarkers (n=2). 
NfL did not discriminate underlying TDP from tau pathology, or improve the performance 
of the ratio, which contrasts to smaller studies showing high NfL levels in FTLD-TDP.10,30 In 
our sample NfL levels strongly varied in patients with C9orf72 repeat expansions, includ-
ing a considerable number of patients with low levels. Including patients with suspected 
pathology did yield higher NfL levels in FTLD-TDP, but this seems to result from very high 
levels in patients with FTD-MND. These findings underline the heterogeneity in pathophysi-
ology in FTLD.
In concordance with earlier reports,10,13,14 we show that the p/t-tau ratio is specific to dif-
ferentiate TDP from tau pathology, which can enable the application of disease-modifying 
agents that target a specific underlying pathology. Compared with previous studies,13,35 we 
report different absolute tau levels and ratios because of different measurement platforms; 
this impedes direct comparison of the studies and illustrates the need for local cutoffs or 
multicenter evaluation. 
The pathophysiological background of a low p/t-tau ratio is not entirely clear; the p/t-tau 
ratio differed between patients and controls because of elevated t-tau levels – represent-
ing neuronal loss – in concordance with prior studies.10,33,36 In contrast, the observed differ-
ences between underlying TDP and tau pathology were mainly driven by low p-tau levels 
in FTLD-TDP. Prior studies have reported conflicting results: p-tau was decreased in TDP 
pathology,13,32,35 t-tau was increased,14 or no differences were found.10,33 These differences 
may be explained by variation in cohort compositions, especially regarding the proportion 
of genetic patients, of concomitant MND, and of AD copathology. We found similar p/t-tau 
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ratios in patients with low versus high AD copathology, but it is not possible to draw firm 
conclusions since the group with copathology was too small and mostly excluded because 
of the study design. A recent study observed an association of antemortem CSF p-tau, and 
not t-tau, with post mortem cerebral tau pathology, suggesting that low p-tau levels reflect 
the low tau burden in FTLD-TDP.35 
In the day-to-day practice, prognostic markers are important to inform patients and 
caregivers and to customize treatment plans. The present study corroborates the associa-
tion of NfL and the p/t-tau ratio with survival,9,10,37 and shows 5-year survival rates that can 
be applied to clinical patients, if replicated. In clinical trials, this can aid in sample size 
estimations that will facilitate trial efficiency. 
Lastly, these biomarkers – especially NfL – could serve as surrogate endpoints in 
therapeutic trials, supported by the association with disease severity we show, as in ear-
lier reports.7,9,27 For example, in multiple sclerosis, a dynamical decrease of CSF NfL was 
observed after treatment intervention.38 A similar application in dementia is endorsed by 
an amyloidosis mouse model, in which BACE1-inhibitor treatment reduced the amyloid-β 
deposits along with CSF NfL levels.39 Furthermore, CSF NfL strongly correlates with serum 
NfL in FTD,9,24 implicating that NfL can be determined in a less invasive way, enabling 
repeated sampling. In this clinical study, we have investigated CSF, because its collection 
(and not serum) is an integral part of our diagnostic process to exclude AD, and has the 
advantage of allowing measurement of NfL simultaneously with markers unmeasurable 
in blood (i.e. p/t-tau ratio). In future trial settings, one could envision a CSF measurement 
of the ratio and NfL at baseline, to stratify on suspected underlying pathology and disease 
progression, and subsequent serum NfL measurements for monitoring.
Strengths of this study include a large, well-characterized, cohort with a large number of 
definite FTD diagnoses (n=68). This study was an important head-to-head comparison of 
NfL versus the p/t-tau ratio across the entire FTD spectrum, including PSP and CBS, which 
is representative of a memory clinic population. We also show the differences in p/t-tau 
ratio across clinical diagnoses. Our information can aid in moving these biomarkers from 
benchside to clinical practice. The exclusion of patients with a low CSF Aβ42 and high tau 
may have excluded some patients with FTLD,3 however it ensures that no concomitant AD 
pathology is causing alterations in the studied biomarkers and therefore enabled a pure 
study cohort. A limitation is the retrospective design, which resulted in missing data and 
the lack of FTD-specific scales (e.g. Frontotemporal Dementia Rating Scale or FTD-CDR-
SB),40 and the fact that we did not include longitudinal samples, which are necessary to 
determine the usability in trial settings. 
Both NfL and the p/t-tau ratio thus show similar patterns in discriminating clinical FTD 
groups and predicting survival. This implies that the markers are interchangeable for 
these applications, and NfL has the advantage of being measurable in blood (although the 
performance in blood remains to be proven). However, to stratify underlying TDP from tau 
pathology, the p/t-tau ratio should be used since it outperforms NfL.
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Supplementary material
Supplementary Table 1. Differences of CSF NfL between the patient and control groups
bvFtD FtD-MND svppa nfvppa lvppa CBS pSp
Controls 2194 18258 2177 1371 757 1690 933
p-value <0.001 <0.001 <0.001 <0.001 0.97 <0.001 <0.001
bvFtD 16064 -17 -823 -1437 -504 -1261
p-value <0.001 1.00 1.00 0.98 1.00 0.002
FtD-MND -16081 -16887 -17501 -16568 -17325
p-value <0.001 <0.001 <0.001 <0.001 <0.001
svppa -805 -1419 -487 -1244
p-value 1.00 0.99 1.00 0.10
nfvppa -614 319 -439
p-value 1.00 1.00 1.00
lvppa 933 175
p-value 1.00 1.00
CBS -757
p-value 0.61
Differences between medians are displayed (column minus row). Significances (corrected for multiple compari-
sons)	of	the	ANCOVA	analysis	with	correction	for	age	are	displayed.
bvFtD: behavioural variant FtD; CBS: corticobasal syndrome; CSF: cerebrospinal fluid; FtD: frontotemporal 
dementia; FtD-MND: FtD with concomitant motor neuron disease; lvppa: logopenic variant ppa; NfL: neuro-
filament light chain; nfvppa: non-fluent variant ppa; ppa: primary progressive aphasia; pSp: progressive supra-
nuclear palsy; svppa: semantic variant ppa
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Supplementary Table 2. Differences of CSF p/t‑tau ratio between the patient and control groups
bvFtD FtD-MND svppa nfvppa lvppa CBS pSp
Controls -0.052 -0.089 -0.057 -0.033 -0.043 -0.044 -0.026
p-value <0.001 <0.001 <0.001 0.003 0.17 <0.001 <0.001
bvFtD -0.037 -0.005 0.019 0.009 0.008 0.026
p-value <0.001 1.0 0.75 1.0 0.95 0.001
FtD-MND 0.032 0.056 0.046 0.045 0.063
p-value <0.001 <0.001 0.16 <0.001 <0.001
svppa 0.024 0.014 0.013 0.031
p-value 0.91 1.0 1.0 0.054
nfvppa -0.010 -0.010 0.007
p-value 1.0 1.0 1.0
lvppa -0.001 0.017
p-value 1.0 1.0
CBS 0.017
p-value 0.89
Differences between medians are displayed (column minus row). Significances (corrected for multiple compari-
sons)	of	the	ANCOVA	analysis	with	correction	for	age	are	displayed.
bvFtD: behavioural variant FtD; CBS: corticobasal syndrome; CSF: cerebrospinal fluid; FtD: frontotemporal 
dementia; FtD-MND: FtD with concomitant motor neuron disease; lvppa: logopenic variant ppa; NfL: neuro-
filament light chain; nfvppa: non-fluent variant ppa; ppa: primary progressive aphasia; pSp: progressive supra-
nuclear palsy; svppa: semantic variant ppa
Supplementary Table 3. Diagnostic performance of CSF NfL, p/t‑tau ratio and the combination
aUC 95%	CI	AUC p-value Cut-off Sensitivity Specificity NPV PPV
Case vs control
NfL 0.87 0.81-0.92 <0.001 ≥1613 78.5% 88.9% 35.7% 98.1%
p/t-tau ratio 0.86 0.83-0.90 <0.001 ≤0.153 73.3% 93.3% 30.9% 98.9%
Combined 0.91 0.88-0.95 <0.001 ≥0.860 79.8% 93.3% 38.9% 98.9%
FtLD-tDp vs FtLD-tau
NfL 0.59 0.45-0.73 0.26 n.s. n.s. n.s. n.s. n.s.
p/t-tau ratio 0.73 0.60-0.87 0.005 ≤0.121 66.7% 76.5% 44.8% 88.9%
Combined 0.75 0.62-0.88 0.004 ≤0.212 59.1% 87.5% 43.8% 92.9%
Diagnostic performance per application and per biomarker or combination. to discriminate cases from con-
trols, the combination outperformed NfL (p=0.04 compared to aUC of combination) and the ratio (p<0.01) alone. 
to discriminate tDp from tau pathology, the ratio performed similar to the combination of NfL and the ratio 
(p=0.95).
AUC:	area	under	the	curve	from	the	receiver	operating	curve	analysis;	CI:	confidence	interval;	CSF:	cerebrospinal	
fluid; FtLD-tau: frontotemporal lobar degeneration with tau inclusions; FtLD-tDp: frontotemporal lobar degen-
eration	with	TAR	DNA-binding	protein	43	 inclusions;	NfL:	neurofilament	 light	chain;	NPV:	negative	predictive	
value;	n.s.:	not	significant;	PPV:	positive	predictive	value.	
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Supplementary Table 4. Association of NfL and p/t‑tau ratio with demographic and clinical vari‑
ables.
NfL p/t-tau ratio
rs n p-value rs n p-value
age at CSF collection -0.03 335 0.65 0.12 352 0.03
Sex n/a 335 0.38 n/a 352 0.53
Disease duration at CSF collection -0.22 335 <0.001a 0.15 352 0.006b
Genetic statusc n/a 334 0.001c n/a 351 0.005c
MMSe -0.15 273 0.01d 0.10 291 0.08
FaB -0.15 201 0.03a 0.12 219 0.07
CDr 0.08 208 0.25 -0.08 227 0.25
CDr-SB 0.38 51 0.005a -0.31 51 0.03a
all clinical patients and no controls were included in the correlation analysis. For the cognitive scales, only as-
sessments within 6 months of CSF collection were considered.
aafter stratification on clinical diagnosis, an association was confirmed in bvFtD. bStratification by clinical di-
agnosis did not yield an association. cthe following groups were compared: patients with a mutation in GRN, 
C9orf72, MAPT, and patients without a known mutation, one patient with a optineurin mutation was excluded; 
post-hoc analysis showed higher NfL levels and lower p/t-tau ratios in GRN mutations than in those without a 
known mutation. dafter stratification on clinical diagnosis, an association was confirmed in CBS.
bvFtD: behavioural variant frontotemporal dementia; CBS: corticobasal syndrome; CDr: clinical dementia rat-
ing scale; CDr-SB: clinical dementia rating scale sum of boxes; CSF: cerebrospinal fluid; FaB: frontal assessment 
battery; MMSe: Mini-Mental State examination; n/a: not applicable; NfL: neurofilament light chain; rs: Spear-
man’s correlation coefficient.
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Supplementary Figure 1. NfL and p/t‑tau ratio levels by suspected pathology. 
(a) NfL levels and (B) the p/t-tau ratio in patients with suspected FtLD-tDp or FtLD-tau pathology. patients 
with suspected pathology [Clinical pSp (green hexagons) in FtLD-tau group; clinical FtD-MND (grey downward 
triangle) and clinical svppa (blue filled hexagon) in FtLD-tDp-43 group] were combined in this analysis with 
those with known underlying pathology [FtLD-tau pathology (blue circles); MAPT mutation (filled light-purple 
squares); pSp pathology (red squares); CBD pathology (grey filled upward triangles); FtLD-tDp pathology (ac-
qua upward triangles); GRN mutation (filled blue downward triangles); C9orf72 repeat expansion (purple filled 
diamonds); OPTN mutation (green diamonds)]. horizontal lines represent medians. 
the median of p-tau levels in suspected FtLD-tDp pathology was 39 pg/ml (interquartile range 33-49) and 38 
pg/ml (30-49) in suspected FtLD-tau pathology; median t-tau level was 352 pg/ml (271-471) for suspected FtLD-
tDp, and 267 pg/ml (177-353) for suspected FtLD-tau pathology.
***: p<0.001; CBD: corticobasal degeneration; CSF: cerebrospinal fluid; FtD-MND: frontotemporal dementia with 
concomitant motor neuron disease; FtLD-tau: frontotemporal lobar degeneration with tau inclusions; FtLD-
tDp: frontotemporal lobar degeneration with tar DNa-binding protein 43 inclusions; NfL: neurofilament light 
chain; n.s.: not significant; pSp: progressive supranuclear palsy; svppa: semantic variant primary progressive 
aphasia.
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Abstract
Background: Neurofilament light chain (NfL) is a promising biomarker in neurodegenera-
tive diseases. Elevated NfL levels in CSF and blood have been observed in a growing num-
ber of neurodegenerative disorders, including frontotemporal dementia and Alzheimer’s 
disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) 
in relation to disease severity and survival. 
Methods: Serum NfL levels were determined in a retrospective cohort of 131 patients with 
PSP and 95 healthy controls. Detailed clinical examination was performed and disease 
severity was assessed by several rating scales. 
Results: We found that serum NfL levels in PSP were twice as high as those in controls, and 
that NfL levels correlated with worse functional, motor and cognitive functioning. During 
follow-up, 119 PSP patients had died, and higher NfL levels were associated with a shorter 
survival. 
Conclusions: This study provides evidence that serum NfL is a relevant and promising bio-
marker in PSP for disease severity, and may be used as a prognostic tool to predict survival 
in clinical practice.
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Introduction
There is an urgent need for sensitive, easily accessible biomarkers in neurodegenerative 
disorders to monitor both disease progression and the effects of treatment. Elevated levels 
of neurofilament light chain (NfL), a neuronal cytoskeletal protein, reflect neuronal injury 
and have been found in the cerebral spinal fluid (CSF) of patients with several neurodegen-
erative disorders.1 An important recent finding is that NfL levels can be reliably measured 
in blood, and that these correlate well with NfL levels in CSF.2 
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized 
by parkinsonism, frequent falls, supranuclear gaze palsy and widespread tau positive 
inclusions at brain autopsy. Elevated NfL levels have been found in PSP patients’ CSF.3–6 
Blood NfL has recently been shown to be a useful biomarker for assessing disease severity 
and predicting disease progression in PSP patients.7 In addition, blood NfL has a good 
diagnostic performance in the discrimination of atypical parkinsonism (including PSP) 
from Parkinson’s disease.8 NfL levels have been associated with survival in frontotemporal 
dementia (FTD), Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).9–11 This 
prognostic value has not been studied in PSP, except for a small study of 12 patients where 
mortality at 24-month follow up was associated with high CSF NfL levels.3
In this retrospective case-control study, we investigated serum NfL levels in a large and 
well characterized cohort of PSP patients, demonstrating its relationship with disease 
severity and survival. 
Methods
Subjects 
PSP patients were enrolled between 2003 and 2014 as part of a Dutch genetic epidemio-
logical PSP study.12 The study was approved by the Medical Ethical committee of Erasmus 
MC; all participants or legal representatives signed informed consent. Inclusion in the 
study took place at the out-patients clinic, or by visiting patients at home or in nursing 
homes. At study entry, detailed clinical assessment was performed, including an interview 
with the caregiver and an extensive neurological examination with the assessment of the 
following rating scales: PSP-rating scale (PSP-RS), Mini Mental State Examination (MMSE), 
Frontal Assessment Battery (FAB), Hoehn and Yahr (HY) scale and Schwab and England 
Activities of Daily Living (SEADL). In a consensus meeting, medical records and MR images 
were reviewed, and the diagnosis PSP was established according to the National Institute 
for Neurological Disorders and Society for PSP (NINDS-SPSP) criteria. Controls were healthy 
spouses or caregivers from stroke patients, above 55 years of age and randomly selected 
from a large database. 
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NfL measurements
Serum samples from PSP patients and controls were centrifuged the same day and stored 
at -80°C. We used a recently developed, ultrasensitive Simoa assay to measure the sample 
NfL levels.2 The measurements were performed in one round of experiments using one 
batch of reagents by board-certified technicians who were blinded to clinical data. For a 
quality control sample with a concentration of 16.8 pg/ml, repeatability was 7.36% and 
intermediate precision was 7.43%. For a quality control sample with a concentration of 127 
pg/ml, repeatability was 6.69% and intermediate precision was 8.24%.
Statistical analysis
Differences in demographics between cases and controls were analyzed using parametric 
and non-parametric statistics as appropriate (SPSS version 21.0). 
Six subjects (2 controls and 4 cases) with extremely high NfL values (>2 SD above the 
mean) were considered as outliers and their NfL values were replaced by values cor-
responding to the upper 2 SD cut off. Because of non-normality, log transformation of 
NfL data was performed. Age was correlated with NfL levels in both cases (Spearman’s 
rho=0.37, p<0.001) and controls (Spearman’s rho=0.55, p<0.001). We conducted therefor an 
ANCOVA to analyze NfL levels between cases and controls adjusted for age. The diagnostic 
accuracy of NfL was examined using receiver operating characteristic (ROC) curve analysis, 
with optimal cut off according to Youden’s index. Correlations between NfL and disease 
severity (measured by PSP-RS, MMSE, FAB, SEADL and HY scale) were studied using linear 
regression analyses, with age and gender as covariates. 
During follow up, 119 PSP patients had died and survival time was calculated from the 
moment of serum collection till date of death. In twelve patients the deceased status was 
unknown and in these subjects survival time was calculated from the moment of serum 
collection till last contact alive and entered as censored data. Survival in PSP patients was 
compared between NfL tertiles by Kaplan-Meier curves with log-rank tests and Cox regres-
sions adjusted for age and gender. 
Results
Serum NfL levels were determined in 131 PSP patients and 95 controls. PSP patients 
showed significantly higher NfL levels compared to controls (Table 1 and Figure 1A). This 
significance held after correction for age and sex on log-transformed NfL (p<0.001). We 
were able to accurately distinguish PSP patients from controls using serum NfL (area under 
the curve 0.87, 95% confidence interval 0.83-0.92). A cutoff value of 38.3 pg/ml provided 
a sensitivity of 90% and specificity of 63%. During follow-up, the diagnosis PSP was con-
firmed at autopsy in 23 subjects (filled black circles in Figure 1A).
Significant correlations were found between NfL levels and PSP-RS sum scores (β= 0.37, 
p<0.001), SEADL scores (β= -0.32, p=0.001), HY scale (β=0.30, p=0.001), FAB scores (β= -0.29, 
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p=0.004) and MMSE scores (β= -0.18, p=0.05), indicating that higher NfL levels are associ-
ated with more severe motor, functional and cognitive disability. No associations were 
found between NfL levels and age at symptom onset or disease duration from onset till 
serum collection. 
PSP-patients with higher NfL levels showed worse survival (Log Rank test p<0.001, Figure 
1B). After adjusting for age and sex, NfL levels remained significantly associated with worse 
survival (Hazard Ratio 1.5 [1.1-1.9], p=0.003). 
Discussion 
This study shows that serum NfL levels are elevated in PSP patients, and that these are 
associated with disease severity and survival. Serum NfL is thus a promising biomarker in 
PSP with the major advantages over CSF that sample collection is minimally invasive and 
can be easily repeated over time. Because of the association with disease severity and 
survival, serum NfL may serve as a prognostic tool in clinical practice. Additionally, it can 
facilitate study design for therapeutic trials and genetic studies to categorize patients into 
disease subtypes.
The NfL concentrations in PSP patients were twice as high as those in controls, which is 
similar to the results from two previous studies on blood-based NfL in PSP.7,8 We further 
demonstrate that NfL levels correlate with motor, cognitive and functional disability in PSP. 
Comparably, a previous study showed that blood NfL levels were correlated with HY stage 
Table 1. Demographic and clinical characteristics of PSP patients and controls.
pSp patients
(n=131)
Controls
(n=95)
p-value
Gender, % female 45 54 0.23a
age at serum sampling, years 71.3 (7.7) 68.5 (6.3) 0.003b
age at disease onset, years 66.4 (7.6) n/a
Disease duration at serum sampling, years 4.9 (2.9) n/a
Median NfL level, pg/ml (interquartile range) 64.2 (42.4-86.1) 30.6 (20.1-41.1) <0.001c
NINDS-SPSP	criteria,	number	possible/probable/definite 49/59/23 n/a
pSp-rS [n=113] 47.2 (15.5) n/a
hoehn and Yahr scale [n=116] 4.3 (0.8) n/a
MMSe [n=107]d 23.9 (4.6) n/a
FaB [n=92] 10.0 (3.5) n/a
Deceased subjects, n 119 n/a
Disease duration from onset till death, years 7.8 (3.3) n/a
Values	are	presented	as	means	(standard	deviations)	unless	otherwise	stated.	aChi-square test, bStudent’s t test, 
cMann-Whitney test, dIn	20	subjects,	the	maximal	possible	score	was	less	than	30	due	to	severe	motor	disability.
FaB, Frontal assessment Battery; MMSe, Mini-Mental state examination; n/a, not applicable; NfL, neurofilament 
light chain; pSp, progressive supranuclear palsy, pSp-rS, pogressive supranuclear palsy rating scale.
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and UPDRS-III (Unified Parkinson’s disease rating scale III) motor scores,8 while in another 
study, high baseline NfL levels were associated with a more rapid neurological, functional 
and neuropsychological decline.7 In addition to this, we show that high serum NfL levels 
are associated with shorter survival. This prognostic value, has been demonstrated for NfL 
in a few other neurodegenerative diseases, but usually measured in CSF,9–11 whereas in 
blood, this association has only been demonstrated in ALS and FTD patients so far.9,13,14
Absolute NfL concentrations differed between our cohort and previous studies, which 
has been observed before.8 There are many factors which may explain this difference such 
as age, disease severity, sampling or storage effects, inter-laboratory variation and the 
application of serum versus plasma. Before the implementation of NfL in clinical practice, 
standardized procedures with uniform protocols across sites and the establishment of 
cut-off levels are necessary.
In 23 individuals (18%), the diagnosis PSP was confirmed at autopsy and these patients 
showed mild to strongly increased NfL levels, not different from clinically diagnosed PSP 
patients (Figure 1A). A few PSP patients showed extremely high NfL levels. It is possible that 
other comorbidities (such as a minor stroke or head trauma) may have influenced NfL lev-
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Figure 1. Serum NfL levels are elevated in PSP patients versus controls and are associated with sur‑
vival. 
(a) Serum NfL levels in pSp patients and controls. horizontal solid lines represent median values. Dotted line (i.e. 
at 38.3 pg/ml) corresponds to the optimal cut off to discriminate pSp patients from controls (sensitivity of 90% 
and specificity of 63%). Filled black circles indicate pSp patients with pathological confirmation. (B) Survival 
curves for pSp patients with low (green line), intermediate (blue line), and high (red line) NfL levels.
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els at that time in these patients. The presence of high NfL values in a few control subjects 
remains unresolved, as we have no additional clinical information or neuroimaging data.
The strengths of the current study are the large sample size with substantial pathological 
confirmation, a clinically well characterized cohort with the assessment of several rating 
scales, and the long period of follow-up, including information on survival. We also ac-
knowledge some limitations. First, this study relies on cross-sectional acquired data, with 
many patients at an advanced disease stage. Longitudinal data would have been valuable 
in helping to determine whether and how NfL concentrations in PSP patients change over 
time. Studies in ALS patients have shown stable NfL levels over time,13,14 while in patients 
with primary progressive aphasia, serum NfL increased after one year follow-up.15 Secondly, 
many samples were stored at – 80°C for more than 10 years. While the effect of long stor-
age on serum NfL levels is unknown, the NfL concentrations in CSF appeared stable under 
pre-analytical variations, and no negative effect was observed due to long-term storage or 
delayed processing.16 In summary, we demonstrate that serum NfL is a promising, easily 
accessible biomarker for monitoring disease severity and survival in PSP. 
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Abstract
Objective: To evaluate cerebrospinal fluid (CSF) and serum neurofilament light chain (NfL) 
levels in genetic frontotemporal dementia (FTD) as a potential biomarker in the presymp-
tomatic stage and during the conversion into the symptomatic stage. Additionally, to 
correlate NfL levels to clinical and neuroimaging parameters. 
Methods: In this multicenter case-control study, we investigated CSF NfL in 174 subjects 
(48 controls, 40 presymptomatic carriers and 86 patients with microtubule-associated 
protein tau (MAPT), progranulin (GRN), and chromosome 9 open reading frame 72 (C9orf72) 
mutations), and serum NfL in 118 subjects (39 controls, 44 presymptomatic carriers, 35 
patients). In 55 subjects both CSF and serum was determined. In two subjects CSF was 
available before and after symptom onset (converters). Additionally, NfL levels were cor-
related with clinical parameters, survival and regional brain atrophy. 
Results: CSF NfL levels in patients (median 6762 pg/ml, interquartile range 3186-9309 pg/
ml) were strongly elevated compared with presymptomatic carriers (804 pg/ml, 627-1173 
pg/ml, p<0.001), resulting in a good diagnostic performance to discriminate both groups. 
Serum NfL correlated highly with CSF NfL (rs=0.87, p<0.001) and was similarly elevated in 
patients. Longitudinal samples in the converters showed a three- to four-fold increase in 
CSF NfL after disease onset. Additionally, NfL levels in patients correlated with disease 
severity, brain atrophy, annualized brain atrophy rate and survival. 
Interpretation: NfL in both serum and CSF has the potential to serve as a biomarker for 
clinical disease onset and has a prognostic value in genetic FTD.
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Introduction
Mutations in the microtubule-associated protein tau (MAPT), progranulin (GRN) or chromo-
some 9 open reading frame 72 (C9orf72) genes are major causes of genetic frontotemporal 
dementia (FTD) and are associated with considerable clinical heterogeneity.1–5 The pre-
symptomatic stage offers a unique window to study the earliest disease stages.6 Changes 
in neuroimaging biomarkers have been found in presymptomatic FTD, similar to findings 
in familial Alzheimer’s disease (AD) and Huntington’s disease.6–9 However, fluid biomarkers 
determining disease onset and progression are lacking, which are essential for forthcom-
ing trials on disease modifying treatments. Neurofilament light chain (NfL) in cerebrospinal 
fluid (CSF) is elevated in FTD, and other neurodegenerative diseases such as amyotrophic 
lateral sclerosis (ALS), AD, and vascular dementia, and dynamically decreases in response 
to anti-inflammatory treatments in multiple sclerosis.10–14 In contrast, small series of 
presymptomatic carriers of FTD-causing mutations have shown low CSF NfL levels.10,15 
NfL is one of the three subunits of neurofilaments, which are the major constituent of the 
neuroaxonal cytoskeleton and are essential for axonal growth, transport, and signalling 
pathways.16,17 CSF NfL has been correlated with disease severity, disease progression, and 
brain atrophy in neurodegenerative diseases.10,13,18 Blood-derived NfL levels have proven 
to highly correlate with CSF NfL in ALS.18 An important question is whether NfL levels may 
serve as a biomarker for conversion from presymptomatic to symptomatic genetic FTD 
and be useful in tracking disease severity and progression. To evaluate the potential of NfL 
levels as a biomarker in genetic FTD, we determined CSF and serum NfL in presymptomatic 
carriers and patients with pathogenic mutations in MAPT, GRN or C9orf72, and correlated 
these levels with clinical and neuroimaging measures.
Methods
Subjects
For this study, three subject groups were included from 11 centers collaborating in the 
Genetic FTD Initiative (GENFI)19: (1) patients with FTD caused by a pathogenic mutation 
in GRN, MAPT or C9orf72 (n=102); (2) presymptomatic carriers of a pathogenic mutation 
(n=63); and (3) cognitively healthy subjects without mutation (controls, n=73). A pathogenic 
C9orf72 expansion was defined as more than 30 repeats.5 For GRN, only nonsense muta-
tions were included (Table 1), for MAPT, published pathogenic mutations and those pre-
dicted as pathogenic were taken into account (software package Alamut v2.6.1, Interactive 
Biosoftware, Rouen, France; Table 1). Participants were recruited as part of GENFI (n=126) 
or ascertained before participation in GENFI (n=112). Participants were either patients 
with a mutation, or known presymptomatic carriers, or 50% at-risk individuals (presymp-
tomatic carriers and controls), or cognitively healthy family members without a mutation 
(controls). At-risk individuals are first-degree relatives of a known carrier of a pathogenic 
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mutation. Genotyping of all participants was performed at local sites and clinical investi-
gators were blinded for the mutation status of at-risk individuals. At-risk individuals and 
control subjects underwent neuropsychological examination. Subjects were categorized 
as presymptomatic or symptomatic according to criteria at the time of inclusion.20–22 At-risk 
individuals were followed yearly or two yearly to assess conversion into symptomatic FTD. 
We defined conversion as the presence of symptoms of behavioural variant FTD (bvFTD), 
primary progressive aphasia (PPA) or amnestic FTD as reported by informants and sup-
ported by neuropsychological assessment and neuroimaging. Disease onset in patients 
(n=102) and converters (n=4) was defined as the moment of first symptoms noted by a 
caregiver. In presymptomatic carriers, estimated time from onset was calculated as age 
at sample collection minus mean familial age at onset, resulting in a negative measure 
in carriers younger than the estimated onset derived from onset ages in their family.6 
Mini-Mental State Examination (MMSE) was used to measure global cognition,23 disease 
severity was assessed by the Clinical Dementia Rating scale (CDR) including, if available, 
the sum of boxes (CDR-SB);24 we only considered scale measurements within 90 days of 
biosample collection. In seven subjects (five CSF, one serum, one both; five C9orf72, two 
GRN mutations)25 ALS-symptoms were present at sample collection; five of them met El 
Escorial criteria at collection, the other two 6 months after collection.26 No ALS-patients 
without FTD symptoms were included. Local ethics committees at each site approved the 
study and all participants (or a legal representative) provided written informed consent at 
enrollment.
Procedures
CSF (n=179) was collected according to standardized local procedures. Serum samples 
were collected from Dutch participants only (n=120). Both CSF and serum collection within 
1 year were available in 57 out of 61 subjects with both CSF and serum (same day n=37, 
range 0-360 days). Longitudinal CSF samples were available in five subjects, including 
converters; in one converter a third CSF sample was available. T1-weighted MRI-images 
within 6 months of CSF collection were available in 101 subjects and a follow-up scan in 22 
subjects. Detailed data on available biosamples and MRI scans in the three subgroups after 
exclusion of outliers (see statistical analysis) are presented in Supplementary Figure  1. 
Grey matter volumes were determined by anatomical parcellation of the whole brain, us-
ing a multiatlas segmentation propagation approach,27,28 with the anatomical definitions 
following the brainCOLOR protocol for the cortical regions and Neuromorphometrics pro-
tocol for subcortical regions and other structures.29,30 Regions-of-interest were combined 
to calculate grey matter volumes of the frontal, temporal, parietal, occipital, cingulate, 
and insular cortices.28 Whole-brain volumes were calculated by combining all regions from 
the automated brain segmentation method.30 All volumes are presented as percentage of 
total intracranial volume (TIV). Atrophy rates were calculated as the percentage decrease 
in volume per year relative to baseline.
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Laboratory methods
Measurements of NfL (in CSF and serum) were performed in one laboratory (of CET respec-
tively JK), blinded to clinical information and mutation status. CSF NfL was measured in 
duplicates using the enzyme-linked immunosorbent assay (ELISA) of Uman Diagnostics 
(Umeå, Sweden), according to the manufacturer’s instructions over four different batches. 
Median intra-assay coefficient of variation (CV) was 0.8% (range 0-66.5%), inter-assay vari-
ability was below 20%. Serum NfL concentrations were measured in duplicate by an earlier 
described, slightly modified, electrochemiluminescence immunoassay with antibodies 
identical to those used in the CSF ELISA (Supplementary Methods).31,32 
Statistical analyses
Statistical analyses were performed in SPSS 21.0 for Windows (Armonk, NY, USA) and Graph-
Pad Prism 6 (La Jolla, California, USA) applying a significance level of p<0.05. NfL values with 
an intra-assay CV of >20% (n=1) and outliers (values > three standard deviations from the 
mean: four CSF and two serum samples) were excluded. CSF and serum NfL were analyzed 
using non-parametric tests (Mann-Whitney U tests and Kruskal-Wallis with Dunn’s post-hoc 
tests). Since the data were not normally distributed, and log-transformation did not nor-
malize the data, square root transformed CSF and serum NfL were used to correct for age 
in all subjects and disease duration in patients using analysis of covariance (ANCOVA) with 
post-hoc Bonferroni corrections where appropriate. Spearman’s correlation coefficient (rs) 
was used to correlate serum with CSF NfL, NfL levels with clinical measures and CSF NfL 
with brain volumes, the latter also with correction for gender and study site (partial rank 
correlations). Diagnostic performance was assessed by areas under the curve (AUC) with 
95% confidence intervals (CIs) obtained by receiver operating characteristic (ROC) analy-
ses, with optimal cut-off levels at the highest Youden’s index (sensitivity+specificity-1).33 In 
analogy to the study of Lu et al.,18 survival in patients was compared between NfL tertiles 
by Kaplan-Meier curves and Cox regressions adjusted for age and disease duration. NfL 
concentrations are described as medians.
Results
Demographic and clinical data 
The total group of 234 subjects consisted of 101 patients (53 GRN, 29 C9orf72, 19 MAPT), 
62 presymptomatic carriers (34 GRN, 14 C9orf72, 14 MAPT) and 71 controls (Table 1, 
Supplementary Figure 1). Patients were older than presymptomatic carriers (p<0.001) and 
controls (p<0.001). GRN and C9orf72 patients were older than MAPT patients (p=0.01 and 
p=0.04 respectively). The age at onset in patients was highly variable ranging between 39 
and 76 years and several presymptomatic carriers were past their estimated age at onset. 
However, 50% percent of the patients had an onset between 52 and 62 years; and the age 
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of both converters was close to the estimated onset age. The disease duration in C9orf72 
patients was longer than in GRN patients (p=0.007). The clinical presentation was bvFTD 
(n=60), PPA (n=17), FTD-ALS (n=7), predominant memory phenotype (n=4), mild cognitive 
impairment (n=4), progressive supranuclear palsy or corticobasal syndrome (n=2), and 
dementia not otherwise specified (n=7). 
NfL in CSF and in serum 
CSF NfL levels in patients (6762 pg/ml) were more than eight times higher than in presymp-
tomatic carriers (804 pg/ml) and controls (650 pg/ml, both p<0.001, Figure 1A), without a 
difference between the latter two groups (p=0.46, Supplementary Figure 2A). The eleva-
Table 1. Subject characteristics
Controls presymptomatic carriers patients p-value
Number 71 62 101
Male gender 29 (41%) 23 (37%) 49 (49%) 0.32
Age	at	collection,	years	(IQR) 54  
(43-61)
49 (42-57) 59 (56-65) <0.0001
age at onset, years (range) - 55 (46-70)a 56 (39-76)b 0.84
Disease	duration,	years	(IQR) - - 2.0 (1.3-3.4)
time to onset or estimated 
onset,	years	(IQR)
- 7.3 (2.5 – 13.2)a -
MMSE	(IQR) 29  
(29-30)
30 (29-30) 25 (21-28) <0.0001
Concomitant aLS 0 0 7 0.005
Gene specific information GRN C9orf72 MAPT GRN C9orf72 MAPT
Number per gene 34c 14 14d 53e 29 19f
Age	at	collection,	years	(IQR) 55 
(48-58)
45 
(42-49)
41
(36-49)
60 
(57-65)
61 
(55-68)
57 
(53-59)
age at onset, years (range) 58 
(47-76)
55 
(39-75)
53 
(42-70)
Disease	duration,	years	(IQR) 1.8 
(1.1-2.6)
3.0 
(2.0-5.0)
2.1 
(1.5-3.7)
0.008
time to onset or estimated 
onset,	years	(IQR)
5.8 
(1.6-11.0)
11.5 
(5.9-14.8)
7.3 
(3.3-15.8)
0.19
Values	are	displayed	as	median	(IQR).	In	case	of	multiple	samples	in	one	subject,	characteristics	at	first	collec-
tion are displayed. aFour presymptomatic subjects converted during follow-up into symptomatic stage after 
collection (2 with CSF, 1 with serum and 1 with CSF and serum). bIn	2	patients	the	age	at	onset	was	unknown.	c17 
Ser82fs,	8	Gln125X,	5	Gly35fs,	2	Val411fs,	2	Cys416fs.	d8 Pro301Leu,	3	Gly272Val,	1	Arg406Trp,	1	Leu135Arg,	1	Ser-
320phe; e16	Thr272fs,	7	Ser82fs,	4	Gly35fs,	4	IVS1+5G>C,	3	Cys366fs,	3	Tyr294X,	2	Gln125X,	1	c.708+6+9delTGAG,	
1	Gln257fs,	1	Val279fs,	1	Gln341X,	1	Thr278fs,	1	Cys314X,	1	c.709-3C>G	homozygous,	1	Gln130fs,	1	Cys149fs,	1	
Cys157fs,	1	Cys315X,	1	Asn188fs,	1	Val200fs,	1	Pro127fs.	f10	Pro301Leu,	2	Gly272Val,	3	Arg406Trp,	1	Leu315Arg,	1	
Val337Met,	1	Val287Ile,	1	Ser305Thr.	
IQR:	interquartile	range;	ALS:	amyotrophic	lateral	sclerosis;	MMSE:	mini-mental	state	examination.
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tion was confirmed after genetic stratification (Figure 1B). GRN patients had higher CSF 
NfL levels than C9orf72 and MAPT patients (p<0.001 and p=0.004 respectively, Figure 1B). 
CSF NfL did not differ between the three presymptomatic groups (p=0.17, Supplementary 
Figure 2B). Correction for age in all subjects and disease duration in patients on square 
root transformed CSF NfL yielded similar p-values as without transformation, except for 
presymptomatic C9orf72 cases versus C9orf72 patients (before correction p<0.001, after 
correction p=0.04, all corrected p-values are displayed in Figure 1 and transformed data 
is presented in Supplementary Figure 3). NfL levels in serum showed a similar pattern 
as in CSF, with higher levels in patients (31.5 pg/mL) than in presymptomatic carriers 
(3.5 pg/mL, p<0.001) and controls (2.9 pg/mL, p<0.001, Figure 1C), without a difference 
between the latter two groups (Supplementary Figure 2C). Consistently, the elevation 
was confirmed after genetic stratification. GRN patients had higher serum NfL levels than 
MAPT patients (p=0.03, Figure 1D), both did not differ from C9orf72 patients. Serum NfL did 
not differ between the three presymptomatic groups (p=0.76, Supplementary Figure 2D). 
Correction for age and disease duration showed similar results, except for the difference 
between presymptomatic carriers and patients which showed only a trend for the MAPT 
and C9orf72 mutations (both p=0.11, Figure 1D and Supplementary Figures 3C and 3D), 
probably due to the small groups.
Correlation between CSF and serum NfL
CSF NfL correlated strongly with serum NfL (Figure 2A, entire group rs=0.87, p<0.001). The 
correlations were strongest in carriers (patients rs=0.77, p<0.001 and presymptomatic car-
riers rs=0.83, p<0.001), whereas controls showed only a trend (rs= 0.50, p=0.06). Sample sets 
collected on the same day showed slightly,  although not significantly, stronger correla-
tions (n=37, entire group rs=0.90, presymptomatic carriers rs=0.90, and patients rs=0.86, all 
p<0.001). 
Correlation with demographical and clinical characteristics
Age correlated with CSF NfL levels in presymptomatic carriers and controls (rs=0.79, 
p<0.001 respectively rs=0.58, p<0.001), but not in patients (rs=0.13, p=0.22). In serum, a simi-
lar pattern was found (presymptomatic carriers rs=0.46, p<0.002, controls rs=0.70, p<0.001, 
patients rs=0.23, p=0.19). Females and males showed similar NfL levels (CSF p=0.18, serum 
p=0.08). CSF NfL levels in patients correlated positively with CDR and CDR-SB, but not with 
MMSE or disease duration (Table 2, Figure 2B); serum NfL correlated positively with CDR-SB 
and not with MMSE or disease duration (Table 2). CSF NfL in four of the six patients with 
concomitant ALS fell in the highest 20% (Figure 1A). Associations between NfL concentra-
tions and estimated onset in presymptomatic carriers are displayed in Supplementary 
Figure 2E and 2F.
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Figure 1. Neurofilament light chain (NfL) levels in presymptomatic carriers and patients. 
NfL in (a) cerebrospinal fluid (CSF) and (C) serum by controls, presymptomatic carriers and patients; patients 
with concomitant amyotrophic lateral sclerosis are displayed as filled orange diamonds. Upper blue dashed 
lines represent the cut-off line to separate presymptomatic carriers from patients at 2165 pg/ml for CSF (sensi-
tivity 84%, specificity 100%) and at 18.0 pg/ml for serum (sensitivity 77%, specificity 98%). Lower green dashed 
lines represent the cut-off line to separate controls from patients at 1190 pg/ml for CSF (sensitivity 97%, specific-
ity 98%) and at 9.3 pg/ml for serum (sensitivity 91%, specificity 100%). NfL levels in (B) CSF and (D) serum speci-
fied by genetic group and clinical stage. Significances from the analysis of covariance analyses are displayed 
(corrected for age in all comparisons and additionally for disease duration in the comparisons between affected 
genes	in	patients).	In	Supplementary	Figure	3,	graphs	of	the	transformed	data	are	shown.	ns:	not	significant;	
*: p≤0.05; **: p≤0.01; ***: p≤0.001.
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CSF NfL levels versus brain volumes
Whole-brain volume as a percentage of TIV was lower in patients than in presymptomatic 
carriers (p<0.001) and lower in presymptomatic carriers than in controls (p=0.04). Cortical 
volumes were lower in patients than in presymptomatic carriers in all investigated areas, 
except for occipital (all areas p<0.001), without differences between controls and presymp-
tomatic carriers. 
CSF NfL in carriers negatively correlated with whole-brain volume (Figure 2C) and with 
frontal, temporal, parietal, insular and cingulate cortices (Table 3 and Supplementary Fig-
ure 4), indicating smaller volumes in case of higher CSF NfL. The analysis of patients only 
(n=28) yielded significant negative correlations for whole brain, frontal cortex, and insular 
cortex. In presymptomatic carriers, negative correlations were found for whole brain and 
frontal, temporal, and parietal cortices. Subgroup analyses of scans from presymptomatic 
and symptomatic carriers combined and a CSF-MRI interval of 90 days or less, as well as 
correction for gender and age showed similar patterns, albeit with lower correlation coef-
ficients in the latter. Similar results were obtained after correction for study site. Unexpect-
edly, a positive correlation between NfL CSF and occipital cortex volume was found in the 
patient group. 
In the subgroup of carriers with a follow-up scan after CSF collection (7 patients and 10 
presymptomatic carriers, median time between scans 1.1 years [interquartile range 1.0-
2.1]) we found significant correlations between CSF NfL and annualized rate of atrophy for 
whole brain, frontal, temporal, parietal, cingulate, and insular cortices (Table 3 and Figure 
2D). 
Table 2. Association between neurofilament light chain levels (in cerebrospinal fluid [CSF] and se‑
rum) and clinical characteristics or scales in patients. 
CSF Serum
rs p n rs p n
Disease duration -0.07 0.50 84a -0.33 0.06 34a
MMSe -0.19 0.14 66 -0.28 0.13 30
CDr 0.33 0.04 40 0.36 0.08 25
CDr-SB 0.60 0.001 27 0.53 0.02 19
aIn	two	patients	with	CSF	and	one	patient	with	serum,	disease	onset	was	unknown.	
MMSe: Mini-Mental State examination; CDr: Clinical Dementia rating scale; CDr-SB: Clinical Dementia rating 
scale sum of boxes.
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Figure 2. Correlations between neurofilament light chain (NfL) levels and clinical or imaging data. 
(a) Correlation between serum and cerebrospinal fluid (CSF) NfL, circles represent controls, squares represent 
presymptomatic carriers and triangles represent patients; filled data points are collected on the same day; a 
log-scale is used for display purposes, one sample had a serum NfL of 0 pg/ml and is thus excluded from the 
graph, but not from the analysis. (B) Correlation of CSF NfL with disease duration in patients (orange triangles). 
Correlations between CSF NfL and (C) whole-brain volume and (D) insular annualized atrophy rate in presymp-
tomatic carriers (blue squares) and patients (orange triangles). Kaplan-Meier curves of (e) all patients with CSF 
available and (F) all patients with serum available; NfL levels were stratified into tertiles: the blue upper lines 
represent the lowest tertiles, the green middle lines the middle tertiles and the orange lower lines the highest 
tertiles; information on survival was available in 72 out of 86 patients with CSF and all patients with serum 
(n=35). 
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Table 3. Correlations of cerebrospinal fluid (CSF) neurofilament light chain (NfL) with MRI volumes. 
Cross-sectional	MRI Longitudinal	MRI
region of interest
all carriers, 
n=55
patients, 
n=28
presymptomatic 
carriers, n=27
annualized atrophy rate, 
all carriers, n=17
Whole-brain rs -0.78 -0.66 -0.43 0.79
p <0.001 <0.001 0.03 <0.001
Frontal rs -0.72 -0.54 -0.59 0.64
p <0.001 0.003 0.001 0.006
temporal rs -0.51 -0.001 -0.50 0.74
p <0.001 1.00 0.008 0.001
parietal rs -0.67 -0.24 -0.41 0.76
p <0.001 0.23 0.03 <0.001
Occipital rs 0.004 0.56 -0.28 0.48
p 0.98 0.002 0.16 0.05
Cingulate rs -0.43 -0.32 -0.21 0.72
p 0.001 0.10 0.29 0.001
Insula rs -0.63 -0.59 -0.24 0.83
p <0.001 0.001 0.23 <0.001
Correlations of CSF NfL with whole-brain and grey matter volumes at baseline are displayed in the first three 
columns. Correlations of CSF NfL with annualized atrophy rate from longitudinal scans are displayed in the last 
column.	MRI:	magnetic	resonance	imaging.
Diagnostic performance
ROC analyses on CSF NfL levels showed a high AUC to separate patients both from controls 
(AUC 0.99 [95% CI: 0.97-1.00]) and from presymptomatic carriers (AUC 0.97 [0.94-0.99]), with 
a sensitivity of 84% and specificity of 100% for a cut-off level of 2165 pg/ml (Figure 1A). 
Lower AUCs, although not significantly lower, were found for serum NfL (patients versus 
controls 0.97 [0.93-1.00], patients versus presymptomatic carriers 0.93 [0.87-0.98]). Serum 
NfL had a sensitivity of 77% and a specificity of 98% to separate patients from presymp-
tomatic carriers (cut-off level of 18.0 pg/ml, Figure 1C). To separate presymptomatic carri-
ers from controls, CSF NfL levels showed an AUC of 0.65 (0.53-0.77) with a sensitivity of 40% 
and a specificity of 94% for a cut-off level of 1066 pg/ml (Supplementary Figure 2A); the 
AUC of serum NfL for controls versus presymptomatic carriers was 0.63 (95% CI: 0.51-0.75, 
sensitivity 34% and specificity 97% at a cut-off level of 8.3 pg/ml, Supplementary Figure 
2C).
Survival analyses
The median survival after CSF collection of deceased patients was 3.6 years (range 0.4-8.1, 
n=34), the median follow-up of alive patients was 2.8 years (range 0.4-10.7, n=38). High CSF 
NfL levels were associated with a poor survival (estimated hazard ratio (HR) of 2.21 (95% 
CI: 1.30-3.77), p=0.004, corrected for age and disease duration, Figure 2E). This association 
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was most prominent in C9orf72 cases, even after correction for ALS (estimated HR 24.59, 
p=0.02, corrected for ALS, age, and disease duration). Dividing the cohort into two groups 
gave similar results; dividing into four groups gave major overlap in CIs. Cox-regressions on 
‘raw’ CSF NfL confirmed the association with mortality: hazard ratio 1.02 for each increase 
in 1000 pg/ml (p<0.001). Serum NfL was also associated with survival (estimated HR on 
tertiles 3.10, 95% CI: 1.09-8.76, p=0.03, Figure 2F, 14 deceased and 21 alive; estimated HR 
on ‘raw’ serum NfL 1.02, p=0.02); gene-specific analyses in serum yielded no significant 
results. 
Longitudinal samples
Longitudinal CSF samples of the two GRN converters, showed a three- to four-fold increase 
in NfL levels over conversion into the symptomatic stage (interval 3.1 and 2.0 years re-
spectively; Supplementary Figure 5), with a 5.8-fold increase (from 9.5 to 55.3 pg/ml) in 
serum samples available in one converter. A decrease (-48% in one year) in CSF NfL of the 
third relative to the second sample was seen in the symptomatic stage of one converter. 
Longitudinal CSF samples of one patient and two presymptomatic carriers showed a 0.8-
1.5-fold change (Supplementary Figure 5); the CVs of all described longitudinal samples 
were below 5%.
Discussion
The present study on a large cohort of carriers of pathogenic GRN, MAPT or C9orf72 muta-
tions showed eight-fold higher CSF NfL levels in patients than in presymptomatic carriers 
and controls. CSF NfL discriminated presymptomatic carriers from patients and might be 
useful to determine conversion. Serum NfL correlated highly with CSF NfL and showed a 
similar elevation in patients. Additionally, NfL levels in patients correlated with disease 
severity, brain atrophy, annualized brain atrophy rate, and survival. Hence, NfL in CSF or 
blood has the potential to serve as a biomarker for clinical disease onset and severity with 
a prognostic value. 
The finding of elevated CSF and serum NfL levels in patients, with a good diagnostic 
performance to separate them from presymptomatic carriers, confirms the earlier findings 
in small series of presymptomatic carriers.10,15 The strong correlation between CSF and 
serum NfL levels, alike in ALS,15,18 suggests a promising role for serum NfL as a biomarker, 
as blood collections are more patient friendly than lumbar punctures. The trend for a lower 
correlation between serum and CSF NfL in controls than in mutation carriers is probably 
explained by the small group in combination with a suboptimal sensitivity of the serum 
assay in the lower range of values. Forthcoming new platforms have a higher sensitivity in 
this lower range; however, this will probably not influence the conclusions of the current 
study, as genetic FTD patients showed high serum NfL levels.
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The higher NfL levels in GRN patients than in MAPT patients are supported by earlier 
findings of higher CSF NfL in cases with TDP-43-pathology than with tau-pathology,34 and 
suggest mutation-specific underlying mechanisms. An intriguing question is whether NfL 
levels merely reflects the extent of neuronal cell death or white matter involvement, as has 
been reported in FTD-GRN.35 Correlation of NfL levels with white matter damage has been 
found in FTD, AD, vascular dementia, and ALS.10,36,37 On the other hand, neurofilament pro-
teins are also integral components of synapses with an important role in receptor-specific 
synaptic plasticity.17 Therefore, mutation-specific NfL elevation may reflect distinct patho-
physiological mechanisms with a more white matter and/or synaptic origin of the disease 
process in GRN mutations. The wide range of NfL levels in our C9orf72 patients correlated 
with the clinical phenotype, with mostly high levels in subjects with concomitant ALS and/
or fast progression and low levels in patients with a slow progression. This is in line with 
high NfL levels in genetic ALS (half C9orf72 carriers) and sporadic ALS, the latter correlating 
with a fast progression and DTI abnormalities.15,18,37 Although DTI analyses across multiple 
centers are at the moment challenging to harmonize, future DTI studies combined with NfL 
levels in the different genetic subtypes of FTD, may elucidate the relationship with white 
matter integrity.
The identified correlations of NfL levels with disease severity and survival in genetic FTD 
patients are also in line with earlier reports in sporadic FTD, AD, and ALS.10,11,13,18 Specifi-
cally, the association of high NfL levels with a poor survival could serve as a meaningful 
prognostic clinical tool. The lack of correlation between NfL levels and age in patients as 
opposed to the controls and presymptomatic carriers, is likely explained by the magnitude 
of the disease effect outweighing the effect of age.
The negative correlation between CSF NfL and brain and cortical volumes is in line with 
findings in a cohort of mainly sporadic FTD patients in which a negative correlation with 
grey and white matter volume was found.10 This supports the hypothesis that NfL levels 
reflect the extent of neurodegeneration.16 So far, the positive correlation between CSF NfL 
and occipital volume in our patients is difficult to explain. Perhaps gene-specific differences 
are underlying, since the occipital lobe is often affected in C9orf72,38 which is associated 
with relatively low NfL levels in current study, and spared in GRN, showing high NfL levels; 
however groups were too small for gene-specific analyses. The correlation between CSF 
NfL and annualized rate of atrophy in the subset of carriers with two consecutive scans, 
supports the observed prognostic value of NfL levels in the cross-sectional analysis. Larger 
future studies are needed to determine whether gene-specific rates of atrophy, as found in 
the study by Whitwell et al., could be correlated to corresponding NfL levels.39 
The observed three- to fourfold increase in CSF NfL levels within three years in our 
converters and normal levels over the entire presymptomatic phase in our large series of 
healthy mutation carriers, gives a first indication of the time period in which NfL increases. 
Although the time to onset is difficult to estimate, due to varying age at onset among 
families, we showed only a small increase in asymptomatic subjects approaching their 
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estimated onset. The elevation in NfL levels suggests a rather explosive nature of the dis-
ease process, at least for GRN mutations, in which a rapid breakdown of the neuroaxonal 
compartment takes place, instead of a more linear disease progression. Similar dynamics 
are suggested in ALS.40 NfL levels in CSF and, according to our data, likely also in serum may 
thus serve as a biomarker for an active disease process coinciding with the onset of clinical 
symptoms in genetic FTD. 
Major strengths of our study are the large series of presymptomatic carriers and patients 
with genetic FTD and the multimodal approach in correlating clinical and imaging data 
with a fluid biomarker. NfL determinations were performed in one laboratory which ex-
cludes an important source of variability.41 Additionally, studying genetic FTD allows us to 
investigate the earliest disease processes in subjects with a known underlying pathology, 
which is ideal to identify biomarkers. An important weakness in our study was the interval 
between collection of CSF, serum, and MRI scanning. However, results were similar in the 
carriers with an shorter interval between CSF sampling and MRI scanning as well as similar 
correlations in serum and CSF samples collected on the same day. Secondly, combining 
subjects from multiple centers resulted in variability regarding sample collection, however 
NfL measurements in CSF are known to be robust to preanalytical variables.42 Lastly, too 
few samples were available to draw conclusions on longitudinal dynamics and the mean-
ing of the decrease in CSF NfL in one converter at a third time point. The relatively stable 
NfL levels over time in ALS might indicate that release and accumulation of NfL is counter-
balanced by clearing mechanisms.18 Additionally, in multiple sclerosis CSF NfL have shown 
to dynamically decrease after therapeutical interventions, which suggests a potential to 
serve as a pharmacodynamic biomarker in FTD as well.14 Longitudinal NfL studies in CSF 
and serum in FTD are needed to determine (1) whether yearly NfL measurements are a 
robust biomarker for conversion; (2) changes throughout the disease process; and (3) 
the potential to measure pharmacodynamic response to interventions. In our opinion 
however, our cross-sectional results clearly discriminated presymptomatic carriers from 
patients, making longitudinal studies interesting, but not necessary before the application 
in the clinic.
In conclusion, NfL in both CSF and serum is a promising biomarker for disease onset, 
severity, and survival in genetic FTD. Longitudinal studies are warranted to assess dynam-
ics over time and thereby the usefulness of NfL for clinical trials in FTD.
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Supplementary material
Supplementary methods
Serum NfL concentrations were measured in duplicate by an earlier described, slightly 
modified, electrochemiluminescence (ECL) immunoassay with antibodies identical to 
those used in the CSF ELISA.1,2 The ECL assay was slightly modified: coating was done 
with 0.05 M carbonate-bicarbonate buffer (pH 9.6) at 4°C. Non-specific binding sites were 
blocked with 100 µl of TBS, containing 3% milk powder, per well for 1h. We used 25 µl 
of TBS containing 1% milk powder, 0.1% Tween 20 and 600/300 µg/ml HeteroBlock® 
(Omega Biologicals, Bozeman, MT, USA) as sample diluent. Calibrators were prepared in 
TBS containing 1% milk powder, 0.1% Tween 20 and 300 µg/ml HeteroBlock®. Samples 
below the lowest standard but above the signal of the blank were extrapolated from the 
standard curve, otherwise assigned a concentration of 0 pg/ml.3 Intermediate precision/
repeatability were 6.1%/3.7%, respectively (sample with mean concentration 72.8 pg/ml), 
8.9%/7.1% (52.3 pg/ml) and 14.9%/9.8% (9.1 pg/ml) for the ECL assay.4 All sample CVs of 
duplicate measurements were below 20.0% (median 4.7%).
Supplementary references 
1.  Gaiottino J, Norgren N, Dobson R, et al. Increased Neurofilament Light Chain Blood Levels in 
Neurodegenerative Neurological Diseases. PLoS One 2013;8(9):1–9.
2.  Limberg M, Disanto G, Barro C, Kuhle J. Neurofilament Light Chain Determination from Periph-
eral Blood Samples. Methods Mol. Biol. 2016;1304(October 2013):93–8.
3.  Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-Purpose Method Development and Validation for 
Successful Biomarker Measurement. Pharm. Res. 2006;23(2):312–328.
4.  Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJC, et al. A Practical Guide to Immuno-
assay Method Validation. Front. Neurol. 2015;6(August):179.
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Supplementary figures
Supplementary Figure 1. Patient numbers per collected material and available MR‑imaging. 
Displayed numbers are after exclusion of outliers. *three subjects were excluded from the analysis on the cor-
relation between serum and CSF because the interval between serum and CSF collection was longer than one 
year (1 control, 2 presymptomatic carriers).
CSF:	cerebrospinal	fluid;	MRI:	magnetic	resonance	imaging.
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Supplementary Figure 2. NfL levels in presymptomatic carriers and controls. 
NfL levels in (a) CSF and (C) serum by controls and presymptomatic carriers. Green dashed lines represent the 
cut-off line to separate controls from presymptomatic carriers at 1066 pg/ml for CSF (sensitivity 40%, specificity 
94%) and at 8.3 pg/ml for serum (sensitivity 34%, specificity 97%). NfL levels in (B) CSF and (D) serum in con-
trols and presymptomatic carriers specified by genetic group (GRN, C9orf72 and MAPT). Significances from the 
ANCOVA	analyses	are	displayed	(corrected	for	age).	Association	between	(E)	CSF	NfL	and	(F)	serum	NfL	and	time	
from estimated onset in controls (red circles) and presymptomatic carriers (GRN filled blue triangles, C9orf72 
filled blue squares, MAPT filled blue diamonds). One young individual is omitted from the graphs, but not from 
the analyses, to prevent disclosure of the genetic status. presymptomatic carriers with CSF NfL values (n=9) and 
serum NfL values (n=14) of >2SD above the mean of controls were closer to or beyond the estimated onset (CSF 
mean 1,1 years and serum mean 0,8 years after estimated onset) than the presymptomatic carriers below that 
cut-off (CSF mean 10,2 years and serum 9,1 years to estimated onset, both p<0.001).	In	presymptomatic	carriers,	
both CSF and serum NfL significantly correlated with time to onset or estimated onset (CSF rs=0.69, p<0.001 and 
serum rs=0.57, p<0.001). CSF: cerebrospinal fluid; NfL: neurofilament light chain; ns: not significant. 
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Supplementary Figure 3. Square root transformed NfL levels in presymptomatic carriers and pa‑
tients. 
Square root of NfL in (a) CSF and (C) serum by controls, presymptomatic carriers and patients. additionally, 
square root of NfL levels in (B) CSF and (D) serum specified by genetic group and clinical stage. Significances 
from	the	ANCOVA	analyses	are	displayed	(corrected	for	age	in	all	comparisons	and	additionally	for	disease	dura-
tion in the comparisons between affected genes in patients). CSF: cerebrospinal fluid; NfL: neurofilament light 
chain; ns: not significant; *, p≤0.05; **, p≤0.01; ***, p≤0.001.
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Supplementary Figure 4. Correlation between CSF NfL and MR‑imaging data. 
(a) Correlation of whole brain volume with CSF NfL in controls (red circles) and presymptomatic carriers (GRN 
blue filled triangles, C9orf72 blue filled squares, MAPT blue filled diamonds). Correlations between CSF NfL and 
(B) frontal lobe volume and (C) temporal lobes volume in presymptomatic carriers (blue squares) and patients 
(orange triangles). CSF: cerebrospinal fluid; NfL: neurofilament light chain. 
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Supplementary Figure 5. Longitudinal CSF NfL samples. 
Longitudinal samples of two converters (green and light blue lines), two presymptomatic carriers (dark blue 
lines) and one patient (orange line), plotted by time from onset or estimated onset in years. CSF: cerebrospinal 
fluid; NfL: neurofilament light chain. 
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Abstract 
Objective: To evaluate poly(GP), a dipeptide repeat protein, and neurofilament light chain 
(NfL) as biomarkers in presymptomatic C9orf72 repeat expansion carriers and patients with 
C9orf72-associated frontotemporal dementia. Additionally, to investigate the relationship 
of poly(GP) with indicators of neurodegeneration as measured by NfL and grey matter 
volume. 
Methods: We measured poly(GP) and NfL levels in cerebrospinal fluid (CSF) from 25 pre-
symptomatic C9orf72 expansion carriers, 64 symptomatic expansion carriers with demen-
tia, and 12 non-carriers. We explored associations with grey matter volumes using region 
of interest and voxel-wise analyses.
Results: Poly(GP) was present in C9orf72 expansion carriers and absent in non-carriers 
(specificity 100%, sensitivity 97%). Presymptomatic carriers had lower poly(GP) levels than 
symptomatic carriers. NfL levels were higher in symptomatic carriers than in presymptom-
atic carriers and healthy non-carriers. NfL was highest in patients with concomitant motor 
neuron disease, and correlated with disease severity and survival. Associations between 
poly(GP) levels and small grey matter regions emerged but did not survive multiple com-
parison correction, while higher NfL levels associated with atrophy in frontotemporopari-
etal cortices and the thalamus. 
Interpretation: This study of C9orf72 expansion carriers reveals that: (1) poly(GP) levels 
discriminate presymptomatic and symptomatic expansion carriers from non-carriers, but 
are not associated with indicators of neurodegeneration; and (2) NfL levels associate with 
grey matter atrophy, disease severity and shorter survival. Together, poly(GP) and NfL show 
promise as complementary biomarkers for clinical trials for C9orf72-associated frontotem-
poral dementia, with poly(GP) as a potential marker for target engagement and NfL as a 
marker of disease activity and progression. 
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Introduction
Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by early 
progressive behavioural and/or language deficits.1,2 Up to 15% of patients with FTD con-
comitantly develop motor neuron disease (MND), and 10-20% of patients with MND de-
velop FTD,3 suggesting that the two disorders lie on a clinical continuum. Pathogenic G4C2 
repeat expansions in chromosome 9 open reading frame 72 (C9orf72) are the most com-
mon genetic cause of autosomal dominant FTD and amyotrophic lateral sclerosis (ALS).4,5 
Potential pathomechanisms include the loss of function of normal C9orf72 protein, and/or 
toxicity resulting from the accumulation of G4C2 transcripts that form RNA foci, interact with 
RNA-binding proteins, and impair RNA processing.6 Expanded G4C2 transcripts also lead to 
the production of five dipeptide repeat (DPR) proteins through repeat-associated non-ATG 
(RAN) translation.7,8 RAN translation of sense transcripts of the repeat produces poly(GA), 
poly(GR) and poly(GP), while RAN translation of antisense repeat transcripts produces 
poly(PA), poly(PR) and poly(GP).  
Although promising drugs for C9orf72 expansions have emerged in preclinical studies, 
biomarkers for evaluating their efficacy have not been adequately assessed in humans. 
Disease-modifying therapies advancing towards clinical trials include antisense oligo-
nucleotides (ASOs) and small molecules that target G4C2 transcripts and consequently 
reduce G4C2 RNA foci and DPR proteins in C9orf72 patient-derived cell models and animal 
models.9–13 In parallel with the rapid development of these potential therapeutics, bio-
markers that measure target engagement, disease onset, and disease progression must be 
established for clinical trials to be successful. Previous studies suggest that poly(GP) is a 
promising marker of target engagement. This protein is detectable in the cerebrospinal fluid 
(CSF) of presymptomatic and symptomatic C9orf72 expansion carriers,10,11,14 and poly(GP) 
levels in CSF from (G4C2)66-expressing mice correlate with ASO-induced decreases in G4C2 
RNA expression, RNA foci burden, and DPR protein levels within their brain.11 In addition, 
neurofilament light chain (NfL) is a potential marker of disease severity and progression for 
ALS, FTD, as well as other neurodegenerative diseases, including Alzheimer’s disease.15–17 
This marker for axonal injury is also increased in symptomatic but not presymptomatic 
C9orf72 expansion carriers, and correlates with prognosis and disease severity in genetic 
FTD.18,19 
Prior studies found that poly(GP) in CSF did not correlate with indicators of disease 
progression or neurodegeneration, yet these studies were largely conducted in patients 
with C9orf72-associated ALS.11,14,20 In addition, no imaging data were available to assess 
potential relationships between CSF poly(GP) and grey matter atrophy. In the present 
study, we investigated the clinical correlates of poly(GP) and NfL levels, and we explored 
associations between these biomarkers and grey matter volume in a large cohort of pre-
symptomatic C9orf72 expansion carriers and patients with C9orf72-associated dementia. 
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Materials and methods
Subjects
We examined CSF from 101 subjects from C9orf72 families, which was collected among 
eight sites (five sites participating in the Genetic FTD Initiative (GENFI), the University of 
California, San Francisco, the VU University Medical Center, and IRCCS Fatebenefratelli; 
Supplementary Table 1). These CSF samples were obtained from 64 patients with dementia 
caused by the C9orf72 repeat expansion (symptomatic carriers), and 37 healthy first-degree 
family members of C9orf72 expansion carriers. The unaffected family members consisted 
of 25 presymptomatic C9orf72 expansion carriers and 12 non-carriers, and clinical inves-
tigators were blinded to mutation status. Family members were defined as unaffected if 
they had an absence of motor deficits, behavioural changes, and cognitive changes, as as-
sessed by neurological examination, neuropsychological testing and structured informant 
interviews (e.g., with a spouse or sibling). The presence of a pathogenic C9orf72 repeat 
expansion, defined as more than 30 repeats,4 was ascertained at the local sites. Symptom-
atic C9orf72 expansion carriers were diagnosed according to criteria for behavioural variant 
FTD (bvFTD, n=47; 9 with concomitant MND)1 or primary progressive aphasia (PPA, n=6; 2 
with concomitant MND)2 at time of inclusion. Subjects with mild cognitive or behavioural 
symptoms who did not meet these diagnostic criteria for FTD were classified as having 
mild impairment (n=9), and were included in the symptomatic carrier group. Among these 
nine subjects with mild symptomatology, seven had behavioural symptoms and two had 
memory symptoms. Lastly, two patients had dementia with a predominant memory pre-
sentation, without known behavioural or motor changes. ALS patients without cognitive 
or behavioural symptoms were not included in the present study because the number of 
available subjects was too small to perform statistical analyses on this subgroup (n=2). Of 
the 101 subjects, 33 were included in our previous study on CSF NfL.18
Age at disease onset was defined as the age when caregivers first noted a behavioural, 
motor or cognitive change, and disease duration was defined as the interval between the 
age at disease onset and CSF collection. Mini-Mental State Examination (MMSE) was used 
to measure global cognition,21 and the Clinical Dementia Rating scale (CDR) was used to 
assess symptom severity.22 All cognitive test scores were collected within 90 days of CSF 
collection. 
Local ethics committees approved the study and all participants (or their legal represen-
tative) provided written informed consent.
CSF analyses
CSF was collected according to standardized local procedures and longitudinal samples 
were available from 10 C9orf72 expansion carriers who remained in the same clinical stage 
(presymptomatic or symptomatic) as when the baseline CSF was collected. Measurements 
of poly(GP) and NfL were performed blinded to clinical information. We performed each 
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biomarker measurement in one laboratory to eliminate variability caused by testing at 
multiple sites. Poly(GP) was measured at the Mayo Clinic in Jacksonville, FL, and NfL was 
measured at the VU University medical center. CSF poly(GP) concentrations were measured 
in duplicate wells using a previously described immunoassay.11 
CSF NfL was measured in duplicate using the enzyme-linked immunosorbent assay of 
Uman Diagnostics (Umeå, Sweden), according to the manufacturer’s instructions. Median 
intra-and interassay coefficient of variation were 1.5% (range 0-11%), and 6.3% (range 
6.1-16.7%) respectively. Two samples had NfL levels that exceeded the upper limit of quan-
tification of the assay (10,000 pg/ml). Since there was insufficient CSF available to measure 
NfL upon the dilution of these samples, they were excluded from the NfL analyses. Among 
the longitudinally collected samples, NfL measurements were not performed on two be-
cause of insufficient CSF volumes. 
For a given clinical subgroup (non-carriers, presymptomatic carriers, and symptomatic 
carriers), CSF NfL and poly(GP) levels did not significantly differ among the different centers 
at which CSF was collected.
MRI acquisition and preprocessing
T1-weighted MRI-images (1,5 or 3 Tesla) captured within 3 months of CSF collection were 
included for imaging analyses (n=72). After excluding poor quality scans (e.g. motion arte-
fact, n=6) and scans from subjects with structural abnormalities (including extensive white 
matter hyperintensities or lacunar infarcts, n=3), scans were available for 63 subjects (11 
non-carriers, 24 presymptomatic carriers, and 28 symptomatic carriers) from 11 different 
scanners across seven sites. The NfL level was unavailable for one symptomatic carrier. 
MRI images were analyzed using two methods: region of interest (ROI) analysis and voxel-
based morphometry (VBM). For ROI analysis, scans were parcellated into brain regions as 
previously described,23 using an atlas propagation and label fusion strategy,24 combin-
ing bilateral ROIs to calculate grey matter cortical (frontal, temporal, parietal, occipital, 
cingulate, insular), subcortical (hippocampus, amygdala, caudate, putamen, thalamus), 
and cerebellar volumes.25,26 Whole brain volumes were calculated by combining all grey 
and white matter regions extracted from the automated brain segmentation method. 
All volumes were expressed as percentage of total intracranial volume (TIV), computed 
with SPM12 (Statistical Parametric Mapping, Wellcome Trust Centre for Neuroimaging, 
London, UK) running under Matlab R2014b (Math Works, Natick, MA, USA).27 For the VBM 
preprocessing, T1 images were normalized using standard spatial normalization in SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/), modulated, corrected for non-linear 
warping, then segmented into grey and white matter images. Grey matter images were 
smoothed using a half-maximum isotropic Gaussian kernel with a size of 8mm full-width 
chosen due to the heterogeneity of scanners in the study. 
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Statistical analysis
Statistical analyses were performed in SPSS 21.0 for Windows (Armonk, NY, USA) and 
graphs were drafted with GraphPad Prism 7 (La Jolla, California, USA). Test statistics were 
considered significant at p<0.05 (two-tailed). Since the poly(GP) concentrations were non-
normally distributed, a log-transformation was applied after adding a constant of 0.1 to all 
values to avoid values of zero. CSF NfL was log-transformed to normalize the data; three 
samples with levels >10,000 pg/ml [all had concomitant MND with either bvFTD (n=2) or 
nonfluent variant PPA (n=1)] continued to skew the data and were therefore set at 10,000 
pg/ml prior to the transformation to allow further parametric analysis. Group comparisons 
of poly(GP) and NfL were first performed by Kruskal-Wallis (with Dunn’s post-hoc tests) 
or Mann-Whitney tests on raw data, followed by ANCOVAs on log-transformed data with 
correction for age and gender. When longitudinal CSF samples were available, only the 
time-point close to MRI or the first time point was used in group comparisons. Area un-
der the curve (AUC) with a 95% confidence interval (CI), obtained by receiver operating 
characteristic analyses, was used to examine diagnostic performance, with optimal cut-off 
levels at the highest (sensitivity+specificity-1). Correlations with age at CSF collection, age 
at disease onset, disease duration and cognitive scores were assessed with Spearman 
correlations on non-transformed data. Survival in patients was compared among tertiles 
of poly(GP) and NfL, by Kaplan-Meier curves and Cox regressions adjusted for age, gender, 
presence of MND and disease duration, with living patients included as censored data. 
The Cox regressions were also performed using poly(GP) or NfL as a continuous variable. 
Although we had a relatively small number of carriers with longitudinal samples (n=10), 
exploratory analyses on poly(GP) and NfL change were undertaken by calculating the an-
nual change [(second concentration – first concentration) / interval between time-points] 
and testing these values against zero using a one-sample Wilcoxon signed rank test. 
All imaging analyses were controlled for age at CSF collection, gender, scanner and TIV. 
Linear regressions were used to explore the associations between transformed poly(GP) 
or NfL and the ROIs. VBM analyses were conducted in SPM12 using subjects’ smoothed, 
modulated grey matter segments. Within SPM’s general linear model framework, we used 
one sample t-test designs in two separate analyses to correlate either log-transformed 
poly(GP) levels or NfL with grey matter volume among all C9orf72 expansion carriers. We 
repeated these correlations between poly(GP) and NfL with grey matter in presymptomatic 
and symptomatic expansion carrier subgroups. Results were regarded as significant at 
p<0.05 family-wise error corrected for multiple comparisons (pfwe). When associations were 
not significant at this threshold, a less stringent threshold of p<0.001 was used. Mean raw 
grey matter intensities were extracted from regions showing significant results at p<0.001 
using the MARSBAR toolbox for SPM8,28 and plotted against poly(GP) and NfL concentra-
tions for visualization purposes. 
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Results
Demographic and clinical data
In total, 64 symptomatic C9orf72 repeat expansion carriers, 25 presymptomatic expansion 
carriers, and 12 healthy non-carriers were included in our study (Table 1). The clinical 
phenotypes of the symptomatic carriers were: bvFTD (n=38), bvFTD-MND (n=9), subjects 
with mild impairment (n=9), PPA [n=6; four nonfluent variant PPA (two had concomitant 
MND), one with semantic variant PPA, and one with logopenic variant PPA], and dementia 
with a memory presentation (n=2). For presymptomatic carriers, the clinical diagnoses of 
affected family members included: dementia only (n=16), dementia and/or MND (n=8) or 
MND only (n=1). As expected, symptomatic carriers were older, performed worse on the 
MMSE, and had higher CDR sum of boxes (CDR-SB) scores compared to both non-carriers 
and presymptomatic carriers (Table 1). The median age at disease onset in symptomatic 
carriers was 56 years but varied widely (17-76 years). The median disease duration at CSF 
collection was 2.8 years. Twenty-four symptomatic carriers died during follow-up with a 
median survival of 2.1 years after CSF collection (IQR 1.0–4.2); the median follow-up inter-
val of patients living at follow up was 2.8 years (IQR 1.2–4.5). 
Table 1. Demographic, clinical and biochemical characteristics of non‑carriers, presymptomatic 
and symptomatic C9orf72 repeat expansion carriers
  Non-carriers, 
n=12
presymptomatic carriers, 
n=25
Symptomatic carriers, 
n=64
p-value
Male : female, n 7 : 5 8 : 17 35 : 29 0.13
age at CSF collection, years 
(IQR)
44 (34-53) 47 (41-57) 60 (55-66)a <0.001
age at onset, years (range) n/a n/a 56 (17-76) n/a
Disease duration, years 
(range)
n/a n/a 2.8 (0.5-28.9) n/a
Concomitant MND, n n/a n/a 11 n/a
MMSE	(IQR) 30 (28-30) 29 (29-30) 25 (22-28)b <0.001
CDrc	(IQR) 0 (0-0) 0 (0-0) 1 (0.5-1)a <0.001
CDr-SBd	(IQR) 0 (0-0) 0 (0-0) 6 (3-8)a <0.001
CSF	Poly(GP),	ng/ml	(IQR) 0.00 (0.00-0.00) 0.75 (0.33-1.50)e 1.44 (0.49-2.51)e <0.001
CSF NfLf,	pg/ml	(IQR) 333 (212-536) 429 (336-830) 1885 (848-2841)a <0.001
MRI	available,	n 11 24 28 n/a
Medians	are	displayed	for	continuous	variables,	with	according	IQRs	unless	otherwise	specified.
ahigher than non-carriers and presymptomatic C9orf72 expansion carriers, blower than in non-carriers and pre-
symptomatic C9orf72 expansion carriers, cavailable in 9 non-carriers, 18 presymptomatic C9orf72 expansion car-
riers and 32 symptomatic carriers, davailable in 9 non-carriers, 18 presymptomatic and 28 symptomatic C9orf72 
expansion carriers, ehigher than in non-carriers, favailable in 12 non-carriers, 25 presymptomatic and 62 symp-
tomatic C9orf72	repeat	expansion	carriers.	CSF:	cerebrospinal	fluid;	IQR:	interquartile	range;	MND:	motor	neuron	
disease;	MRI:	magnetic	resonance	imaging;	n/a:	not	applicable;	NfL:	neurofilament	light	chain.
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Figure 1. poly(Gp) and NfL levels by clinical stage and diagnosis. (a) poly(Gp) levels were higher in 
presymptomatic and symptomatic C9orf72 expansion carriers than in healthy non-carriers, and higher in 
symptomatic carriers than in presymptomatic carriers after correction for age and gender. (B) poly(Gp) 
levels did not differ between different diagnoses. (C) NfL levels were elevated in symptomatic C9orf72 repeat 
expansion carriers when compared to non-carriers and presymptomatic carriers. (D) NfL levels were highest in 
symptomatic carriers with concomitant MND.
patients with concomitant MND at CSF collection are displayed as orange filled squares, those who developed 
MND after collection are displayed as blue filled triangles. horizontal lines represent group medians. P-values 
from	the	ANCOVA	analyses	are	displayed	(corrected	for	age	and	gender)	as	follows:	*: p≤0.05; **: p≤0.01; ***: 
p≤0.001; ns: not significant. 
bvFtD: behavioural variant frontotemporal dementia; CSF: cerebrospinal fluid; MND: motor neuron disease; 
NfL: neurofilament light chain; ppa: primary progressive aphasia.
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Poly(GP) levels
C9orf72 expansion carriers had higher poly(GP) levels than non-carriers (p<0.001, Figure 
1A), which discriminated carriers from non-carriers with high accuracy (AUC 0.98, p<0.001), 
with a specificity of 100%, and a sensitivity of 96.6% (cut-off of > 0.00 ng/ml, three expan-
sion carriers fell below this cut-off). Poly(GP) levels trended higher in symptomatic carriers 
compared to presymptomatic carriers (p=0.10), and this observation became statistically 
significant upon correction for age and gender (post-hoc Bonferroni corrected p=0.04). 
Poly(GP) levels did not differ between males and females, among presymptomatic carri-
ers grouped by their relatives’ diagnoses, among clinical diagnoses of the symptomatic 
carriers, nor between patients with or without concomitant MND (Figure 1A and 1B). No 
significant associations were found between poly(GP) and age at CSF collection, age at 
disease onset, disease duration at time of CSF collection, MMSE, CDR, or CDR-SB. No as-
sociation between poly(GP) and survival was found. 
In our exploratory longitudinal analysis of 10 C9orf72 expansion carriers, a modest but 
significant increase in poly(GP) was observed, and this was especially evident in the four 
presymptomatic carriers (p=0.03, Figure 2A). The median annual change in poly(GP) was 
0.04 ng/ml, and the median time between the first and second samples was two years 
(range 1.0-5.4 years).
NfL levels
CSF NfL levels were significantly higher in symptomatic carriers than in presymptomatic 
carriers and non-carriers (both p<0.001, Figure 1C, Table 1), and did not differ between the 
latter two groups. High CSF NfL levels differentiated symptomatic from presymptomatic 
carriers with a specificity of 96.0% and sensitivity of 65.4% (cut-off at 1169 pg/ml, AUC 0.89, 
p<0.001). Patients with concomitant MND at the time of CSF collection had higher NfL levels 
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Figure 2. Longitudinal CSF poly(Gp) and NfL levels. Longitudinal poly(Gp) (a), but not NfL levels (B), 
increased significantly over time (p=0.03 and p=0.89, respectively) in presymptomatic (purple circles and 
connecting lines) and symptomatic (blue squares with connecting lines) C9orf72 repeat expansion carriers. 
CSF: cerebrospinal fluid; NfL: neurofilament light chain.
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(median 5468 pg/ml) than those without concomitant MND (median 1819 pg/ml, p=0.001, 
Figure 1C and 1D). NfL did not differ between males and females, but did correlate with 
age in the total group and in each subgroup (entire cohort rs=0.60, p<0.001, carriers rs=0.53, 
p<0.001). NfL did not correlate with age at onset or disease duration at CSF collection, 
but negatively correlated with MMSE, and positively correlated with CDR and CDR-SB in all 
carriers combined (MMSE rs=-0.57, p<0.001, CDR rs=0.73, p<0.001, CDR-SB rs=0.72, p<0.001), 
and in symptomatic carriers after stratification into presymptomatic versus symptomatic 
stage (MMSE rs=-0.42, p=0.01, CDR rs=0.39, p=0.03, CDR-SB rs=0.43, p=0.03). High NfL levels 
associated with a poorer prognosis in terms of survival [Figure 3A, hazard ratio on NfL 
tertiles of 4.2 (95% CI 2.0-8.6), p<0.001].
NfL did not correlate with poly(GP) in all carriers combined (p=0.33, Figure 3B), nor in 
presymptomatic or symptomatic carriers separately (p=0.58 and p=0.85 respectively). In 
an exploratory longitudinal analysis, NfL levels increased over time in some individuals 
but decreased in others, resulting in no significant longitudinal change at the group level 
(p=0.89, n=8, Figure 2B). The different trajectories were not explained by evident differences 
in clinical characteristics.
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Figure 3. NfL predicts survival, does not correlate with poly(GP), and negatively correlates with 
frontal cortical volume. 
(a) Kaplan-Meier curve representing survival of symptomatic C9orf72 expansion carriers based on NfL levels; 
NfL levels were stratified into lowest (orange upper line), middle (blue middle line) and highest (purple lower 
line) tertiles; vertical ticks represent living patients censored at the date the patient was last known to be alive. 
patients in the highest NfL tertile had the shortest survival. (B) NfL does not correlate with poly(Gp) in pre-
symptomatic (purple circles) or symptomatic (blue squares) C9orf72 expansion carriers, and (C) higher NfL levels 
significantly associated with lower frontal cortical volumes across presymptomatic (purple circles) and symp-
tomatic (blue squares) C9orf72	expansion	carriers	combined	(ROI	analysis).	
CSF:	cerebrospinal	fluid;	NfL:	neurofilament	light	chain;	ROI:	region	of	interest;	TIV:	total	intracranial	volume.
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Table 2. Associations between poly(GP) or NfL and grey matter regions of interest in C9orf72 expan‑
sion carriers
  poly(Gp) NfL
ROI  
all 
carriers, 
n=52
presymptomatic 
carriers, n=24
Symptomatic 
carriers, n=28
all 
carriers, 
n=51
presymptomatic 
carriers, n=24
Symptomatic 
carriers, n=27
Whole brain β -0.11 -0.22 -0.09 0.19 -0.22 0.38
p 0.52 0.35 0.73 0.41 0.54 0.21
Frontal β -0.25 -0.35 -0.17 -0.60 -0.28 -0.70
p 0.045 0.10 0.48 <0.001a 0.38 <0.001a
temporal β -0.20 -0.49 -0.02 -0.42 -0.45 -0.19
p 0.12 0.02 0.92 0.01 0.17 0.43
parietal β -0.16 -0.08 -0.06 -0.43 -0.40 -0.35
p 0.24 0.69 0.78 0.01 0.17 0.12
Occipital β -0.19 0.07 -0.18 -0.32 0.06 -0.34
p 0.19 0.73 0.38 0.09 0.84 0.14
Cingulate β -0.31 -0.05 -0.51 -0.07 0.04 -0.07
p 0.02 0.81 0.02 0.69 0.88 0.79
Insula β 0.01 -0.07 0.09 -0.15 -0.02 -0.13
p 0.97 0.76 0.63 0.31 0.94 0.53
Cerebellum β -0.19 -0.31 -0.01 0.04 -0.36 0.32
p 0.24 0.19 0.98 0.87 0.30 0.26
hippocampus β -0.02 -0.23 -0.01 0.03 0.10 -0.05
p 0.87 0.35 0.97 0.97 0.80 0.83
amygdala β -0.23 -0.24 -0.88 -0.35 0.10 -0.32
p 0.15 0.29 0.39 0.10 0.77 0.28
Caudate nuclei β -0.25 -0.35 -0.23 -0.10 -0.21 -0.27
p 0.07 0.05 0.30 0.62 0.45 0.30
putamen β -0.24 -0.12 -0.31 -0.33 -0.27 -0.41
p 0.06 0.62 0.11 0.05 0.53 0.06
thalamus β -0.08 -0.09 -0.16 -0.02 0.05 0.07
p 0.52 0.68 0.49 0.91 0.89 0.95
associations between poly(Gp) (first three columns) and NfL (last three columns) concentrations and 
different	brain	and	grey	matter	ROIs	in	C9orf72 repeat expansion carriers, by means of linear regression 
corrected for age, gender and scanner. P-values below 0.05 are bolded.
asignificant after correction for multiple testing (Bonferroni corrected p -value: p<0.004).
NfL:	neurofilament	light	chain,	ROI:	region	of	interest
Imaging associations
Associations of poly(GP) with grey matter volume: Although none of the correlations 
between grey matter volume and poly(GP) reached significance when corrected for 
multiple comparisons, trends of interest were noted. Across all C9orf72 expansion carriers 
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combined, higher levels of poly(GP) trended with lower frontal and cingulate grey matter 
volumes from the ROI analysis (Table 2); this trend remained after excluding FTD-patients 
with concomitant MND. The voxel-wise grey matter analysis showed poly(GP) tended to 
associate with regions of bilateral dorsomedial prefrontal and medial frontal cortices and 
lateral temporal cortex at p<0.001 (Figure 4A, Supplementary Table 2). Within these grey 
matter regions, bvFTD-MND and bvFTD showed the lowest grey matter intensities (Figure 
4B). For the presymptomatic carriers, higher poly(GP) levels tended to associate with lower 
temporal ROI volume (Table 2), and lower volume in medial prefrontal cortex and scattered 
Figure 4. Voxel‑wise associations of grey matter deficits with higher poly(GP) levels. 
(a) Cross-sectionally, regions in bilateral dorsolateral prefrontal and medial frontal cortices, and lateral tempo-
ral cortex showed lower grey matter volume associated with higher poly(Gp) levels in the voxel-wise analysis 
of C9orf72 repeat expansion carriers. Significant clusters were defined at a t-threshold of p<0.001 uncorrected, 
no significant clusters were found at pfwe<0.05. Color bars represent t-scores, and statistical maps are super-
imposed	on	the	Montreal	Neurological	 Institute	template	brain.	The	left	side	of	the	axial	and	coronal	 images	
corresponds to the left (L) side of the brain. (B) Mean grey matter intensity versus log-transformed poly(Gp) 
within the p<0.001 map in (a), for 24 presymptomatic C9orf72 expansion carriers (grey dots), 4 mild impairment 
(orange dots), 17 bvFtD (pink dots), 5 bvFtD-MND (green dots), and 1 ppa (purple dot) plotted for visualization 
purposes	only.	In	general,	FTD-MND	showed	the	lowest	grey	matter	intensities	compared	to	the	other	diagnostic	
groups. (C) For presymptomatic carriers, grey matter volume was negatively correlated with poly(Gp) in medial 
prefrontal cortex and scattered regions within lateral temporal cortices. (D) For symptomatic carriers, a small 
dorsomedial frontal cluster showed lower grey matter volume associated with higher poly(Gp) levels. bvFtD: 
behavioural variant frontotemporal dementia; fwe: family-wise error correction; MND: motor neuron disease; 
ppa: primary progressive aphasia.
141
Chapter 3.2  |  poly(gp) and nfl In c9orf72 expansIon carrIers
Ch
ap
te
r 3
regions within lateral temporal cortices in the VBM analysis (p<0.001, Figure 4C, Supple-
mentary Table 2). For symptomatic carriers, higher poly(GP) levels trended with lower 
cingulate grey matter ROI volume (Table 2), and with lower volume in a small dorsomedial 
frontal cluster in the VBM analysis (p<0.001, Figure 4D). 
Associations of NfL levels with grey matter volume: Higher CSF NfL levels were associated 
with lower frontal (Figure 3C), temporal and parietal ROI grey matter volumes in all carriers 
combined, but the latter two ROIs did not survive multiple comparisons correction (Table 
2). In the VBM analysis, higher NFL levels were associated with lower grey matter volumes 
in the ventral and dorsomedial prefrontal cortex, ventral and dorsal insula, anterior cingu-
late, caudate, medial thalamus, and several other frontotemporoparietal regions (p<0.001, 
Figure 5A and 5B, Supplementary Table 2). At pfwe<0.05, higher NfL levels were associated 
with lower grey matter volume in small regions of dorsolateral prefrontal cortex, dorsal 
posterior insula, and the left caudate. In a subgroup analysis of presymptomatic carriers 
only, no significant correlations between grey matter ROIs and NfL emerged, and voxel-
wise, NfL levels correlated with grey matter deficits in the inferior and middle frontal gyrus, 
pre-and post-central gyrus, operculum, superior temporal gyrus, lateral parietal regions, 
and the caudate only at p<0.001 (Figure 5C, Supplementary Table 2) with no significant 
regions at pfwe<0.05. For symptomatic carriers, NfL significantly correlated with frontal 
cortex in the ROI analysis, and the VBM showed associations with bilateral dorsolateral 
prefrontal cortex, anterior and mid cingulate cortex, dorsal insula, pre-and post-central 
gyrus, medial parietal regions and the caudate (p<0.001, Figure 5D), with no significant 
regions at pfwe<0.05.  
Discussion 
In this study, CSF poly(GP), NfL and grey matter volumes were determined in a cohort of 
89 C9orf72 repeat expansion carriers to examine associations among these measures. 
Poly(GP) was detected in CSF of both presymptomatic and symptomatic C9orf72 expan-
sion carriers, and not detected in non-carriers. In contrast, we found high NfL levels exclu-
sively in symptomatic carriers, while levels in presymptomatic carriers remained similar to 
healthy non-carriers. Higher NfL levels correlated with greater disease severity as well as 
shorter survival. In addition, higher NfL levels associated with lower grey matter volumes in 
regions known to show smaller grey matter volume in presymptomatic and symptomatic 
carriers, but for poly(GP), only trends were observed. As such, CSF NfL and complementary 
biomarkers for disease detection and future treatment monitoring.
Poly(GP) is a highly sensitive and specific biomarker for C9orf72 expansion carriers
We showed that CSF poly(GP) has high power to differentiate C9orf72 expansion carriers 
and non-carriers, consistent with previous reports.10,11,14 Interestingly, poly(GP) levels were 
undetectable in three C9orf72 expansion carriers, who had various clinical presentations, 
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including a presymptomatic individual, a bvFTD patient, and a PPA patient. Future stud-
ies may inform whether alternative detection strategies with increased sensitivity would 
detect poly(GP) in these individuals, or whether their poly(GP) levels are truly negligible. 
Should post-mortem tissue become available for these individuals and others, it would be 
of particular interest to evaluate how CSF poly(GP) levels compare to the frequency of DPR 
protein pathology and levels of repeat-containing transcripts in the brain. As in previous 
studies,11,14 we found that poly(GP) was detectable in CSF from presymptomatic C9orf72 
expansion carriers, suggesting that DPR protein production emerges prior to neurodegen-
eration and that poly(GP) can be actively released from putatively healthy neurons. This 
notion is supported by in vitro experiments that show that DPR proteins are secreted from 
Figure 5. Voxel-wise associations of grey matter deficits with higher NfL levels. (a) Widespread regions 
including ventral and dorsomedial prefrontal cortex, ventral and dorsal insula, anterior cingulate, caudate, 
and medial thalamus showed lower grey matter volume (voxel-wise analysis) associated with higher NfL 
levels. Significant clusters were defined at a t-threshold of p<0.001 uncorrected (blue-green colored) and 
pfwe<0.05 (red colored). Color bars represent t-scores, and statistical maps are superimposed on the Montreal 
Neurological	Institute	template	brain.	The	left	side	of	the	axial	and	coronal	images	corresponds	to	the	left	(L)	
side of the brain. (B) Mean grey matter intensity versus log-transformed NfL levels within the p<0.001 map 
in (a), for 24 presymptomatic C9orf72 expansion carriers (grey dots), 4 mild impairment (orange dots), 17 
bvFtD (pink dots), 4 bvFtD-MND (green dots), and 1 ppa (purple dot) plotted for visualization purposes only. 
Both presymptomatic (C) and symptomatic carriers (D) show associations of NfL with grey matter atrophy in 
bilateral dorsolateral prefrontal cortex, parietal regions and caudate. Symptomatic carriers (D) additionally 
show grey matter atrophy associated with NfL in key hubs targeted in bvFtD, including anterior and mid 
cingulate cortex and insula. 
bvFtD: behavioural variant frontotemporal dementia; fwe: family-wise error correction; MND: motor neuron 
disease; NfL: neurofilament light chain; ppa: primary progressive aphasia.
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cultured cells.11,29 Reports of autopsy studies in C9orf72-patients have also described wide-
spread DPR protein pathology prior to the formation of TDP-43 inclusions and neuronal 
loss.30–32 These studies provide converging evidence that poly(GP) expression arises early 
in the lifespan of C9orf72 expansion carriers. 
Poly(GP) levels are higher in symptomatic C9orf72 expansion carriers compared to 
presymptomatic carriers
Symptomatic carriers had higher poly(GP) levels compared to presymptomatic car-
riers after correcting for age and gender. In parallel, we found a modest increase of CSF 
poly(GP) over time in a small subset of 10 C9orf72 expansion carriers, most frequently in 
the presymptomatic subjects. In contrast, other studies had not identified a significant dif-
ference in poly(GP) levels between presymptomatic and symptomatic carriers,11,14 nor an 
increase in poly(GP) levels over time.11 The time interval between repeated CSF collections 
was longer in the present exploratory analysis, suggesting that changes in poly(GP) might 
only emerge over longer periods. Measuring poly(GP) in larger cohorts over extended time 
periods as individuals convert from the presymptomatic to symptomatic phase will further 
help elucidate the temporal trajectory of poly(GP), and whether levels change relative to 
symptom onset.
We found that poly(GP) levels did not differ among clinical phenotypes, and did not 
correlate with age at disease onset or survival. Although there is a possibility of a type II 
error (i.e., a false-negative association) given that several clinical subgroups had a small 
sample size, these data are in line with the lack of associations between clinical pheno-
types and other C9orf72-associated features, such as repeat size and RNA foci burden.33,34 
While we were unable to examine correlations between CSF poly(GP) and repeat length 
in blood because repeat length data were not available, such an analysis would likely be 
complicated given the substantial variation of repeat sizes among various tissues from 
the same individual.33 Furthermore, a previous study has shown no association between 
CSF poly(GP) and repeat length in blood,14 and we observed no association between 
poly(GP) levels in the cerebellum or frontal cortex and repeat length in these regions.35 
Nonetheless, examining associations between antemortem CSF poly(GP) and repeat size, 
poly(GP) levels, and levels of other DPR proteins in various neuroanatomical regions will be 
of interest when postmortem tissue becomes available from a suitable number of cases. 
Also, as arginine-containing DPR proteins, poly(GR) and poly(PR), are considered to be 
highly toxic,6 it is possible that elevated levels of these DPR proteins may correlate with 
clinical features and measures of neurodegeneration. The development of immunoassays 
quantifying these proteins remains technically challenging, but may lead to more insights 
into C9orf72 disease mechanisms.
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NfL is normal in presymptomatic C9orf72 expansion carriers and is elevated in 
symptomatic carriers
Determining symptom onset in C9orf72 repeat expansion carriers is notoriously challeng-
ing. Presymptomatic carriers have a high incidence of psychiatric symptoms overlapping 
with bvFTD symptomatology,36 and some carriers have a mild, slowly progressive pro-
dromal phase spanning several decades.37 Consequently, surrogate endpoints reflecting 
neurodegeneration are critical for assessing disease onset and the efficacy of therapeutic 
interventions. Our data show that NfL is elevated during the symptomatic phase of 
C9orf72-associated dementia and correlate with indicators of disease severity (i.e., MMSE, 
CDR, and CDR-SB), survival and grey matter atrophy, consistent with other studies of NfL in 
sporadic and genetic FTD.18,38,39 In mouse models, NfL also correlates with disease severity, 
specifically with the burden of α-synuclein, tau, or β-amyloid inclusions, and NfL levels 
are attenuated with treatment.40 Thus, NfL could be utilized in clinical trials to stratify 
patients into more homogeneous groups with respect to disease severity and to assess the 
neuroprotective effect of therapeutic interventions. Furthermore, the strong association 
between CSF NfL and survival supports the use of NfL as prognostic marker. NfL can now be 
reliably measured in serum and plasma, which is collected less invasively than CSF, making 
it promising for clinical use, especially when frequent measures are needed.17,18,41
Our small longitudinal study of CSF NfL levels did not show consistent changes over 
the time intervals assessed. Previous studies on ALS patients reported stable NfL levels, 
but showed an increase over time for a subset of patients with a rapid disease progres-
sion.17,42,43 Serum NfL levels have also been shown to progressively increase in sporadic 
PPA patients.44 The discrepancy between our and previous findings could be attributable 
to the small size of our longitudinal cohort, and the range of clinical phenotypes and dis-
ease durations among individuals at the time of sample collection. Given that the rate of 
neurodegeneration can differ not only throughout the course of disease but also among 
patients, additional longitudinal studies on larger cohorts of C9orf72 expansion carriers are 
needed to fully understand the temporal trajectory of NfL in relation to clinical changes.
Relationships between poly(GP) and indicators of neurodegeneration 
The present study did not show a significant relationship between poly(GP) levels and indi-
cators of neurodegeneration, as reflected by NfL levels and grey matter volumes. Similarly, 
previous studies show no correlation between poly(GP) and NfL,14 nor neurofilament heavy 
chain (a different neurofilament subunit) in C9orf72-associated ALS.20 Because previous 
studies have shown lower grey matter volumes in both presymptomatic and symptomatic 
carriers compared to controls,23,36,45,46 we had hypothesized that higher levels of poly(GP) 
might be associated with lower grey matter volumes in C9orf72-targeted regions. We found 
a trend toward higher poly(GP) with lower frontal and cingulate volume in our ROI analysis. 
In parallel with the ROI analysis, the voxel-wise analysis showed that certain sparse regions 
of lower grey matter volumes tended to associate with higher poly(GP), which included 
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regions in the bilateral dorsolateral prefrontal, medial frontal, and lateral temporal corti-
ces. Although higher poly(GP) levels showed a relatively weak association with lower grey 
matter volumes in our analyses, the regions identified include those atrophied in C9orf72-
associated FTD patients,45,47–49 and show reduced volume in presymptomatic C9orf72 
expansion carriers.23,36 
Interestingly, our subgroup analysis of presymptomatic carriers showed a trend for as-
sociation between higher poly(GP) and reduced bilateral medial orbitofrontal cortex, but 
symptomatic carriers showed only sparse regions that trended towards an association with 
high poly(GP). One potential explanation for this result is that DPR accumulation may arise 
focally during the presymptomatic phase and become widespread during the symptom-
atic phase, thus attenuating any potential relationship between grey matter atrophy and 
poly(GP) during the symptomatic phase. Overall, our results suggest that higher poly(GP) 
levels may be associated with some key foci in C9orf72-associated regions, particularly for 
presymptomatic carriers, but poly(GP) levels are not a marker for neurodegeneration per 
se. 
Higher NfL levels are associated with grey matter deficits 
Elevated NfL levels were associated with lower grey matter volume based on both types 
of analysis. These data reveal vulnerable neuroanatomical structures during the pre-
symptomatic and symptomatic stages, which include ventral and dorsomedial prefrontal 
cortex, ventral and dorsal insula, anterior cingulate, caudate, and the medial thalamus. 
These regions are highly anatomically congruent with atrophy patterns found in C9orf72-
associated frontotemporal dementia.45,47–50 Notably, several studies confirmed that the 
medial thalamus is a region affected across C9orf72 expansion carriers,50 even during the 
presymptomatic phase.23,36,46 Interestingly, our subgroup analysis of presymptomatic carri-
ers showed that higher NfL levels were associated with smaller bilateral frontoparietal and 
caudate volumes, which may indicate that these regions are among the earliest regions 
of neurodegeneration, but longitudinal presymptomatic studies are needed to test this 
hypothesis.
Conclusion
The strength of the present study is the use of a multimodal approach combining two CSF 
biomarkers with quantitative structural imaging metrics to investigate the relationship 
between poly(GP) and indicators of neurodegeneration in a large cohort of presymptom-
atic and symptomatic C9orf72 expansion carriers. To the best of our knowledge, this is the 
largest study thus far on poly(GP) in C9orf72-associated FTD, and the first in examining 
associations between DPR protein levels and grey matter volume. We used two neuroim-
aging methods: ROI analyses, the metrics of which are reliable and can be readily analyzed 
by clinical groups, and voxel-wise analyses which can refine grey matter deficits in a more 
granular fashion. We show that poly(GP) and NfL are promising complementary biomark-
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ers that capture the effects of the C9orf72 repeat expansion during different phases, and 
demonstrate different relationships with grey matter volume. While poly(GP) may display 
less utility as a prognostic or staging biomarker, it shows great promise as a pharmacody-
namic biomarker for therapeutic approaches that target G4C2 RNA in preclinical models.11 
Importantly, poly(GP) levels are detectable in presymptomatic carriers and would thus 
make the inclusion of this population in clinical trials more feasible. Because NfL reflects 
neurodegeneration and is associated with grey matter atrophy, it will be most useful for 
monitoring disease severity, and predicting disease progression and survival. 
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Supplementary material
Supplementary Table 1. Number of subjects per site.
Site Non-carriers presymptomatic carriers Symptomatic carriers
Karolinska	Institutet,	Stockholm 3 6 19
University of California, San Francisco 0 6 20
erasmus Medical Center, rotterdam 7 9 7
hospital Clinic Barcelona 2 3 5
University of Milan 0 0 7
VU	University	Medical	Center,	Amsterdam 0 0 4
IRCCS	Fatebenefratelli,	Brescia 0 0 2
Université Laval 0 1 0
Supplementary Table 2. Negative correlations between grey matter volume and poly(GP) or NfL for 
all, presymptomatic and symptomatic C9orf72 repeat expansion carriers – peak voxel regions from 
the voxel‑based morphometry analysis.
region Containing peak voxel Ba x,y,z t
# of 
voxels
at 
p<0.001
at 
pfwe<0.05
Grey matter versus poly(Gp) in all C9orf72 expansion carriers
L Middle Frontal Gyrus 9 -28,33,46 5.62 417 X
r Middle temporal Gyrus 21 66,0,-15 4.64 349 X
r Superior Frontal Gyrus 8 32,8,64 4.27 118 X
R	Inferior	Occipital	Gyrus 17 26,-100,-4 4.26 152 X
r Superior parietal Gyrus 5 20,-50,68 4.25 34 X
L Middle temporal Gyrus 21 -57,-3,-18 4.18 205 X
r Superior Frontal Gyrus 6 20,-4,69 4.15 99 X
r Mid Cingulate Cortex 32 2,21,42 4.02 187 X
r Superior Frontal Gyrus, medial 9 3,39,38 3.97 88 X
L Superior Frontal Gyrus 8 -15,33,58 3.93 23 X
L precuneus n/a -12,-44,51 3.92 64 X
L Superior temporal Gyrus 22 -63,-9,6 3.88 38 X
L Middle temporal Gyrus 21 -66,-24,-6 3.85 44 X
r Superior Frontal Gyrus, medial 10 6,75,3 3.73 23 X
r Superior Frontal Gyrus 8 14,33,58 3.69 24 X
L Superior Frontal Gyrus, medial orbital 10 -2,66,-2 3.59 21 X
L Superior Frontal Gyrus 6 -21,4,57 3.57 21 X
Grey matter versus poly(Gp) in presymptomatic C9orf72 expansion carriers
L Middle Frontal Gyrus, orbital 11 -21,64,-12 8.76 372 X
L Superior Frontal Gyrus. orbital 10 -2,56,-4 7.91 1142 X
r Middle temporal Gyrus 21 64,-10,-12 6.27 120 X
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Supplementary Table 2. Negative correlations between grey matter volume and poly(GP) or NfL for 
all, presymptomatic and symptomatic C9orf72 repeat expansion carriers – peak voxel regions from 
the voxel‑based morphometry analysis. (continued)
region Containing peak voxel Ba x,y,z t
# of 
voxels
at 
p<0.001
at 
pfwe<0.05
L Middle temporal Gyrus 21 -69,-34,-14 5.91 133 X
r thalamus n/a 12,-4,15 5.45 23 X
L Middle temporal Gyrus 21 -64,-9,-18 5.38 36 X
r Middle temporal pole 38 57,16,-26 5.30 106 X
L Mid Cingulate Cortex n/a -16,-34,45 5.27 109 X
r precentral Gyrus 4 46,-9,60 5.16 36 X
r Superior Frontal Gyrus, medial 10 3,60,10 5.15 153 X
L Middle Frontal Gyrus 9 -34,32,45 4.98 101 X
r Superior Frontal Gyus, orbital 11 16,64,-14 4.96 75 X
L Calcarine Fissure and surrounding cortex 17 -4,-57,8 4.85 92 X
L precentral Gyrus 6 -52,10,46 4.77 56 X
L Superior temporal Gyrus 21 -57,2,-12 4.61 63 X
L Middle temporal Gyrus 21 -58,4,-33 4.52 48 X
L Middle Frontal Gyrus 10 -32,64,9 4.31 36 X
r Middle temporal pole 21 57,3,-16 4.24 36 X
r Middle Frontal Gyrus, orbital 10 34,62,-2 4.06 32 X
Grey matter versus poly(Gp) in symptomatic C9orf72 expansion carriers
r Superior Frontal Gyrus, medial 8 12,33,56 5.11 47 X
Grey matter versus NfL in all C9orf72 expansion carriers
L Middle Frontal Gyrus 6 -24,2,57 8.84 1603 X X
R	Insula 48 44,-6,10 6.83 36960 X X
R	Inferior	Frontal	Gyrus 48 45,14,26 6.81 77 X X
r Caudate Nucleus n/a 9,10,12 6.16 1167 X X
r Middle Frontal Gyrus 8 28,4,56 6.01 2491 X X
L Caudate Nucleus 25 -9,10,12 5.82 1177 X
r anterior Cingulate and paracingulate Gyri 32 2,46,21 5.78 7937 X
r Middle Frontal Gyrus, orbital 47 34,39,-12 5.43 542 X
r Calcarine Fissure and surrounding cortex 17 21,-56,8 5.38 1220 X
r precuneus 7 14,-64,63 5.04 515 X
L Middle Frontal Gyrus 46 -36,33,38 4.98 690 X
L Middle Frontal Gyrus 46 -42,48,8 4.92 1259 X
L Lingual Gyrus 18 -10,-58,3 4.81 835 X
L Frontal Middle Gyrus, orbital 11 -26,34,-14 4.60 402 X
L Supplementary Motor area 6 -3,-6,66 4.57 269 X
r Lingual Gyrus 17 2,-72,-2 4.54 639 X
r Superior Frontal Gyrus, dorsolateral 11 16,66,20 4.43 197 X
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Supplementary Table 2. Negative correlations between grey matter volume and poly(GP) or NfL for 
all, presymptomatic and symptomatic C9orf72 repeat expansion carriers – peak voxel regions from 
the voxel‑based morphometry analysis. (continued)
region Containing peak voxel Ba x,y,z t
# of 
voxels
at 
p<0.001
at 
pfwe<0.05
R	Inferior	Frontal	Gyrus,	orbital 47 46,48,-8 4.34 608 X
L Fusiform Gyrus 30 -15,-32,-15 4.30 124 X
L hippocampus 37 -34,-33,-8 4.25 101 X
L	Inferior	Occipital	Gyrus 19 -50,-72,-8 4.24 89 X
R	Inferior	Temporal	Gyrus 20 39,6,-45 4.15 88 X
r Lenticular Nucleus, putamen 11 20,12,-2 4.14 220 X
r hippocampus 37 30,-36,0 4.11 64 X
L Supramarginal Gyrus 42 -58,-45,26 4.09 47 X
L Middle temporal Gyrus 37 -48,-64,12 3.99 43 X
L Superior Frontal Gyrus, medial orbital 11 -6,68,-6 3.97 87 X
L Middle temporal Gyrus 21 -54,-58,21 3.95 45 X
L Superior parietal Gyrus 1 -24,-45,70 3.94 268 X
r temporal pole, Middle temporal Gyrus 20 39,15,-40 3.92 64 X
r Superior Frontal Gyrus, dorsolateral 6 21,-6,70 3.84 58 X
L postcentral Gyrus 4 -38,-33,68 3.82 58 X
L Fusiform Gyrus 20 -36,-18,-33 3.80 39 X
R	Inferior	Temporal	Gyrus 37 50,-54,-22 3.72 35 X
r Supplementary Motor area 6 16,6,69 3.69 37 X
L Caudate Nucleus 25 0,9,3 3.68 26 X
L Lenticular Nucleus, putamen n/a -21,4,6 3.65 44 X
L Calcarine Fissure and surrounding cortex 27 -10,-46,58 3.61 25 X
r Middle Frontal Gyrus, orbital 11 22,64,-12 3.60 35 X
r Gyrus rectus 11 6,42,-28 3.54 74 X
r precuneus 5 4,-38,56 3.54 34 X
L	Inferior	Frontal	Gyrus,	triangular	part 45 -56,38,2 3.46 54 X
Grey matter versus NfL in presymptomatic C9orf72 expansion carriers
L	Inferior	Frontal	Gyrus,	triangular	part 45 -57,27,10 9.94 244 X X
R	Inferior	Frontal	Gyrus 44 58,12,24 8.11 1524 X
L Lenticular Nucleus, putamen 48 -30,0,60 8.04 488 X
r Superior temporal Gyrus 21 68,-27,10 7.75 282 X
L Supplementary Motor area 6 -10,3,70 6.97 406 X
L postcentral Gyrus 43 -63,-10,21 6.86 646 X
L Middle temporal Gyrus 22 -64,-12,-3 6.65 76 X
L angular Gyrus 39 -48,-57,42 6.44 572 X
r Caudate Nucleus n/a 15,14,14 6.38 407 X
r Superior Frontal Gyrus, medial 9 6,54,36 6.29 346 X
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Supplementary Table 2. Negative correlations between grey matter volume and poly(GP) or NfL for 
all, presymptomatic and symptomatic C9orf72 repeat expansion carriers – peak voxel regions from 
the voxel‑based morphometry analysis. (continued)
region Containing peak voxel Ba x,y,z t
# of 
voxels
at 
p<0.001
at 
pfwe<0.05
L Middle Occipital Gyrus 19 -34,-72,45 6.13 164 X
r Superior Frontal Gyrus, dorsolateral 6 33,-3,68 6.02 711 X
L Superior parietal Gyrus 5 -21,-54,66 5.96 200 X
r Middle Frontal Gyrus 46 32,42,33 5.92 61 X
L Lingual Gyrus 17 -6,-78,-8 5.90 122 X
L Lingual Gyrus 18 -21,-69,-10 5.74 246 X
r Superior parietal Gyrus 7 24,-75,50 5.60 97 X
r Supramarginal Gyrus 40 58,-40,46 5.46 191 X
L Supramarginal Gyrus 40 -63,-39,33 5.40 130 X
L	Inferior	Parietal,	excluding	Supramarginal	and	
angular 2 -52,-30,50 5.40 141 X
r Superior Frontal Gyrus, medial 10 12,69,18 5.39 152 X
r Fusiform Gyrus 19 22,-64,-10 5.30 83 X
L Superior temporal Gyrus 48 -58,3,0 5.28 198 X
r Calcarine Fissure and surrounding cortex 19 26,-52,63 5.26 32 X
L Middle Frontal Gyrus 46 -33,42,34 5.23 78 X
L	Inferior	Temporal	Gyrus 20 -52,-8,-32 5.18 105 X
L Caudate Nucleus n/a -12,3,16 5.09 316 X
L Middle Frontal Gyrus 46 -42,48,9 5.07 23 X
L Superior Frontal Gyrus, dorsolateral 8 -14,28,57 5.01 40 X
L Middle temporal Gyrus 22 -69,-38,10 5.00 57 X
r Cuneus Cortex 19 16,-82,40 5.00 50 X
L Superior temporal Gyrus 22 -64,-24,12 4.91 79 X
L	Insula 48 -42,8,44 4.89 35 X
r Middle temporal Gyrus 21 58,2,-24 4.82 52 X
L Fusiform Gyrus 19 -36,-68,-16 4.78 24 X
L Middle temporal Gyrus 21 -62,-54,9 4.77 40 X
r Superior temporal Gyrus 22 69,-12,10 4.75 39 X
R	Insula 48 40,-6,-6 4.74 47 X
R	Inferior	Temporal	Gyrus 20 51,-16,-34 4.69 69 X
L Calcarine fissure and surrounding cortex 17 4,-98,6 4.69 42 X
r precentral Gyrus 6 21,-20,74 4.62 25 X
L Olfactory Cortex 25 -2,18,-10 4.60 29 X
r Caudate Nucleus n/a 9,10,70 4.59 131 X
r Crus 1 Cerebellum 19 33,-80,-24 4.49 52 X
r Lingual Gyrus 27 9,-42,2 4.48 24 X
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Supplementary Table 2. Negative correlations between grey matter volume and poly(GP) or NfL for 
all, presymptomatic and symptomatic C9orf72 repeat expansion carriers – peak voxel regions from 
the voxel‑based morphometry analysis. (continued)
region Containing peak voxel Ba x,y,z t
# of 
voxels
at 
p<0.001
at 
pfwe<0.05
R	Inferior	Temporal	Gyrus 36 30,10,-44 4.39 59 X
L Superior Frontal Gyrus, orbital part 11 -32,58,0 4.38 20 X
r precuneus 7 14,-63,63 4.38 20 X
r Fusiform Gyrus 18 22,-81,-14 4.38 28 X
L Superior Frontal Gyrus, medial 8 -3,34,54 4.36 104 X
r Superior Frontal Gyrus, dorsolateral 10 18,62,28 4.36 27 X
L postcentral Gyrus 3 -50,-18,62 4.33 31 X
r Calcarine Fissure and surrounding cortex 18 16,-96,6 4.31 21 X
L Superior Frontal Gyrus, medial 10 -6,66,4 4.21 27 X
r precentral Gyrus 6 30,-22,70 4.13 31 X
R	Hemispheric	Lobule	VI	of	Cerebellum n/a 9,-70,-20 4.04 20 X
Grey matter versus NfL in symptomatic C9orf72 expansion carriers
L Superior Frontal Gyrus, dorsolateral 8 -20,22,54 10.93 1579 X X
L precentral Gyrus 6 -20,-26,62 9.46 2232 X X
r Superior Frontal Gyrus, dorsolateral 6 24,4,60 8.62 1302 X
L Middle Occipital Gyrus 7 -34,-66,39 8.24 198 X
r Cuneus Cortex 19 14,-81,36 7.86 306 X
r Middle Frontal Gyrus, orbital part 47 34,39,-12 7.61 193 X
L	Insula 48 -42,6,6 7.4 1308 X
L Superior Frontal Gyrus, dorsolateral 11 -28,51,2 6.34 130 X
L precuneus 7 -6,-64,45 6.29 109 X
L Superior Frontal Gyrus, dorsolateral 9 -18,42,38 6.16 138 X
r Middle Frontal Gyrus 9 27,33,34 6.13 169 X
L anterior Cingulate and paracingulate gyri 24 -4,26,30 6.12 1484 X
L	Inferior	Frontal	Gyrus,	triangular	part 47 -36,40,10 6.05 44 X
L Supplementary Motor area 6 -3,-8,63 6.04 92 X
r Superior temporal Gyrus 48 50,-8,34 6.02 328 X
L Superior parietal Gyrus 7 -24,-62,58 5.89 64 X
r Middle Frontal Gyrus 9 21,48,34 5.57 48 X
r postcentral Gyrus 6 24,-26,60 5.54 274 X
r Lenticular nucleus, pallidum 48 24,0,-6 5.48 32 X
L Superior Frontal Gyrus, dorsolateral 11 -20,63,4 5.47 91 X
L Superior Frontal Gyrus, dorsolateral 11 -21,54,16 5.36 150 X
L rolandic Operculum 48 -51,4,21 5.31 234 X
L	Cerebellum	Hemispheric	Lobule	IV/V n/a -6,-42,3 5.29 18 X
L Superior parietal Gyrus 7 -16,-69,48 5.26 145 X
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Supplementary Table 2. Negative correlations between grey matter volume and poly(GP) or NfL for 
all, presymptomatic and symptomatic C9orf72 repeat expansion carriers – peak voxel regions from 
the voxel‑based morphometry analysis. (continued)
region Containing peak voxel Ba x,y,z t
# of 
voxels
at 
p<0.001
at 
pfwe<0.05
L Middle Frontal Gyrus, orbital part 47 -32,38,-12 5.09 217 X
L Caudate Nucleus n/a -10,14,14 5.02 452 X
r precuneus 23 16,-63,27 5.01 173 X
r angular Gyrus 39 39,-62,40 5.01 48 X
r rolandic Operculum 48 48,-6,8 4.98 242 X
r Superior Frontal Gyrus, dorsolateral 9 20,40,42 4.95 58 X
r Lingual Gyrus 27 9,-39,4 4.93 77 X
r Middle temporal Gyrus 37 50,-58,14 4.85 76 X
L Cuneus Cortex 19 -16,-84,34 4.79 21 X
L Superior Frontal Gyrus, medial 10 -4,58,8 4.78 81 X
r Middle Frontal Gyrus 47 42,46,3 4.77 30 X
r Middle Frontal Gyrus 46 36,42,28 4.69 62 X
r postcentral Gyrus 3 27,-39,56 4.68 91 X
L Superior parietal Gyrus 5 -21,-48,74 4.65 67 X
r Superior Occipital Gyrus 7 24,-69,48 4.63 28 X
L Superior Frontal Gyrus, dorsolateral 9 -24,34,33 4.63 51 X
r Caudate Nucleus 25 10,14,8 4.62 564 X
R	Insula 48 39,21,6 4.53 168 X
L anterior Cingulate and paracingulate gyri 10 -4,48,28 4.51 277 X
r Superior temporal Gyrus 48 54,-20,9 4.5 56 X
r Superior Frontal Gyrus, medial 9 3,39,40 4.45 65 X
r Median Cingulate and paracingulate Gyri 32 8,16,46 4.42 26 X
L precuneus 5 -14,-50,63 4.42 63 X
r Calcarine Fissure and surrounding cortex 19 20,-51,6 4.38 57 X
r Superior parietal Gyrus 5 18,-58,66 4.31 37 X
r Median Cingulate and paracingulate Gyri n/a 9,-40,52 4.31 70 X
r Supramarginal Gyrus 2 56,-36,36 4.23 25 X
r Lenticular nucleus, putamen n/a 18,10,0 4.23 35 X
L Lingual Gyrus 17 -14,-51,4 4.21 43 X
r Superior Frontal Gyrus, medial 8 2,28,52 4.19 38 X
R	Inferior	Temporal	Gyrus 20 63,-21,-27 4.18 21 X
L Lenticular Nucleus, putamen n/a -21,3,8 4.16 23 X
L Middle temporal Gyrus 21 -66,-32,-4 4.16 25 X
r Lenticular nucleus, putamen n/a 24,2,9 4.14 39 X
Ba: Brodmann area; fwe: family wise error corrected; NfL: neurofilament light chain in cerebrospinal fluid; t: 
t-score
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Abstract
Background: Pathogenic mutations in the granulin gene (GRN) are causative in 5-10% 
of patients with frontotemporal dementia (FTD), mostly leading to reduced progranulin 
protein (PGRN) levels. Upcoming therapeutic trials focus on enhancing PGRN levels. 
Methods: Fluctuations in plasma PGRN (n=41) and its relationship with cerebrospinal fluid 
(CSF, n=32) and specific single nucleotide polymorphisms, were investigated in pre- and 
symptomatic GRN mutation carriers and controls.
Results: Plasma PGRN levels were lower in carriers than in controls and showed a mean co-
efficient of variation of 5.3% in carriers over one week. Although plasma PGRN correlated 
with CSF PGRN in carriers (r=0.54, p=0.02), plasma only explained 29% of the variability in 
CSF PGRN. Rs5848, rs646776 and rs1990622 genotypes only partly explained the variability 
of PGRN levels between subjects. 
Conclusions: Plasma PGRN is relatively stable over one week and therefore seems suitable 
for treatment monitoring of PGRN-enhancing agents. Since plasma PGRN only moderately 
correlated with CSF PGRN, CSF sampling will additionally be needed in therapeutic trials.
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Introduction
Frontotemporal dementia (FTD), a common type of presenile dementia, shows an autoso-
mal dominant inheritance in 20-30%.1 Pathogenic mutations in granulin (GRN) are a major 
cause of heritable FTD and mostly reduce progranulin protein (PGRN) levels in blood and 
cerebrospinal fluid (CSF) by haploinsufficiency.2–6 PGRN plays an important role in neurite 
outgrowth and inflammation, which may be the link to neurodegeneration.7 
As PGRN levels vary greatly between individuals, various genetic and environmental 
regulators may play a role.5,8–10 A number of single nucleotide polymorphisms (SNPs) have 
been associated with altered CSF or plasma PGRN levels: rs5848 (GRN), rs646776 (near 
sortilin 1 [SORT1]) and rs1990622 (near transmembrane protein 106B [TMEM106B]).10–14
Current FTD research is shifting towards disease-modifying agents, and sensitive bio-
markers are essential to evaluate these potential agents in the clinic. Histone deacetylase 
inhibitors, alkalizing reagents and inhibitors of vacuolar ATPase, have been shown to 
enhance PGRN expression in carrier-derived cells and might therefore inhibit the disease 
process.15,16 Although blood PGRN poorly correlates to CSF PGRN in healthy controls and 
Alzheimer’s disease, sporadic FTD and amyotrophic lateral sclerosis,10,17,18 this information 
is lacking in GRN mutation carriers. To use PGRN levels as biomarkers in therapeutic trials 
on PGRN-enhancing agents, a better understanding in GRN mutation carriers is needed 
on correlations between levels in blood and CSF, fluctuations over time and variability 
between subjects. 
In this study patients and presymptomatic carriers of pathogenic GRN mutations were 
studied to investigate (1) the correlation between plasma and CSF levels in GRN mutation 
carriers, (2) the fluctuations of plasma PGRN over time, and (3) the associations between 
three SNPs (rs5848, rs646776 and rs1990622) and PGRN levels in plasma and CSF. 
 Methods
Subjects
A group of 57 (37 women, 20 men) asymptomatic first-degree relatives of patients with FTD 
caused by a pathogenic GRN mutation (at-risk group), was selected from our longitudinal 
neuropsychological and MRI study in genetic FTD.19 Participants were selected depending 
on the availability of plasma and/or CSF (no biosample available: n=10). The participants 
originate from three different families with GRN mutations (p.Ser82Valfs, p.Gln125* or 
p.Val411Serfs mutation). After screening of these GRN mutations,20 participants were 
divided into those with (presymptomatic carriers, n=28) and those without a pathogenic 
GRN mutation (controls, n=29); investigators and at-risk individuals remained blinded to 
the individual carrier status. Plasma was available from all 57 at-risk individuals; a lumbar 
puncture was carried out in 28 of them (16 presymptomatic GRN carriers and 12 controls, 
see Supplementary Figure 1). Longitudinal blood samples for the determination of vari-
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ability of plasma PGRN were collected in 37 at-risk subjects (18 presymptomatic GRN 
carriers and 19 controls), and the other 20 subjects did not participate mainly because of 
logistical reasons (e.g. long travel distance) or a lack of motivation.
Additionally, ten patients with a pathogenic GRN mutation (p.Ser82Valfs, p.Gln125*, 
p.Val411Serfs and p.Gln130Serfs) were included from our previously described cohorts.21,22 
Plasma was available from 7 patients (longitudinal sampling in 4) and CSF from 7 (plasma 
also available in 4). 
The study was approved by the medical ethics committee. All participants or legal repre-
sentatives provided written informed consent for the blood and/or CSF collections. 
Plasma and CSF Collection
Blood collections were performed according to standard procedures. For longitudinal 
analyses, blood was collected in a local hospital or nursing home at five time points during 
one week: 0 hours (h), 6 h, 12 h, 24 h and 7 days (d). The collections at the time points 0 
h, 24 h and 7 d were performed in the morning, while the 6 h time point was performed 
after noon and the 12 h time point in the evening. To diminish the burden for FTD patients 
resident in a nursing home, the venipuncture at 12 h was omitted (n=3). To assess the 
influence of fasting on plasma PGRN, participants fasted for a minimum of 8 h before the 
venipuncture at 24 h. Plasma was isolated from K2EDTA coated tubes (Becton Dickinson) 
by direct centrifugation at 1300 relative centrifugal force (RCF) for 20 minutes at room 
temperature, aliquoted and directly stored at -80°C.
CSF was collected using standard procedures into polypropylene tubes. The first 1-3 ml 
were discarded and samples were centrifuged in the polypropylene tube at 2000 RCF for 10 
min at +4°C. CSF was aliquoted into polypropylene vials and immediately stored at -80°C.
Laboratory Methods
All measurements were performed blinded to the mutation status and clinical stage. PGRN 
concentrations in plasma and CSF samples were determined using a qualified immunoas-
say based on an enzyme-linked immunosorbent assay (ELISA) kit from BioVendor (Brno, 
Czech Republic) following kit instructions. Low, medium and high PGRN concentration 
quality control samples were run on each assay plate with an acceptance coefficient of 
variation (CV) cut-off of ≤20%. PGRN replicates with a CV of >20% were excluded from the 
analyses. CSF was diluted 1:2 and plasma 1:40. All reported concentrations fell within the 
qualified range of the assays. PGRN concentrations were determined on a standard curve 
by plotting optical density versus concentration, using four-parameter logistic curve-fitting. 
DNA was extracted from whole blood following standard procedures. SNPs rs5848 
(NM_002087.2(GRN):c.*78C>T), rs646776 (NM_001408.2(CELSR2):c.*1859C>T, near SORT1) 
and rs1990622 (NM_000007.13:g.12283787A>G, near TMEM106B) were genotyped us-
ing Taqman assays (respective assay numbers C_7452046_20, C_3160062_10 and 
C_11171598_10; Life Technologies, Carlsbad, USA) on a 7900HT Fast Real-Time PCR System 
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(Applied Biosystems, Carlsbad, USA). Genotypes were assigned using SDS v3.1 software 
(Applied Biosystems, Carlsbad, USA).
Statistical analysis
Statistical analyses were performed in SPSS 21.0 for Windows (Chicago, USA) and GraphPad 
Prism 6 (La Jolla, USA), applying a significance level of p<0.05. Comparisons between two 
groups were made by Mann-Whitney U tests because of non-normally distributed data; 
multiple groups were compared by Kruskal-Wallis tests. Pearson’s correlation coefficient (r) 
was used to correlate two normally distributed variables; otherwise Spearman’s correlation 
coefficient (rs) was used. To assess the variability (variance) in CSF PGRN levels accounted 
for by plasma PGRN, the coefficient of determination (R2 = r2) was used.10 Age at onset (AAO) 
was defined as the age of first symptoms noted by a caregiver. For the longitudinal blood 
withdrawals, repeated measures ANOVAs were used and variability per individual was as-
sessed by the CV (ratio of the standard deviation to the mean) and compared between the 
groups with t-tests. In the case of longitudinal withdrawals, the median of each individual 
was used for comparisons of single plasma PGRN values; for plasma-CSF-correlations, we 
used the plasma sample closest in time to the lumbar puncture. Associations between SNP 
genotypes and PGRN levels were analyzed by multivariate regression with GRN mutation 
status, age and gender as covariates. 
Table 1. Subject characteristics. 
plasma available (n = 64) CSF available (n = 35)
Controls GRN mutation 
carriers
Controls GRN mutation 
carriers
Number (male) 29 (11) 35a (12) 12 (4) 23 (9)
Number of symptomatic subjects - 7 - 7
MMSe (range) 30 (25-30)c 30 (0-30)b 30 (28-30) 29 (18-30)
Age	at	onset,	years	(IQR) - 59.1 (57.6-65.8)c - 57.6 (55.1-65.5)c
Age	at	collection,	years	(IQR) 58.6 (51.8-
63.5)
58.1 (53.4-64.3) 58.1 (50.8-
64.0)
57.4 (54.7-61.0)
time between onset and collection, 
years (range)
- 2.3 (-1.2-5.3) - 2.0 (-1.2-5.0)
time between plasma and CSF 
collection, days (range)
35 (0-265) 19 (0-597) 35 (0-265) 19 (0-597)
pGrN level, ng/ml (range) 28.5 (21.5-
39.2)
8.0 (5.2-11.3) 0.76 (0.60-
1.25)
0.29 (0.15-0.46)
Values	 are	 displayed	 as	 medians;	 aMutations: n=23	 p.Ser82Valfs;	 n=9 p.Gln125*; n=2	 p.Val411Serfs;	 n=1 
p.Gln130Serfs; bpresymptomatic GRN mutation carriers median MMSe 30 (range 26-30), symptomatic carriers 
median MMSe 18 (range 0-26); conly known age at onset in 7 patients and one presymptomatic carrier who con-
verted	after	collection.	CSF:	cerebrospinal	fluid;	IQR:	interquartile	range;	MMSE:	Mini-Mental	State	Examination:	
pGrN: progranulin.
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Results
Cohort Characteristics
The baseline characteristics of the cohort are displayed in Table 1. Presymptomatic car-
riers, controls and patients did not differ in age (p=0.08). Mini Mental State Examination 
(MMSE) scores were lower in patients than in at-risk individuals (p<0.01); no differences 
were found between controls and presymptomatic carriers (p=0.51).
Plasma PGRN Levels 
GRN mutation carriers had lower plasma PGRN levels than controls, without any overlap 
between the groups (p<0.001, Table 1 and Figure 1A). Median level in carriers was 28% of 
that in the controls. Maximum variation between subjects was a factor of 1.8 in controls 
and 2.2 in carriers (ratio of the highest to the lowest expression per group). PGRN levels 
did not differ between presymptomatic carriers and patients (p=0.51). Differences between 
various mutations did not reach significance (p=0.06), and limited numbers across the mu-
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Figure 1. PGRN levels in plasma and CSF. 
pGrN in (a) plasma from healthy controls (n=29), presymptomatic GRN mutation carriers (n=28) and GRN pa-
tients (n=7) and in (B) CSF from healthy controls (n=12), presymptomatic GRN mutation carriers (n=16) and GRN 
patients (n=7). each individual is represented as a data point and labeled by type of mutation. horizontal lines 
are median plasma levels per group.
CSF: cerebrospinal fluid; pGrN: progranulin.
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tations did not allow for post-hoc testing. Plasma PGRN did not correlate with age (Figure 
2A), gender or AAO. 
CSF PGRN Levels
Median CSF PGRN in carriers was 39% of that in controls, without overlap of the levels be-
tween the groups (p<0.001, Table 1 and Figure 1B). In carriers, the lowest expression level 
of CSF PGRN was 3.1 times lower than that of the highest expression level; in controls this 
was a 2.1-fold difference. CSF PGRN did not differ between presymptomatic carriers and 
patients (p=0.58), or between various GRN mutations (p=0.16). CSF PGRN did not correlate 
with age (Figure 2B), gender or with AAO.
Correlation between Plasma and CSF
Within the group of subjects with both plasma and CSF samples (16 presymptomatic carri-
ers, 4 GRN patients and 12 controls), PGRN plasma levels correlated significantly with CSF 
levels (rs=0.80, p<0.001, Figure 3). The median interval between blood and CSF collection 
was 32 days, range 0–597 (also see Table 1). The correlation between PGRN levels in CSF 
and plasma collected on the same day in 13 subjects (6 presymptomatic carriers, 3 GRN 
patients and 4 controls) was similar to the total group (rs=0.78, p=0.002). The correlation 
between PGRN levels in plasma and CSF was weaker when both subgroups were sepa-
rately analyzed: r=0.54 (p=0.02) in carriers and r=0.21 (p=0.51) in controls. The coefficient of 
determination, R2, was 0.29 in carriers; this means that in our group of carriers, 29% of the 
variability in CSF PGRN levels is explained by the variability in plasma PGRN levels and the 
remaining 71% is still unaccounted for.
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Figure 2. PGRN levels as a function of age. 
Scatterplots of pGrN levels in plasma (a) and CSF (B) by age at collection in healthy controls (squares), presymp-
tomatic GRN mutation carriers (triangles) and GRN patients (diamonds). to prevent disclosure of genetic status, 
a 23-year-old subject was excluded from the graph (but not from the analyses). CSF: cerebrospinal fluid; pGrN: 
progranulin.
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Longitudinal Plasma PGRN Levels
Plasma PGRN levels were found to be stable over one week in carriers and controls (Figure 
4), with a mean CV in carriers of 5.3% (range 2.3-9.7%) and in controls of 4.7% (range 1.4-
8.6%; not statistically different, p=0.32). Repeated measures analyses showed no signifi-
cant differences over the five time points (p=0.13 in carriers and p=0.053 in controls); the 
trend for a difference in controls was caused by a non-significant lower plasma PGRN 6 h 
vs 0 h (p=0.09 Bonferroni post hoc test). The fasting PGRN plasma levels (24 h time point) 
were not significantly different from other time points (e.g. fasting PGRN level versus time 
point 0 h in carriers p=0.18, paired t-test). 
Associations between SNPs and PGRN Levels
The associations of the SNPs with PGRN levels are displayed in Supplementary Table 1 
and Supplementary Figure 2. GRN mutation carriers had lower PGRN plasma levels with 
each additional minor allele (A) of rs5848 (GRN) without an effect in CSF. In contrast, in the 
control group an effect was found in CSF only. The minor allele (G) of rs646776 (near SORT1) 
was associated with lower PGRN levels in plasma of GRN mutation carriers, without a sig-
nificant effect in controls or in CSF. For rs1990622 (near TMEM106B), the minor allele (C) was 
associated with lower plasma PGRN levels in the entire group of subjects; no significant 
associations were observed for CSF. 
Figure 3. Correlation plasma versus CSF PGRN.
Scatterplot of the correlation (rs=0.80, p<0.001) between pGrN levels in plasma and CSF in 12 healthy controls 
(squares), 16 presymptomatic GRN mutation carriers (triangles) and 4 GRN patients (diamonds).
CSF: cerebrospinal fluid; pGrN: progranulin.
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Discussion
This study showed that CSF PGRN levels in a large series of presymptomatic GRN mutation 
carriers were already lower than in age-matched controls. Plasma PGRN levels strongly 
correlated with CSF levels, however, this was largely explained by the difference in GRN car-
rier status and in carriers, only 29% of the variability in CSF PGRN was explained by plasma 
PGRN. Plasma PGRN levels within subjects fluctuated by 5% over a one-week period, which 
has major implications for the clinical trial design aiming at PGRN restoration. Known SNPs 
only partly explained variation in plasma and CSF PGRN levels between subjects. 
The significantly lower plasma PGRN levels in GRN mutation carriers than in healthy 
controls found in this study, and the similar levels in presymptomatic carriers and patients, 
are in line with previous reports.4,5,8,9,11 The gap between plasma PGRN levels in our carriers 
versus non-carriers was even larger and the spread of PGRN levels was smaller than in 
previous studies.4,5,8 This might be explained by a standardized collection of samples and 
the use of a new qualified ELISA assay with strict performance acceptance criteria and 
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Figure 4. Longitudinal plasma PGRN.
pGrN levels over time in plasma of healthy controls (n = 19, squares), presymptomatic GRN mutation carriers 
(n = 18, triangles) and GRN patients (n = 4, diamonds). each withdrawal is represented with a data point; lines 
connect data points of each individual. at the 12-hour time point, 3 data points are missing (all GRN patients).
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quality control samples on each plate. As previously suggested, plasma PGRN can serve as 
a reliable screening tool for pathogenic GRN mutations in patients with seemingly sporadic 
FTD or with an unspecified early onset dementia.4,5,9 Plasma PGRN can also serve as a rapid 
ex vivo screening tool in patients with variants of unknown significance in GRN. This iden-
tification of pathogenic GRN mutations becomes even more important with forthcoming 
potential treatments increasing PGRN expression. 
PGRN levels in CSF of presymptomatic carriers and patients did not show overlap with 
controls at all ages, which is in line with earlier reports in small series of GRN patients.4,6 
With the development of PGRN-enhancing therapies, a crucial question remains whether 
and at what age enhancing PGRN will have an effect on disease course. As this study 
showed for the first time that CSF PGRN levels are already reduced in the presymptomatic 
stage, additional biomarkers (clinical, neuroimaging and/or biochemical) are needed to 
determine disease onset and to track disease progression in therapeutic trials.
The strong correlation between peripheral and CSF PGRN levels contrasts with a weaker 
correlation found in studies in healthy controls (partial r=0.17 and r=0.36) and no signifi-
cant correlation in sporadic FTD.10,17,18 This could be explained by the clear dichotomy in 
PGRN levels between GRN mutation carriers and non-carriers; our observed correlation 
was mainly driven by GRN genotype, as subgroup analyses by carrier status showed lower 
correlations. In our opinion, plasma PGRN levels can serve as an easily accessible bio-
marker to assess target engagement for potentially disease-modifying agents. However, 
since plasma PGRN levels in carriers explained only 29% of the variability of CSF PGRN 
levels, plasma PGRN cannot predict CSF PGRN. Moreover, these and previous data sug-
gest a differential regulation of PGRN in plasma/serum versus CSF and likely the majority 
of CSF PGRN is synthesized in the central nervous system,10,18,23 therefore it could also be 
that PGRN-enhancing agents have differential effects on different tissues. Although it is 
unknown whether CSF indeed reflects PGRN levels in the brain and/or interstitial space,18 
drug effects could be missed in the worst case if solely relying on plasma PGRN, and CSF 
sampling will additionally be needed to evaluate effects of pharmacological interventions. 
The performance of plasma versus CSF PGRN as a surrogate biomarker depends on ef-
fect place and –size of potential PGRN-restoring agents, and remains to be investigated in 
longitudinal trials. 
This first observation of stable PGRN levels over a one-week period in carriers has impor-
tant implications for therapeutic trials of pharmacological agents aiming to restore PGRN 
levels. It is in line with the findings of no significant differences over a longer time period 
in mainly non-carriers.23 The mean observed CV over a week of 5% can be technically ex-
plained by the assay variability. Plasma PGRN did not alter under fasting conditions, which 
additionally indicates that plasma PGRN levels can be a suitable biomarker of target en-
gagement. Furthermore, our data can support sample size estimations greatly facilitating 
clinical trial design: using intra-subject over inter-subject variability, significantly reduces 
trial size in this rare disease.
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It was recently published that more commonly used PGRN ELISA kits (Adipogen and 
R&D) detected CSF PGRN in non-GRN-carriers only at the lower detection range of the kits.24 
Because CSF PGRN of GRN-carriers is at least 50% lower, we opted for the more sensitive 
protocol of Biovendor; R&D and Biovendor yielded similar PGRN concentrations, addition-
ally, Biovendor was qualified to detect low ranges of CSF PGRN [qualified range: 0.018-2.1 
ng/ml, data not shown]. A limitation is that comparison with studies that used Adipogen 
and meta-analyses for cut-off levels would be complicated, due to different normality 
values among the kits.
PGRN levels are known to vary widely among subjects and several factors have been 
found which partly explain this variability. In this study, neither age at collection, nor gender 
were correlated with PGRN levels, in contrast to some earlier reports in non-carriers.4,5,10,12,13 
This might be explained by the limited age range and the small sample size. However, in 
carriers, previous studies did not detect a correlation with age, similar to our result.8,9 The 
same holds true for AAO, for which conflicting results have been reported and this study 
did not find a correlation.5,8,9
Several SNPs have been found to influence PGRN levels: rs5848 in GRN, rs646776 near 
SORT1, and rs1990622 near TMEM106B. The correlation between lower PGRN levels and 
the minor allele of rs5848 in our series is in line with findings from previous studies.10,12,25 
Probably microRNA-659 binds more efficiently to this minor allele, resulting in translational 
suppression of PGRN.26 The significantly lower plasma PGRN levels with each minor allele 
in our GRN mutation carriers, suggest that the translational suppression also takes place 
when there is only one functional GRN allele. 
In our GRN mutation carriers and in previous studies, rs646776 (near SORT1) correlated 
significantly with plasma PGRN levels, but not with PGRN CSF levels.10,13,27 This SNP is prob-
ably a liver-specific regulator of SORT1 and therefore only a peripheral modifier.10,28
The minor allele (C) in rs1990622 (TMEM106B) was not associated with higher plasma 
PGRN levels, in contrast to the strong association in GRN patients and healthy controls 
found in previous studies.11,14 Such an association was supported by a proposed functional 
link between TMEM106B and PGRN and by a delay in AAO with each minor allele.11,14,29–31 
Our findings might be explained by analysis in a few families resulting in genetic bias. 
Larger cohorts are needed in order to investigate the exact role of TMEM106B on PGRN and 
AAO in various genetic backgrounds. 
Major strengths of our study include longitudinal plasma collections over a week within 
the same individuals, uniformly performed by a single investigator and collection protocol. 
Furthermore, presymptomatic carriers and controls were well matched since they originate 
from the same families. A methodological weakness of this study is the interval of more 
than one day between plasma and CSF collection in half of the cases. However, a subgroup 
analysis of samples collected on the same day showed a correlation comparable to that in 
the entire group. This might be expected given the demonstrated low variability in plasma 
PGRN levels over time in this study and in CSF PGRN levels recently reported.23 Future 
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studies are warranted to analyze variations between plasma sampled more than one week 
apart and fluctuations in PGRN CSF over time in GRN mutation carriers. Additionally, the 
population was too small to get robust conclusions on the effect of the studied SNPs on 
PGRN levels in GRN mutation carriers and should be studied in larger cohorts. 
To conclude, PGRN levels in plasma and CSF were already low in presymptomatic GRN 
mutation carriers and separated completely from non-carriers. Although PGRN levels in 
plasma and CSF strongly correlated, plasma PGRN levels only explain 29% of the variability 
of CSF PGRN levels in GRN mutation carriers, and therefore both blood and CSF sampling is 
needed in PGRN-enhancing trials. Plasma PGRN levels can serve as biomarker of target en-
gagement for potentially disease-modifying agents addressing PGRN steady-state, as they 
were relatively stable over one week. Further research is required to elucidate which other 
factors are associated with PGRN regulation with emphasis on the differences between the 
regulation in plasma and CSF.
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Supplementary material
Supplementary Figure 1. Number of subjects per type of collected sample. 
a12 controls, 16 presymptomatic carriers and 7 GRN patients; b12 controls, 16 presymptomatic carriers and 4 
GRN patients; c29 controls, 28 presymptomatic carriers and 7 GRN patients; d19 controls, 18 presymptomatic 
carriers and 4 GRN patients. CSF: cerebrospinal fluid.
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Supplementary Figure 2. Associations of SNPs versus PGRN levels. 
Scatterplots of rs5848, rs646776 and rs1990622 genotype with plasma pGrN (a, B and C) and with CSF pGrN (D, 
e and F) , data points represent individual values and horizontal lines are median pGrN levels per group (carri-
ers of a pathogenic GRN mutation versus controls). Genotyping for rs1990622 failed in one presymptomatic GRN 
mutation carrier and one control. 
CSF: cerebrospinal fluid; pGrN: progranulin.
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Supplementary Table 1. PGRN levels by SNP genotype 
SNp (minor allele) genotype βa p-valuea
rs5848 (a), GRN GG Ga aa
plasma entire group 9.5 (5.2-34.0) 11.3 (5.7-39.2) 21.6 (6.5-25.0) -.050 0.25
n= 24 37 3
Carriers 8.6 (5.2-9.8) 7.6 (5.7-11.3) 6.5b -.399 0.04
n= 15 19 1
Controls 28.5 (25.0-34.0) 28.8 (21.5-39.2) 23.3 (21.6-25.0) -.078 0.72
n= 9 18 1
CSF entire group 0.36 (0.22-1.25) 0.39 (0.15-0.84) 0.56 (0.33-0.78) -.165 0.06
n= 12 21 2
Carriers 0.26 (0.22-0.44) 0.29 (0.15-0.46) 0.33b .024 0.91
n= 9 13 1
Controls 1.13 (0.77-0.13) 0.73 (0.60-0.84) 0.78b -.794 0.03
n= 3 8 1
rs646776 (G), near SORT1 aa aG GG
plasma entire group 11.0 (5.7-39.2) 8.1 (6.4-33.7) 5.2b -.051 0.19
n= 53 10 1
Carriers 8.2 (5.7-11.3) 7.3 (6.4-8.4) 5.2b -.423 0.01
n= 28 6 1
Controls 28.6 (21.5-39.2) 26.3 (22.2-33.7) - -.098 0.61
n= 25 4 0
CSF entire group 0.39 (0.15-1.25) 0.31 (0.26-1.13) - .100 0.25
n= 31 4 0
Carriers 0.30 (0.15-0.46) 0.28 (0.26-0.33) - -.048 0.83
n= 20 3 0
Controls 0.76 (0.60-1.25) 1.13b - .562 0.10
n= 11 1 0
rs1990622 (C), near TMEM106B tt tC CC
plasma entire group 9.6 (6.5-39.2) 15.5 (5.2-36.9) 24.2 (6.5-31.6) -.095 0.02
n= 21 34 7
Carriersc 8.4 (6.5-11.3) 7.4 (5.2-9.5) 8.4 (6.5-8.9) -.347 0.06
n= 14 17 3
Controlsc 32.0 (25.4-39.2) 28.4 (21.5-36.9) 25.6 (24.2-31.6) -.337 0.08
n= 7 17 4
CSF entire group 0.33 (0.20-0.76) 0.40 (0.15-1.25) 0.25 (0.22-0.84) .065 0.47
n= 13 19 3
Carriers 0.29 (0.20-0.46) 0.34 (0.15-0.44) 0.23 (0.22-0.25) -.106 0.66
n= 10 11 2
Controls 0.64 (0.60-0.76) 0.77 (0.62-1.25) 0.84b .367 0.32
n= 3 8 1
Comparisons of median (range) pGrN levels (plasma and CSF in ng/ml) within genotype of rs5848, rs646776 and 
rs1990622. aMultivariate regression with correction for age and gender; bn=1, therefore no range is displayed; 
cgenotyping for rs1990622 failed in one presymptomatic carrier and one control.
CSF: cerebrospinal fluid; SNp: single nucleotide polymorphism.
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Frontotemporal dementia (FTD) is an early-onset dementia, predominantly character-
ized by behavioural disturbances (behavioural variant FTD [bvFTD]) and/or language 
deterioration (primary progressive aphasia [PPA], including semantic variant PPA [svPPA] 
and nonfluent variant PPA [nfvPPA]). The clinical spectrum also comprises phenotypes 
with prominent motor problems: FTD with concomitant motor neuron disease (MND), 
corticobasal syndrome (CBS), and progressive supranuclear palsy (PSP). FTD is highly 
heritable and 10–20% of all cases are caused by autosomal dominant mutations in either 
MAPT (microtubule-associated protein tau), GRN (progranulin), or C9orf72 (chromosome 9 
open reading frame 72) repeat expansions.1 Postmortem brain examination shows fronto-
temporal lobar degeneration (FTLD) with inclusions of either tau protein (FTLD-tau), TAR 
DNA-binding protein 43 (TDP-43; FTLD-TDP), or FET (fused in sarcoma, Ewing’s sarcoma 
and TAT-binding protein-associated factor 15; FTLD-FET).
This disease is devastating for patients and their relatives, and therefore therapeutic in-
terventions are critically needed. Currently, only symptomatic treatments are applied that 
have not been designed for FTD, nor properly studied with placebo-controlled trials.2 Key 
problem in FTD is its heterogeneity on multiple levels: in symptomatology, age at onset, 
underlying genetics and underlying pathology. As we enter an era of disease-modifying 
interventions for neurodegenerative diseases, it is of utmost importance to overcome this 
heterogeneity and be able to appropriately select and monitor patients in treatment trials. 
Various biomarkers can aid in this process by virtue of their different applications (contexts 
of use), e.g. as diagnostic, staging, pharmacodynamic or prognostic markers. In this thesis, 
we have investigated the utility of biomarkers in cerebrospinal fluid (CSF) and blood – fluid 
biomarkers – across the FTD spectrum. Specifically, the aims were to:
1. investigate the application of neurofilament light chain (NfL) across the sporadic FTD 
spectrum (Chapter 2); and
2. identify and study the value of blood and CSF biomarkers in genetic forms of FTD 
(Chapter 3).
In Table 1, the different fluid biomarkers studied in this thesis are summarized by their ap-
plication in specific subtypes within the FTD spectrum. This chapter presents the results of 
our studies in perspective of existing knowledge, discusses methodological considerations 
and suggests future directives.
1. Neurofilament light chain – a multipurpose biomarker
Neurofilaments are specific to neurons, constitute the main components of their cytoskel-
eton, and are composed of light, medium and heavy subunits.3 Beside having important 
structural and functional roles in maintaining axonal integrity and transport, neurofila-
ments also play important roles in the synaps.4 The results of this thesis illustrate different 
potential applications for NfL (Table 1), as discussed below.
Chapter 4  |  general dIscussIon
196
1.1 NfL in blood strongly correlates with CSF
We showed a strong correlation between NfL levels in serum and CSF, in line with other re-
ports in FTD and different neurodegenerative diseases.5–10 The discovery of a blood-based 
biomarker is exciting and stimulating for research, since blood markers are highly advanta-
geous over those in CSF; their collection is less invasive and therefore more patient-friendly 
and applicable for frequent measurements, collection is cost- and time-effective and 
feasible at the population level.11 
Since most studies have shown similar performances between blood- and CSF-derived 
NfL, results from these compartments are discussed together below. Of note however, 
a few studies suggested that CSF NfL levels are elevated earlier than blood – since it is 
hypothesized that most blood NfL derives from the central nervous system – and therefore 
slightly more sensitive, especially in subjects with narrow ranges of levels (e.g. controls).12,13
1.2 NfL as a diagnostic biomarker
Throughout this thesis it becomes clear that elevated NfL levels, either in blood or CSF, can 
discriminate all different FTD subtypes from controls. In our large clinical cohort comprising 
the entire FTD spectrum as encountered in the day-to-day practice, we show that patients 
with FTD-MND can be distinguished by their extraordinary high CSF NfL levels, but other 
Table 1. Biomarkers studied in this thesis summarized by their application in specific FTD subtypes
Diagnostic Staging prognostic pharmacodynamic
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NfL entire spectrum + ± - ± + +
svppa + ± -
pSp + + +
Genetic FtDa + ± + + +
p/t-tau ratio entire spectrum + ± + ± + +
pGrN GRN mutation carriers + - +
poly(Gp) C9orf72 expansion carriers + - - ± - +
the differential diagnosis with different dementia’s was outside the scope of this thesis, and thus not included.
+: can be used for this application; ±: differences were found, but no or limited applied value; -: cannot be used 
for this application; blank cells are not studied in this thesis or not applicable.
aIncluding	subjects	with	C9orf72 repeat expansions who were also studied separately.
C9orf72: chromosome 9 open reading frame 72 gene; FtD: frontotemporal dementia; GRN: granulin gene; NfL: 
neurofilament light chain; pGrN: progranulin protein; pSp: progressive supranuclear palsy; p/t-tau: phospho-
tau181 to total-tau; svppa: semantic variant primary progressive aphasia
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clinical forms show similar levels. Although patients with bvFTD had higher CSF NfL levels 
than PSP patients, and GRN-patients higher NfL levels than C9orf72- and MAPT-patients, 
the overlap in concentrations does not allow diagnostic differentiation of these subtypes 
using NfL. In PPAs, serum NfL may have a diagnostic role since svPPA and nfvPPA (variants 
caused by FTLD) patients had higher levels than those with the logopenic variant (often 
caused by Alzheimer’s disease [AD] pathology).14 Additionally, high blood NfL distinguishes 
atypical parkinsonian disorders – including PSP – from patients with Parkinson’s disease;10 
and high CSF NfL differentiated bvFTD from primary psychiatric disorders, often presenting 
with similar symptoms.15
NfL is a rather aspecific neuronal injury marker and elevated in a range of neurological 
diseases, including (but not limited to) FTD, AD, amyotrophic lateral sclerosis (ALS), mul-
tiple sclerosis (MS), and traumatic brain injury.7,16–19 NfL will therefore be of limited value 
– apart from the above-mentioned exceptions – in the differential diagnosis between 
different dementia types, but will be rather used as a staging and prognostic marker (see 
below). In addition, one could envision using serum NfL as a screening tool to identify 
patients with neurodegeneration, but first longitudinal population-based series would be 
needed to determine cut-offs.20 
1.3 NfL increases with symptom onset in genetic FTD
Predicting and establishing disease onset in genetic FTD is notoriously challenging due to 
the high variability in onset age and the presence of early subtle symptoms. It is therefore 
of great help that CSF and serum NfL levels were normal in our presymptomatic carriers 
and elevated in the symptomatic stage, and thus can serve as a staging marker of disease 
onset. These results are in line with those in presymptomatic genetic ALS,21 but contrast to 
three more recent reports.12,22,23 First, slightly elevated serum NfL levels were shown in pre-
symptomatic carriers of AD-causing mutations, and NfL associated with estimated years to 
onset.22 This difference might be explained by the underlying pathophysiology in AD, char-
acterized by a more gradually progressive preclinical phase with declining CSF amyloid-β 
levels 20-25 years before estimated onset and brain atrophy at 15 years before estimated 
onset.24,25 While in FTD – at least for GRN mutations – a rather explosive start of disease is 
suggested, as exemplified by the steep increase of NfL levels in our two converters, and 
the emergence of white matter integrity and grey matter volume loss between 4 and 2 
years before symptom onset (manuscript under review).26 Secondly, a study in CHMP2B (a 
rare FTD-causing gene) mutation carriers, found elevated CSF NfL levels in presymptomatic 
compared to non-carriers, however this finding did not persist after correction for age, a 
known confounding factor for NfL.23 Thirdly, in a mouse model of three neurodegenerative 
proteopathies (tau, amyloid-β and α-synuclein pathology), CSF NfL increased in parallel 
or slightly before protein deposits became visible, and increased before symptom onset.12 
Again, this difference might be explained by the underlying pathophysiology: a model 
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for TDP-43 pathology was not studied, while most of our mutation carriers were GRN or 
C9orf72 carriers.
In presymptomatic C9orf72 expansion carriers, grey and white matter damage has been 
shown particularly early,27–30 even before the age of 40.31 Moreover, several symptom-
atic C9orf72 expansion carriers with a remarkable slow disease progression have been 
described (so-called phenocopies),32–34 leading to the hypothesis that C9orf72-mediated 
pathology has a neurodevelopmental origin, with early deficits that progress very slowly. 
However, some cross-sectional studies do suggest a specific time point in onset of grey 
matter loss, after the age of 40 in one study,29 and 25 years before estimated onset in the 
Genetic FTD Initiative (GENFI).27 To elucidate this matter, it will be interesting to investigate 
longitudinal NfL measurements together with neuroimaging, to determine whether NfL 
remains stable over time which would support the developmental hypothesis. 
1.4 NfL as a disease severity biomarker
NfL associated with disease severity in sporadic FTD, PSP, and genetic FTD. In line with this, 
we showed in genetic FTD that NfL associates with severity of atrophy, as also reported for 
sporadic FTD.16 This makes NfL a promising staging biomarker to quantify severity both in 
clinical practice and research setting, and use as a monitoring marker/surrogate endpoint. 
Although we also found associations of NfL with severity of atrophy and naming impair-
ment in svPPA, these correlations were only moderate and may therefore be of limited use. 
Measuring disease severity and progression is difficult in the individual patient because 
of the phenotypical heterogeneity in the FTD spectrum, and therefore we used different 
assessments across this thesis. For svPPA, the Boston Naming Test was used, since naming 
difficulties are the hallmark of svPPA;35,36 PSP is characterized by parkinsonism, frequent 
falls and more global cognitive disturbances37 and thus we studied corresponding func-
tional, motor and cognitive scales; lastly, we used the Clinical Dementia Rating Scale – a 
more general measure – in the large genetic and sporadic cohorts with mixed phenotypes. 
Clinical trials should always measure clinically meaningful outcomes. Although FTD-
focused scales have been developed (e.g. the Frontotemporal Dementia Rating Scale38 and 
the FTLD -modified Clinical Dementia Rating39), it is still challenging to capture the entire 
spectrum of FTD symptoms due to the phenotypical heterogeneity . Since NfL seems to be 
a uniform severity marker – except for svPPA – it could complement clinical assessments 
as outcome measure. 
1.5 NfL as a prognostic biomarker
In sporadic FTD, PSP, and genetic FTD, we have shown in well-characterized large cohorts 
that higher NfL levels (either in serum or CSF) are associated with a shorter survival after 
biomarker collection. For the FTD spectrum, we also presented 5-year survival rates that 
are valuable information for individual patients and their relatives to customize treatment 
plans. Additionally, NfL associated with progression of atrophy in genetic FTD, as has been 
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shown in sporadic FTD as well,40 and NfL levels predicted clinical disease progression in 
PSP.6,41 
However, svPPA is the exception to this rule; we did not find an association with survival 
or progression of atrophy, suggesting that (cross-sectional) NfL may not predict clinical 
progression in svPPA patients, at least not in the short term. The pathophysiological back-
ground is completely unclear; a possible explanation might be that a plateau phase of 
language impairment and atrophy is reached, resulting in stable or even decreasing NfL 
levels unrelated to the relatively long survival in svPPA.42,43 Or perhaps changes in NfL are 
indicative of disease progression.
1.6 NfL as a monitoring biomarker
The associations of NfL with disease severity, atrophy, and survival showed that NfL is a 
promising monitoring biomarker, which is supported by two neurodegenerative mouse 
models.12,44 Blocking amyloidβ-lesions in a β-amyloidosis model attenuated the increase 
in NfL levels.12 In a different model, further increases of NfL were prevented when neurode-
generation was switched off after initial induction.44 Furthermore, in human intervention 
studies, a dynamic decrease in both serum and CSF NfL after treatment has been proven, 
for example in MS.18,45 Future trials can thus benefit from this biomarker, not only as sur-
rogate endpoint to track disease progression, but also by creating homogeneous study 
populations regarding disease severity and progression and therefore better powered 
clinical trials. 
1.7 Application of NfL
Overall, in the current clinical setting I envision measuring NfL at time of diagnosis 1) to 
support a neurodegenerative cause of disease and help in the differential diagnosis of e.g. 
psychiatric disorders, parkinsonism and PPAs, and 2) to predict survival (with the exception 
of svPPA patients). NfL levels can be measured in serum when underlying AD pathology is 
not suspected, otherwise in CSF along with the core AD biomarkers. Serum NfL measure-
ments can readily be used in clinical trials, however not yet in the clinical practice since the 
added clinical value remains to be proven (see Future directions).
2. The phosphotau/tau ratio to predict underlying proteinopathy in vivo
Apart from using NfL as biomarker, future clinical trials will likely focus on a specific 
proteinopathy, and therefore predicting underlying pathology in vivo is paramount. We 
showed in 67 patients with known pathology based on autopsy or genetic mutation, that 
the phospho- to total tau (p/t-tau) ratio discriminated FTLD-TDP from FTLD-tau with a 
sensitivity of 67% and a specificity of 76%, while NfL levels did not. In addition, the p/t-tau 
ratio discriminated FTD patients from controls, associated with disease severity and pre-
Chapter 4  |  general dIscussIon
200
dicted survival; however, these findings mirrored those in NfL, and since NfL can reliably be 
measured in blood, the p/t-tau ratio will unlikely have added value in those applications. 
The pathophysiological mechanism underlying decreased p/t-tau ratios in FTLD-TDP 
remains to be elucidated, since the driving factor of a lower ratio (elevated total tau, or 
decreased phospho-tau levels), is inconsistent between previous reports.46–51 Total tau 
levels can be elevated due to extensive neuronal loss, especially in the FTD-MND patients; 
on the other hand, low p-tau levels (the driving factor in our study) may be explained by a 
low tau burden in FTLD-TDP.48
It should be noted that p/t-tau ratio’s in FTLD-TDP considerably overlapped with the 
FTLD-tau group. Both sensitivity and specificity should exceed 85% to be classified as a 
valid biomarker in AD,11 which was not reached in our cohort, nor in three different co-
horts.47,49,50 Thus, more candidate biomarkers to discriminate underlying proteinopathy 
are needed. CSF tau levels do not aid in this discrimination: they are not increased in 
FTLD-tau patients compared with patients with tau-negative or sporadic FTD.52,53 Plasma 
tau levels are elevated in FTD, but application for identifying proteinopathy remains to 
be investigated.54 TDP-43 is a candidate marker being higher in both FTD and ALS than 
controls;55 however up till now, conflicting results are found and quantification remains 
challenging.50,56–58 
3. Genetic‑specific biomarkers 
In addition to accurate prediction of underlying pathology, genetic FTD offers the key 
advantage to study presymptomatic subjects. Evidence from autosomal dominant AD 
and Huntington’s disease suggested that biomarkers change years before symptom onset, 
implying that the disease starts before onset and treatment should be initiated prior to 
symptoms when neuronal damage is still limited.25,59 Our FTD Risk Cohort at the Erasmus 
MC and the international GENFI consortium are designed to study biomarkers in genetic 
FTD from the presymptomatic to the symptomatic stage, by longitudinally following first-
degree relatives of mutation-carriers. A presymptomatic phase is now convincingly proven 
in FTD, providing information on the earliest pathophysiological changes and facilitating 
the search for biomarkers identifying pathology onset and the optimal therapeutic win-
dow.60 Different genotypes cause specific biomarker alterations, which will be discussed 
in this section.
3.1 Dipeptide repeat proteins in C9orf72 repeat expansions 
In Chapter 3.2, we studied biomarkers in C9orf72 repeat expansion carriers, who mainly 
present with FTD and/or ALS. Patients typically have hundreds to thousands hexanucleo-
tide repeats, but repeat size is variable across different tissues within the same person, and 
it is not possible to exactly quantify large expansions.61,62 Three mechanisms have been 
postulated how C9orf72 expansions are pathogenic: 
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1. a loss-of-function through haploinsufficiency of the C9orf72 protein;
and/or a toxic gain-of-function through: 
2. RNA toxicity from bidirectional transcripts of the repeat that form RNA foci, or 
3. repeat-associated non-ATG (RAN) translation resulting in five different dipeptide repeat 
proteins (DPRs): poly(GA), poly(GR), poly(GP), poly(PA), and poly(PR) – where G refers to 
glycine, A to alanine, R to arginine, and P to proline. 
To discern these pathogenic mechanisms is important, as most therapeutic options cur-
rently under development target the gain-of-function mechanisms.63 Loss-of-function 
now seems the most unlikely all-explaining hypothesis, since corresponding models 
show immune related problems, but no neurodegeneration.64 The sequestration of RNA 
foci impairs the normal function of various RNA-binding proteins in C9orf72 repeat expan-
sions.65 However, no association has been shown between the location of RNA foci and the 
clinicopathological variability like disease subgroup (FTD and/or ALS).66 On the other hand, 
DPR accumulation is widespread across the brain of C9orf72-associated FTD and ALS, even 
before symptom onset,67–70 and is unrelated to neuronal loss or clinical symptoms.71,72 In 
line with this, we showed that elevation of CSF poly(GP) – one of the DPRs – is an exclusive 
and early phenomenon in C9orf72 expansion carriers. Also poly(GP) was not associated 
with indicators of neurodegeneration (i.e. NfL and grey matter atrophy). Although these 
observations may point toward no pathological effect of the DPRs, in functional studies 
especially the arginine containing DPRs were toxic,65 and a human autopsy study identi-
fied an association of poly(GR) with disease anatomy including TDP-pathology.63 Perhaps 
early effects are caused by DPR and/or RNA toxicity, followed by TDP-43 dysfunctioning 
and neurodegeneration in a later stage.73 It would be ideal if DPRs in the brain could be 
visualized in vivo, for example by PET ligands, to investigate cause and consequence in the 
pathomechanisms of C9orf72 expansions,74 since post-mortem tissue only allows studying 
end-stage features. 
In summary, there are supporting arguments for all three hypotheses, and perhaps a 
combination of these and other factors causes the disease.74 Although the gain-of-function 
mechanisms are difficult to study separately, antisense oligonucleotides (ASOs) and 
other small molecules will block both. To test the efficacy of these therapeutic agents, 
it is paramount to measure target engagement after blocking the formation of repeat 
RNA and RAN translation. Previously, ASO-treatment was shown to alleviate pathological 
C9orf72-features along with CSF poly(GP) levels in mice and human cell models of C9orf72 
expansions, and thus poly(GP) is a promising pharmacodynamic biomarker.75 We showed 
that poly(GP) is elevated in C9orf72-associated FTD patients, and also in presymptomatic 
expansion carriers, in line with two prior reports.75,76 This is important for the design of 
future trials and enables including presymptomatic carriers, who likely benefit the most 
of disease modifying interventions. The variation in poly(GP) levels between investigated 
subjects could not be explained by clinical features. Poly(GP) levels may depend on vari-
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ous factors, including the size of the repeat expansion, the efficacy of RAN translation and 
clearance mechanisms. Therefore, poly(GP) will especially be useful to monitor poly(GP) 
expression intra-individually as a read out of RAN translation activity over time. 
3.2 Progranulin levels in GRN mutation carriers
Autosomal dominant GRN mutations causing FTLD lead to haploinsufficiency and there-
fore reduced progranulin protein (PGRN) levels in both blood and CSF. PGRN controls neu-
ronal function, suppresses neuroinflammation and has an important role in lysosomes.77 
Various agents can elevate PGRN levels in experimental models through different ways 
including gene therapy, increasing PGRN transcription from the wildtype allele, or by 
enhancing the bioavailability of PGRN by preventing its degradation.77 A recent GRN+/- mice 
study has shown that boosting PGRN levels corrected behavioural deficits.78 Until now, two 
agents advanced to clinical trials (as registered in ClinicalTrials.gov): both nimodipine and 
a histone deacetylase inhibitor (FRM-0334) did not elevate PGRN levels in GRN mutation 
carriers,79 although the results of the latter have not yet been published.
The trial design for PGRN enhancing agents will be facilitated by our findings of stable 
plasma PGRN levels over one week time, and only a moderate correlation between plasma 
and CSF PGRN levels. Previous studies in subjects without GRN mutations found similar 
results,80–83 but it is essential to assess this biomarker in GRN mutation carriers. The con-
sistent finding of differentially regulated PGRN levels between blood and CSF, means 
that blood sampling could measure systemic target engagement, but CSF collections are 
needed to measure target engagement in the central nervous system.
Additionally, we showed that PGRN levels can detect GRN mutations, which is especially 
important when effective treatments come to hand. Although genotyping remains the 
golden standard, plasma PGRN levels can serve as a quick and cheap tool to screen large 
groups of patients, or to assess the pathogenicity of variants of unknown significance in 
GRN.
Much is still unknown about why PGRN levels greatly vary between individuals. In sub-
jects without GRN mutations, PGRN levels seem to increase with age, and differ between 
males and females;81 an effect we and others did not find in GRN mutation carriers.84,85 
Single nucleotide polymorphisms as rs5848, rs646776, and rs1990622 have proven to influ-
ence PGRN levels both in controls and GRN mutation carriers. The latter two are located 
near SORT1 and TMEM106B respectively, two genes implicated in lysosomal function and 
affecting PGRN pathways. Furthermore, the rs1990622 major allele is associated with 
inflammation and neuronal loss especially in the frontal cortex, and with cognitive deficits, 
even in controls.86 It is therefore surprising that we found an association between the 
minor allele of rs1990622 and lower plasma PGRN levels, while before higher levels have 
been reported.87,88 A recent large study did not find an association between plasma PGRN 
levels and rs1990622 in 141 subjects, illustrating the complexity of the regulation of PGRN 
levels.89
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3.3 Discovery of novel biomarkers by proteomics in GRN mutation carriers
Although major advances have been made towards discovering biomarkers, we still cannot 
identify disease onset on a pathophysiological level in presymptomatic mutation carriers 
before symptom onset. Therefore, we also aimed to identify novel biomarkers by applying 
a proteomics approach on CSF from presymptomatic and symptomatic GRN mutation car-
riers. Proteomics’ major advantages are the unbiased investigation, which has proven to 
be successful in FTD before,90 and measuring analytes directly, overcoming the pitfalls of 
indirect measuring with antibodies.11 
We identified multiple proteins that were differentially abundant between symptom-
atic GRN carriers and either presymptomatic- or non-carriers; seven fulfilled our pro-
posed criteria for a candidate biomarker. The most interesting candidate was neuronal 
pentraxin receptor, being downregulated in patients compared to presymptomatic- ánd 
non-carriers. This protein regulates signaling in excitatory and inhibitory synapses and 
is thus implicated in synaptic plasticity.91 It is also a potential progression biomarker in 
AD, even in the pre-dementia stage,92–95 and although we did not find altered levels in 
presymptomatic carriers, this will be interesting to further investigate with more sensitive 
techniques. Also neurosecretory protein VGF and chromogranin A, both involved in synap-
tic plasticity, were decreased supporting an important role for synaptic dysfunction in GRN 
mutations. Furthermore, we detected proteins involved in secretory processes, immunity 
and cytoskeletal structures, reflecting the pathophysiology of GRN mutations, which may 
provide new targets for treatment. It is now important to verify and validate these results 
by a second technique and in different patient cohorts, to determine the specificity of our 
findings and whether these proteins can function as monitoring biomarkers.
4. Towards implementing fluid biomarkers
In general, strengths of the studies in this thesis are well-characterized large cohorts, 
encompassing the entire FTD spectrum, and the multimodal approach combining bio-
markers. Specific strengths and limitations are discussed in the respective chapters. This 
paragraph describes - using experiences from our studies - how I envision the ideal study 
design for FTD biomarkers and what should be studied to move forward in the transition 
from bench to bedside. 
4.1 The ideal study design
4.1.1 Sample size and multicenter cohorts
Since FTD is a rare disease, it is difficult to collect sufficient data in studies of clinical or 
genetic subtypes. Multicenter cohorts are needed to overcome these power problems, but 
we have to face a number of challenges. The ideal multicenter study should use harmo-
nized protocols for prospective and longitudinal data collection that can be easily shared, 
Chapter 4  |  general dIscussIon
204
encompassing clinical and neuropsychological data, fluid and neuroimaging biomarkers, 
and also autopsy data. Biomarkers should be measured in one laboratory, preferably in 
one batch. It is of great importance that FTD consortia (e.g. GENFI, ARTFLL and LEFFTDS) 
are now operating and use harmonized research protocols, enabling large multimodal 
studies and validation of biomarkers. Also, these cohorts form valuable platforms for up-
coming clinical trials, providing a large ready cohort of diverse subjects who can potentially 
participate in trials (see below). 
4.1.2 Sampling methods and timing
The FTD research can learn much from the AD and MS fields, in which major strides in stan-
dardizing and harmonizing biomarker procedures have been made(e.g. the BiomarkAPD, 
SOPHIA and BioMS projects). Collection methods, storage tubes and temperature, diurnal 
variation, and number of freeze-thaw cycles can influence biomarker levels,11,96 underscor-
ing the importance of standardized sampling methods. Also the interval between different 
procedures (collection of fluid biomarkers, neuroimaging and neuropsychological data) 
should be as short as possible and it is at least recommended to collect blood and CSF 
samples on the same day.
4.2 What should be studied?
4.2.1 Verification and clinical validation of fluid biomarkers
In order to implement a novel biomarker, four steps are needed: (1) candidate discovery, 
(2) qualification, (3) verification, and (4) clinical validation.97,98 To determine which novel 
candidates from Chapter 3.4 justify the effort and expense of full validation, next steps are 
qualification, using a targeted technique to confirm the differential expression, followed 
by verification in larger cohorts including different genetic forms and dementia subtypes.97 
The studied biomarkers NfL, p/t-tau ratio, PGRN and poly(GP) are in the phase of clinical 
validation, a complex and time consuming process. Reference intervals of healthy indi-
viduals and identification of factors influencing biomarker measurement (e.g. preanalyti-
cal factors, and biological variability within- and between-subjects like age or fasting) are 
needed to develop cutoff criteria that can be used in individual patients.97 Furthermore, 
the results should be replicated in independent study cohorts and multi-center studies, 
before its possible clinical implementation.98,99 In the research setting of clinical trials, NfL, 
PGRN and poly(GP) can be readily applied; however, implementation in the clinical prac-
tice first requires prove of an added value for individual patients. Preventing asynchronous 
research can accelerate this clinical validation by aligning and prioritizing research proj-
ects, for example by creating an overview of gaps in evidence for FTD biomarkers, using a 
framework as recently proposed for AD.99 
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4.2.2 Longitudinal studies
Knowledge on fluctuations of biomarkers over time are necessary for future application in 
clinical trials. For NfL, a few longitudinal studies in ALS, PSP and PPA, have shown either 
increasing or stable levels over time,7,100–103while these data in bvFTD and genetic FTD are 
still lacking. Longitudinal serum NfL studies in presymptomatic genetic FTD – including 
converters – would answer whether changes in yearly NfL levels predict the onset of 
symptoms and indeed measure conversion to the dementia stage on an individual level. 
By studying biomarker changes within a person (delta’s), sensitivity might be increased by 
filtering out interpersonal differences, also it could yield important insights into disease 
biology. It will also be informative to know whether the increasing poly(GP) levels found 
in a few presymptomatic C9orf72 expansion carriers could be replicated, and to establish 
whether these subjects are closer to disease onset.
To detect non-linear changes it is important to study three or more time points in longi-
tudinal studies. Linear models are not applicable to most neurodegenerative disease,104 as 
illustrated by a sigmoid model in AD that showed a deceleration of atrophy after the initial 
acceleration.105 For FTD, acceleration of neuronal loss is supported a dramatic NfL increase 
in two converters (Chapter 3.1), and by the only subtle presymptomatic neuroimaging and 
neuropsychological abnormalities that become prominent in the symptomatic stage of 
genetic FTD.29,106–108 More longitudinal multimodal data on non-converters, converters, as 
well as sporadic FTD, will help elucidating the sequence of pathological events approach-
ing symptom onset and thereafter.
4.2.3 Combining biomarkers
The association of fluid biomarkers with different modalities as clinical or neuroimag-
ing data allows us to study the clinical value of individual biomarkers (e.g. NfL as proxy 
for disease severity) and provides valuable insights into underlying pathophysiological 
mechanisms (e.g. poly(GP) does not associate with indicators of neurodegeneration). 
The pathophysiological complexity of FTD implicates that a single biomarker cannot 
capture all changes, thus multiple biomarkers reflecting different disease processes should 
be studied in concert. In C9orf72-associated FTD, CSF poly(GP) might be used as a target 
engagement marker, complementary with NfL as a surrogate endpoint. In sporadic FTD, a 
lumbar puncture early in the process can exclude AD pathology and may predict underlying 
pathology by determining the p/t-tau ratio, followed by less invasive serum NfL measure-
ments to monitor disease progression over time. The most common hypothesis is that a 
specific sequence of biomarker abnormalities occurs – at least for genetic FTD – starting 
with fluid biomarkers, followed by connectivity imaging markers, grey matter atrophy, and 
finally clinical metrics.60 Combining these modalities will likely improve pinpointing the 
disease stage of a gene carrier facilitating timing of treatment, and improve diagnostic 
accuracy (clinically and pathologically) in sporadic FTD, especially in the early stages of 
disease when current clinical tools are often insufficient.109 
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4.2.4 Studying treatment options
Two tau-directed treatments, davunetide in PSP110 and TRx0237 in bvFTD111, were unfor-
tunately unsuccessful, but have proven that large international trials are feasible in these 
rare diseases.2
Recent advances in understanding FTLD biology have led to the identification of new 
treatment targets, that hopefully lead to disease modification and prevent or stop disease 
progression. ASOs are promising and feasible agents for various targets, already used in 
clinical practice for spinal muscular atrophy.112 An tau targeting ASO with the goal to reduce 
human tau expression (thus not directed to mutant tau), prevented disease progression in 
mice.113 This ASO is currently under study in mild AD patients,114 and if this approach proves 
to be successful, it will hopefully be a treatment option for other tauopathies, including 
FTLD-tau and PSP.
The genetic forms of FTD may provide a proof-of-principle of treatability of neurode-
generative diseases, since treatment can be initiated before extensive neuronal damage 
(i.e. presymptomatically). Neurodegenerative diseases resulting from gain-of-function 
mutations, are ideal targets for gene suppression therapy, a fast progressing field. Post-
transcriptional inhibition may modify disease in C9orf72 repeat expansion carriers, since 
a single-dose ASO injection reduced RNA foci, DPR accumulation and behavioural deficits 
in mice,64 and first clinical trials are expected to start in 2018.115 The discovery of CRISPR/
Cas9 is a major recent breakthrough in medicine, enabling accurate edits of the genome 
and perhaps correction of mutations in the future.112 
4.2.5 The importance of pathological confirmation 
An important problem remains that underlying pathology in sporadic FTD patients cannot 
be accurately predicted, while treatments will focus on specific molecular pathologies. Dif-
fusion tensor imaging (DTI) shows more severe loss of white matter integrity in tau than in 
TDP pathology,116,117 but this is not yet applicable in individual patients. Although tau PET 
(positron emission tomography) imaging is a promising strategy to discriminate tau from 
TDP and other proteinopathies, off-target binding to non-tau proteins is a problem and 
further development of specific ligands is needed.118,119 New approaches should thus be 
employed to identify this “holy grail”, and may be found in combining known neuroimag-
ing (e.g. grey matter and DTI), fluid (e.g. NfL, p/t-tau) and genetic biomarkers to multimodal 
predictors. Unbiased approaches by means of proteomics or microRNA sequencing,120 
especially in exosomes in blood or CSF that are regarded as enriched sources of biomol-
ecules, may  also be helpful to identify new biomarkers . 
Another issue is that co-pathology frequently occurs and relevant levels of AD co-
pathology are reported in 10-20%.48,121–123 Co-pathology with TDP-43, tau and α-synuclein 
does not only occur in older populations, but is already present in young (≤65 years) pa-
tients.123 Co-pathology is important for two reasons: first, it can influence biomarkers that 
cause misinterpretations. For example, patients with FTD ánd AD co-pathology may have 
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abnormal core AD biomarkers that lead to a misdiagnosis of frontal AD.122,124 Secondly, 
it has important implications for future treatments, since targeting a single protein may 
not be effective in patients with co-pathology.124 The effort to inform patients about the 
importance of brain autopsy for research, should be encouraged since the knowledge we 
acquire from pathological studies remains invaluable.
5. Conclusions
We are on the verge of an exciting era for neurodegenerative diseases, since the pathophysi-
ological knowledge acquired in the past is actively translated to developing therapeutic 
interventions. To expedite the development and testing of these disease-modifying agents, 
biomarkers that aid in selecting appropriate patients and measure efficacy are paramount. 
This thesis has shown that NfL is a promising biomarker in CSF and in blood across the 
entire FTD spectrum, both in sporadic and genetic forms. NfL levels are higher in patients 
than controls and can thus be used to ascertain disease. Also, NfL could monitor disease 
severity and progression and predicts survival – valuable information for the individual 
patient – in most subtypes within the FTD spectrum, except for svPPA. To select patients 
on underlying proteinopathy, the p/t-tau ratio may be useful being decreased in FTLD-TDP 
versus FTLD-tau, but more discriminative markers are needed. Our CSF proteomics study 
in GRN mutations identified potential novel biomarkers and provides knowledge of the 
pathophysiology of GRN mutations. Lastly, for FTD caused by GRN mutations or C9orf72 
repeat expansions, PGRN and poly(GP) respectively identify mutation carriers and are 
target engagement markers for clinical trials that are underway. Our results facilitate the 
implementation of these biomarkers for clinical or research purposes, and provide ad-
ditional understanding of the pathophysiological process underlying FTD, opening new 
avenues towards treating FTD. 
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Summary
Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder, compris-
ing a spectrum of subtypes that are different on the clinical, genetic and pathological level. 
Clinically, symptoms typically present before the age of 65 and include behavioural and/
or language disturbances, yet also motor problems frequently occur. FTD can be heritable, 
and 10-20% of the patients have an autosomal dominant form, which is most frequently 
caused by a mutation in granulin (GRN, also known as progranulin), in microtubule-asso-
ciated protein tau (MAPT), or a repeat expansion in chromosome 9 open reading frame 72 
(C9orf72). Pathological examination shows frontotemporal lobar degeneration (FTLD) with 
inclusions of either TAR DNA-binding protein 43 (FTLD-TDP), tau (FTLD-tau), or FET (fused 
in sarcoma, Ewing’s sarcoma and TAT-binding protein-associated factor 15). 
Currently, major advances are being made to develop therapeutic interventions for FTD. 
However, the heterogeneity of this disorder hampers the diagnostic process, tracking of 
disease progression, and the appropriate selection of patients for clinical trials. Reliable 
biomarkers are therefore critically needed. This thesis investigated the utility of biomarkers 
in cerebrospinal fluid (CSF) and blood, so-called fluid biomarkers, across the entire FTD 
spectrum. 
Chapter 1 introduces the aims and studies of the thesis (Chapter 1.1), and reviews cur-
rent knowledge on neuroimaging and fluid biomarkers in FTD (Chapter 1.2). In the past 
decade, major strides have been made to identify biomarkers for FTD, which are increas-
ingly important for upcoming treatment trials. Magnetic resonance imaging of grey matter 
atrophy, PET-imaging of cerebral hypometabolism, and CSF biomarkers are currently used 
in the clinical practice to diagnose FTD versus other types of dementia. Progress is being 
made in the identification of genetic specific markers and biomarkers for disease staging, 
prediction of underlying pathology, and monitoring of treatment response. Yet, harmo-
nized multicenter studies are important to validate these new biomarkers before they can 
be used in individual patients.
Chapter 2 describes the utility of neurofilament light chain (NfL), a promising biomarker 
reflecting neuronal damage and loss, in sporadic forms of FTD. In Chapter 2.1, we studied 
the clinical value of NfL and the phospho- to total tau ratio (p/t-tau) in CSF, in a well-
defined cohort of 361 patients. The entire FTD spectrum was investigated: behavioural 
variant FTD, semantic variant of primary progressive aphasia (svPPA), non-fluent variant 
PPA, logopenic variant PPA, FTD with motor neuron disease (FTD-MND), corticobasal syn-
drome, and progressive supranuclear palsy (PSP). NfL concentrations were high in all FTD 
patients compared with controls, highest in FTD-MND, but did not differentiate between 
other clinical subtypes. The p/t-tau ratio mirrored the results, being lower in patients than 
controls, and lowest in FTD-MND. Both high NfL and low p/t-tau ratio levels predicted a 
poor survival. Importantly, the p/t-tau ratio, but not NfL, discriminated FTLD-TDP from 
FTLD-tau pathology.
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In Chapter 2.2, we assessed the utility of NfL specifically for svPPA. CSF NfL was measured 
in 162 patients with svPPA from 14 international sites, and correlated to clinical character-
istics, neuropsychological metrics, grey matter atrophy on MRI-scans, and survival. CSF NfL 
was higher in patients with svPPA than in controls, and high levels were only moderately 
associated with more severe naming problems and smaller grey matter volumes of the 
parahippocampal gyri. Unlike in other FTD subtypes however, CSF NfL concentrations were 
not related to progression of grey matter atrophy and did not predict survival, which sug-
gests a limited utility of NfL in svPPA.
In Chapter 2.3, we describe the value of NfL in PSP, by investigating serum NfL and clinical 
characteristics of 131 patients. NfL concentrations were twice as high in patients with PSP 
than in controls, and correlated with worse functional, motor and cognitive performance. 
Additionally, higher NfL levels were associated with shorter survival. These results indicate 
that serum NfL is a promising monitoring and prognostic biomarker for patients with PSP.
Chapter 3 focuses on blood and CSF biomarkers in genetic forms of FTD. Chapter 3.1 
provides evidence that CSF NfL levels reflect disease onset in genetic FTD, since levels were 
low in a large international group of 40 presymptomatic mutation carriers and strongly 
elevated in 86 patients with genetic FTD. Moreover, longitudinal samples in two subjects 
who converted from the presymptomatic to symptomatic stage showed a three- to four-
fold increase of CSF NfL after symptom onset. Importantly, serum NfL correlated strongly 
with CSF NfL, and was similarly elevated in patients compared to presymptomatic carriers. 
This implicates that blood sampling might replace lumbar punctures for this biomarker. 
Additionally, NfL concentrations in patients correlated with disease severity, brain atrophy, 
progression of atrophy, and survival.
Chapter 3.2 reports an international study on CSF NfL and poly(GP) in 25 presymptom-
atic and 64 symptomatic C9orf72 repeat expansion carriers, and 12 non-carriers. Poly(GP) is 
one of the five dipeptide repeat proteins that are translated from the C9orf72 repeat expan-
sion and may therefore be an interesting pharmacodynamic marker.  Poly(GP) levels were 
present in carriers and absent in non-carriers, and were slightly higher in symptomatic than 
presymptomatic carriers. NfL levels were higher in symptomatic than presymptomatic car-
riers, and correlated with disease severity, grey matter atrophy, and survival. Poly(GP) did 
not associate with disease severity, survival, or indicators of neurodegeneration (i.e. NfL 
and grey matter volume). This study showed that NfL and poly(GP) are promising comple-
mentary biomarkers for clinical trials in C9orf72 repeat expansion carriers, where poly(GP) 
can measure target engagement and NfL disease activity and progression.
In Chapter 3.3, we measured progranulin protein levels in plasma and CSF in families 
with GRN mutations, since these mutations reduce progranulin levels and increasing pro-
granulin is thus a promising treatment strategy. Plasma progranulin levels were lower in all 
GRN mutation carriers than in controls, already in the presymptomatic stage. Progranulin 
in plasma was relatively stable over five measurements in one week, and therefore seems 
suitable to monitor the effect of progranulin-enhancing medications. However, plasma 
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could not accurately predict CSF progranulin, and therefore lumbar punctures are addi-
tionally needed in clinical trials for GRN mutation carriers.
In Chapter 3.4 we aimed to identify novel candidate biomarkers for FTD caused by GRN 
mutations, by means of proteomics on CSF. We found no differences between 19 presymp-
tomatic carriers and 24 healthy non-carriers, but identified seven candidate biomarkers for 
the symptomatic stage (9 patients were included). The candidates were neuronal pentraxin 
receptor, receptor-type tyrosine-protein phosphatase N2, Ig alpha-1 chain C region, neu-
rosecretory protein VGF, chromogranin-A, V-set and transmembrane domain-containing 
protein 2B, and complement component C8 gamma chain. These proteins have roles in 
synaptic plasticity, secretory processes and inflammation. Further studies are needed to 
validate the results in larger and more diverse sample sets.
Overall, this thesis has expanded the knowledge on how different fluid biomarkers can 
be applied across the FTD spectrum. Chapter 4 places the main results of this thesis in 
perspective of existing literature, and provides suggestions for future research.
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Samenvatting 
Frontotemporale dementie (FTD) is een heterogene neurodegeneratieve aandoening en 
omvat een spectrum van subtypes die verschillen op klinisch, genetisch en pathologisch 
niveau. Wat betreft het klinische beeld, treden symptomen van gedragsveranderingen en/of 
taalproblemen typisch op voor het 65e levensjaar, maar ook motorische problemen komen 
vaak voor. FTD kan erfelijk zijn en 10-20% van de patiënten met FTD heeft een autosomaal 
dominante vorm, welke meestal wordt veroorzaakt door een mutatie in granuline (GRN, 
ook bekend als progranuline), in microtubule-associated protein tau (MAPT) of een repeat 
expansie in chromosome 9 open reading frame 72 (C9orf72). Pathologisch onderzoek toont 
frontotemporale lobaire degeneratie (FTLD) met eiwit-inclusies van TAR DNA-binding 
protein 43 (FTLD-TDP), tau (FTLD-tau), of FET (fused in sarcoma, Ewing’s sarcoma and TAT-
binding protein-associated factor 15). 
Momenteel wordt er grote vooruitgang geboekt in het ontwikkelen van therapieën voor 
FTD. Echter, de heterogeniteit van het ziektebeeld belemmert het diagnostische proces, 
het meten van ziekteprogressie, en het identificeren van geschikte patiënten voor medi-
cijnonderzoek. Daarom zijn betrouwbare meetinstrumenten, biomarkers, hard nodig. Dit 
proefschrift onderzocht het gebruik van biomarkers in hersenvocht en bloed, zogenaamde 
fluïde biomarkers, voor het gehele FTD spectrum.
hoofdstuk 1 introduceert de doelen van dit proefschrift (hoofdstuk 1.1), en vat de 
huidige kennis op het gebied van imaging en fluïde biomarkers samen (hoofdstuk 1.2). 
Het afgelopen decennia zijn er grote stappen gemaakt in het identificeren van biomarkers 
voor FTD, welke van toenemend belang zijn voor opkomende behandelingsonderzoeken. 
Magnetische resonantie beelden (MRI) van grijze stof atrofie, PET-scans en hersenvocht 
biomarkers worden gebruikt in de huidige klinische praktijk, om de diagnose FTD te stellen 
en onderscheiden van andere vormen van dementie. Vooruitgang wordt geboekt in het 
identificeren van genetisch-specifieke markers, biomarkers voor ziektestadiëring, het vast-
stellen van onderliggende pathologie, en het monitoren van behandelingseffect. Nu zijn 
geharmoniseerde multicenter studies belangrijk om deze nieuwe biomarkers te valideren, 
voordat ze kunnen worden toegepast in individuele patiënten.
hoofdstuk 2 beschrijft het nut van neurofilament light chain (NfL), een veelbelovende 
biomarker die zenuwschade en –verlies meet, in sporadische (niet-genetische) vormen van 
FTD. In hoofdstuk 2.1 onderzochten wij de klinische waarde van NfL en de phospho- op 
totaal-tau ratio (p/t-tau) in hersenvocht, in een goed gekarakteriseerd cohort van 361 pa-
tiënten. Het gehele FTD spectrum werd bekeken: gedragsvariant FTD, semantische variant 
van primair progressieve afasie (svPPA), niet-vloeiende variant PPA, logopenische variant 
PPA, FTD met motorneuronziekte (FTD-MND), corticobasaal syndroom, en progressieve 
supranucleaire parese (PSP). NfL concentraties waren hoog in alle patiënten in vergelij-
king met controles, het hoogste in FTD-MND, maar kon andere klinische subtypes niet 
onderscheiden. De p/t-tau ratio toonde gespiegelde resultaten, zijnde lager in patiënten 
dan controles en het laagst in FTD-MND. Zowel hoge NfL als lage p/t-tau gehaltes konden 
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overleving voorspellen. Een belangrijke bevinding tot slot was dat p/t-tau, maar niet NfL, 
het onderscheid tussen FTLD-TDP en FTLD-tau pathologie kon maken.
In hoofdstuk 2.2 beoordeelden we het nut van NfL specifiek voor svPPA. NfL werd 
gemeten in hersenvocht van 162 patiënten met svPPA uit 14 internationale centra, en we 
onderzochten de samenhang met klinische karakteristieken, neuropsychologische maten, 
grijze stof atrofie op MRI-scans, en overleving. NfL was hoger in patiënten met svPPA dan 
in controles, en hogere concentraties hingen slechts matig samen met ernstigere benoem-
problemen en kleinere grijze stof volumes van de parahippocampale gyri. Anders dan in 
ander FTD subtypes waren NfL gehaltes in hersenvocht niet gerelateerd aan toename van 
atrofie of aan overleving, dit geeft aan dat NfL een beperkt toegepast nut heeft in svPPA.
In hoofdstuk 2.3 beschrijven we de waarde van NfL in PSP, door het bloed van 131 pati-
enten te onderzoeken in relatie tot klinische eigenschappen. NfL gehaltes waren twee keer 
zo hoog in patiënten met PSP dan in controles, en correleerden met slechtere functionele, 
motorische en cognitieve prestaties. Bovendien waren hoge NfL gehaltes geassocieerd 
met een kortere overleving. Deze resultaten laten zien dat NfL in bloed een veelbelovende 
biomarker is voor monitoring van ziekte-ernst en prognose in patiënten met PSP. 
hoofdstuk 3 richt zich op biomarkers in bloed en hersenvocht in erfelijke vormen van 
FTD. hoofdstuk 3.1 toont bewijs dat NfL concentraties in hersenvocht de start van ziekte 
kunnen meten in erfelijke FTD, aangezien gehaltes laag waren in een grote internationale 
groep van 40 presymptomatische mutatiedragers en sterk verhoogd in 86 patiënten met 
erfelijke FTD. Bovendien toonden longitudinale samples in twee personen die converteer-
den van de presymptomatische naar de symptomatische fase, een drie- tot viervoudige 
toename van NfL na het begin van de symptomen. Een zeer belangrijke bevinding is dat 
NfL in bloed sterk correleerde met NfL in hersenvocht, en vergelijkbaar verhoogd was in 
patiënten ten opzichte van presymptomatische dragers. Dit duidt aan dat bloedafnames 
mogelijk ruggenprikken kunnen vervangen voor deze biomarker. Tot slot correleerden NfL 
gehaltes in patiënten met ziekte-ernst, atrofie van de hersenen, progressie van atrofie, en 
overleving.
hoofdstuk 3.2 beschrijft een internationale hersenvochtstudie naar NfL en poly(GP) in 
25 presymptomatische en 65 symptomatische C9orf72 repeat expansie dragers, en 12 niet-
dragers. Poly(GP) is een van de vijf dipeptide repeat eiwitten die gevormd worden door de 
C9orf72 repeat expansie, en zou daarom een interessante farmacodynamische biomarker 
kunnen zijn. Poly(GP) gehaltes waren aanwezig in dragers en afwezig in niet-dragers, en iets 
verhoogd in symptomatische ten opzichte van presymptomatische dragers. NfL concen-
traties waren hoger in symptomatische dan presymptomatische dragers, en hingen samen 
met ziekte-ernst, grijze stof atrofie en overleving. Poly(GP) correleerde niet met klinische 
eigenschappen, survival of maten van neurodegeneratie (NfL en grijze stof volume). Deze 
studie toont dat NfL en poly(GP) veelbelovende biomarkers zijn die elkaar aan kunnen 
vullen in klinische trials voor C9orf72 repeat expansie dragers, waarbij poly(GP) target 
engagement (het biologische effect) kan meten en NfL ziekteactiviteit en –progressie.
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In hoofdstuk 3.3 hebben we concentraties gemeten van het progranuline-eiwit in bloed 
en hersenvocht van families met GRN mutaties, aangezien deze mutaties de progranuline 
gehaltes verlagen en daarom is het verhogen van deze gehaltes een veelbelovende be-
handelingsoptie. Bloed progranuline concentraties waren lager in alle GRN mutatiedragers 
dan in controles, reeds in de presymptomatische fase. Progranuline in bloed was relatief 
stabiel over vijf meetmomenten in één week, en lijkt daarom geschikt om het effect van 
progranuline-verhogende middelen te monitoren. Progranulinegehaltes in bloed konden 
die in hersenvocht niet betrouwbaar voorspellen, en daarom zijn ruggenprikken ook nodig 
in medicijnonderzoek bij GRN mutatiedragers.
hoofdstuk 3.4 had tot doel nieuwe kandidaat-biomarkers te identificeren voor FTD 
veroorzaakt door GRN mutaties, met behulp van proteomics op hersenvocht. Wij vonden 
geen verschillen tussen 19 presymptomatische dragers en 24 gezonde niet-dragers, maar 
vonden zeven kandidaat-biomarkers voor de symptomatische fase (9 patiënten werden on-
derzocht). De kandidaten zijn neuronal pentraxin receptor, receptor-type tyrosine-protein 
phosphatase N2, Ig alpha-1 chain C region, neurosecretory protein VGF, chromogranin-A, 
V-set and transmembrane domain-containing protein 2B, en complement component C8 
gamma chain. Deze eiwitten spelen een rol in synaptische plasticiteit, secretoire proces-
sen en ontsteking. Verdere studies zijn nodig om deze resultaten te valideren in grotere en 
meer diverse patiëntengroepen.
In het algemeen heeft dit proefschrift de kennis uitgebreid over hoe verschillende fluïde 
biomarkers kunnen worden toegepast in het gehele FTD spectrum. hoofdstuk 4 plaatst 
de belangrijkste bevindingen van dit proefschrift in het perspectief van de bestaande 
literatuur, en geeft suggesties voor toekomstig onderzoek.
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ARTFL  Advancing Research and Treatment for FTLD
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C9orf72  chromosome 9 open reading frame 72 gene
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CBS  corticobasal syndrome
CDR  Clinical Dementia Rating scale
CDR-SB  Clinical Dementia Rating scale sum of boxes
CDT  Clock Drawing Test
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CSF  cerebrospinal fluid
CV  coefficient of variation
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DNA  deoxyribonucleic acid
DPR  dipeptide repeat 
DTI  diffusion tensor imaging
ECL  electrochemiluminescence
e.g.  example given
ELISA  enzyme-linked immunosorbent assay
FA  fractional anisotropy
FAB  Frontal Assessment Battery
FDG-PET 18F-fluorodeoxyglucose positron emission tomography 
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coma or TAT-binding protein-associated factor 15 inclusions
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IL  interleukin
IQR  interquartile range
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MAPT  microtubule-associated protein tau gene
MCI  mild cognitive impairment
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MMSE  Mini-Mental State Examination
MND  motor neuron disease
MRI  magnetic resonance imaging
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PET  positron emission tomography
PGRN  progranulin protein
PiB  Pittsburgh compound B
Poly-GP  glycine-proline-repeating protein
PPA  primary progressive aphasia
PSP  progressive supranuclear palsy
PSP-RS  progressive supranuclear palsy rating scale
p-tau  phospho-tau181
pTDP-43  phosphorylated TDP-43
PTPRN   receptor-type tyrosine-protein phosphatase-like N
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RS-fMRI  resting-state functional magnetic resonance imaging
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SNP  single nucleotide polymorphism
SOD1  superoxide dismutase 1 gene
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SPSS  Statistical Package for the Social Sciences
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SQSTM1  sequestosome-1 gene
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TARDP  TAR-DNA binding protein gene
TBK1  TANK-binding kinase 1 gene
TDP or TDP-43 transactive response DNA-binding protein 43
TIV  total intracranial volume
TMEM106B transmembrane protein 106B gene
TMT-A  Trail-making Test part A
TMT-B  Trail-making Test part B
TNF  tumor necrosis factor
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TREM2  triggering receptor expressed on myeloid cells 2
t-tau  total-tau
UPDRS-III Unified Parkinson’s disease rating scale III
YKL-40  chitinase-3-like protein 1
VBM  Voxel-Based Morphometry
VCP  valosin-containing protein gene
VSTM2B  V-set and transmembrane domain-containing protein 2B
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